



**EVENTIDE**

# **ANNUAL REPORT**

**Eventide Balanced Fund**

**Eventide Core Bond Fund**

**Eventide Dividend Opportunities Fund**

**Eventide Exponential Technologies Fund**

**Eventide Gilead Fund**

**Eventide Healthcare & Life Sciences Fund**

**Eventide Large Cap Focus Fund**

**Eventide Limited-Term Bond Fund**

**June 30, 2024**

**Eventide Asset Management, LLC  
One International Place  
Suite 4210  
Boston, MA 02110**

**1-877-771-3836**

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 53.1%</b>	
	<b>AUTOMOTIVE - 0.3%</b>	
11,883	Autoliv, Inc.	\$ 1,271,362
	<b>BANKING - 0.4%</b>	
40,085	Synovus Financial Corporation	1,611,016
	<b>BIOTECH &amp; PHARMA - 0.9%</b>	
129,347	Royalty Pharma plc, Class A	3,410,880
	<b>CHEMICALS - 2.3%</b>	
19,298	Cabot Corporation	1,773,293
83,482	Element Solutions, Inc.	2,264,032
15,910	Sherwin-Williams Company (The)	4,748,021
		<u>8,785,346</u>
	<b>COMMERCIAL SUPPORT SERVICES - 0.7%</b>	
55,421	Rollins, Inc.	2,703,991
	<b>CONTAINERS &amp; PACKAGING - 0.9%</b>	
81,010	International Paper Company	3,495,582
	<b>DIVERSIFIED INDUSTRIALS - 1.3%</b>	
64,362	Pentair PLC	4,934,635
	<b>ELECTRIC UTILITIES - 4.4%</b>	
24,634	CMS Energy Corporation	1,466,462
9,684	Constellation Energy Corporation	1,939,415
54,842	Public Service Enterprise Group, Inc.	4,041,855
16,084	Sempra Energy	1,223,349
39,206	Southern Company (The)	3,041,209
59,509	Vistra Corporation	5,116,584
		<u>16,828,874</u>
	<b>ELECTRICAL EQUIPMENT - 6.3%</b>	
146,044	nVent Electric PLC	11,188,431
37,143	Trane Technologies PLC	12,217,446
		<u>23,405,877</u>

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Shares</u>		<u>Fair Value</u>
	<b>COMMON STOCKS — 53.1% (Continued)</b>	
	<b>HOME CONSTRUCTION - 1.4%</b>	
36,936	DR Horton, Inc.	\$ 5,205,391
	<b>INDUSTRIAL REIT - 1.4%</b>	
30,997	EastGroup Properties, Inc.	5,272,590
	<b>INDUSTRIAL SUPPORT SERVICES - 2.8%</b>	
16,260	Applied Industrial Technologies, Inc.	3,154,440
38,200	Ferguson PLC	7,397,429
		<u>10,551,869</u>
	<b>INSTITUTIONAL FINANCIAL SERVICES - 1.6%</b>	
43,975	Houlihan Lokey, Inc.	5,930,469
	<b>INSURANCE - 3.0%</b>	
38,335	Arthur J Gallagher & Company	9,940,648
10,153	RLI Corporation	1,428,426
		<u>11,369,074</u>
	<b>MACHINERY - 0.4%</b>	
7,926	IDEX Corporation	1,594,711
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 1.3%</b>	
22,603	STERIS plc	4,962,263
	<b>OIL &amp; GAS PRODUCERS - 4.8%</b>	
92,367	Coterra Energy, Inc.	2,463,428
7,503	Diamondback Energy, Inc.	1,502,026
58,674	Targa Resources Corporation	7,556,037
156,721	Williams Companies, Inc. (The)	6,660,643
		<u>18,182,134</u>
	<b>RESIDENTIAL REIT - 1.3%</b>	
23,326	AvalonBay Communities, Inc.	4,825,916
	<b>RETAIL - DISCRETIONARY - 1.7%</b>	
6,532	Group 1 Automotive, Inc.	1,941,833
7,787	Lithia Motors, Inc.	1,965,828

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 53.1% (Continued)</b>	
	<b>RETAIL - DISCRETIONARY - 1.7% (Continued)</b>	
12,313	Lowe's Companies, Inc.	\$ 2,714,525
		<u>6,622,186</u>
	<b>SEMICONDUCTORS - 2.9%</b>	
10,411	KLA Corporation	8,583,973
2,142	Lam Research Corporation	2,280,909
		<u>10,864,882</u>
	<b>SOFTWARE - 4.0%</b>	
17,360	Roper Technologies, Inc.	9,785,138
9,291	Synopsys, Inc. <sup>(a)</sup>	5,528,702
		<u>15,313,840</u>
	<b>SPECIALTY REITS - 1.4%</b>	
59,101	Iron Mountain, Inc.	5,296,631
		<u>5,296,631</u>
	<b>TECHNOLOGY HARDWARE - 1.1%</b>	
33,175	NetApp, Inc.	4,272,940
		<u>4,272,940</u>
	<b>TECHNOLOGY SERVICES - 4.3%</b>	
39,481	CDW Corporation	8,837,427
6,341	MSCI, Inc.	3,054,777
16,070	Verisk Analytics, Inc.	4,331,669
		<u>16,223,873</u>
	<b>TRANSPORTATION &amp; LOGISTICS - 1.2%</b>	
26,576	Old Dominion Freight Line, Inc.	4,693,322
		<u>4,693,322</u>
	<b>WHOLESALE - CONSUMER STAPLES - 0.5%</b>	
26,127	Sysco Corporation	1,865,207
		<u>1,865,207</u>
	<b>WHOLESALE - DISCRETIONARY - 0.5%</b>	
6,101	Pool Corporation	1,875,020
		<u>1,875,020</u>
	<b>TOTAL COMMON STOCKS (Cost \$148,526,989)</b>	<u>201,369,881</u>

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>ASSET BACKED SECURITIES — 1.6%</b>				
	<b>AUTO LOAN — 1.0%</b>				
3,150,000	CarMax Auto Owner Trust Series 2020-4 C		1.3000	08/17/26	\$ 3,084,294
750,000	CarMax Auto Owner Trust Series 2021-2 C		1.3400	02/16/27	719,920
					3,804,214
	<b>OTHER ABS — 0.6%</b>				
2,250,000	PFS Financing Corporation Series C A <sup>(b),(f)</sup>	SOFR30A + 0.800%	6.1330	04/17/28	2,253,916
	<b>TOTAL ASSET BACKED SECURITIES (Cost \$6,160,872)</b>				6,058,130

Principal Amount (\$)			Coupon Rate (%)	Maturity	Fair Value
	<b>COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%</b>				
	<b>CMBS — 0.5%</b>				
1,000,000	Freddie Mac Multifamily Structured Pass Through Certificates Series KG01 A10		2.9390	04/25/29	924,024
1,000,000	Freddie Mac Multifamily Structured Pass Through Certificates Series KG02 A2		2.4120	08/25/29	899,974
					1,823,998
	<b>TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost \$2,031,993)</b>				1,823,998

Principal Amount (\$)			Coupon Rate (%)	Maturity	Fair Value
	<b>CONVERTIBLE BONDS — 0.3%</b>				
	<b>BIOTECH &amp; PHARMA — 0.3%</b>				
950,000	Mirium Pharmaceuticals, Inc.		4.0000	05/01/29	1,277,156
	<b>TOTAL CONVERTIBLE BONDS (Cost \$1,068,522)</b>				1,277,156

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 20.6%</b>				
	<b>ASSET MANAGEMENT — 1.0%</b>				
3,800,000	Vision Fund International <sup>(c),(d),(e)</sup>		3.7250	02/24/25	3,739,496
	<b>AUTOMOTIVE — 0.5%</b>				
2,025,000	Dana, Inc.		4.2500	09/01/30	1,769,409

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 20.6% (Continued)</b>				
	<b>BANKING — 1.9%</b>				
3,725,000	Bank of America Corporation Series N <sup>(f)</sup>	TSFR3M + 1.132%	2.4560	10/22/25	\$ 3,686,669
3,200,000	JPMorgan Chase & Company <sup>(f)</sup>	SOFRRATE + 1.330%	6.0700	10/22/27	3,256,708
					<u>6,943,377</u>
	<b>COMMERCIAL SUPPORT SERVICES — 0.5%</b>				
1,790,000	Waste Management, Inc.		4.9500	07/03/31	<u>1,777,516</u>
	<b>CONSTRUCTION MATERIALS — 0.4%</b>				
1,300,000	Advanced Drainage Systems, Inc. <sup>(b)</sup>		5.0000	09/30/27	<u>1,272,856</u>
	<b>CONTAINERS &amp; PACKAGING — 0.2%</b>				
1,000,000	TriMas Corporation <sup>(b)</sup>		4.1250	04/15/29	<u>917,083</u>
	<b>ELEC &amp; GAS MARKETING &amp; TRADING — 0.2%</b>				
1,000,000	Southern Power Company		0.9000	01/15/26	<u>932,513</u>
	<b>ELECTRIC UTILITIES — 3.3%</b>				
1,235,000	AES Corporation (The)		1.3750	01/15/26	1,157,743
1,750,000	Constellation Energy Generation, LLC		6.1250	01/15/34	1,827,195
1,000,000	Duke Energy Florida, LLC		2.5000	12/01/29	883,493
1,000,000	MidAmerican Energy Company		3.1000	05/01/27	954,411
3,475,000	National Rural Utilities Cooperative Finance Corporation		1.3500	03/15/31	2,726,686
3,600,000	NextEra Energy Capital Holdings, Inc.		1.9000	06/15/28	3,185,933
2,000,000	Wisconsin Power and Light Company		1.9500	09/16/31	1,604,366
					<u>12,339,827</u>
	<b>ENGINEERING &amp; CONSTRUCTION — 1.2%</b>				
1,435,000	Installed Building Products, Inc. <sup>(b)</sup>		5.7500	02/01/28	1,404,669
1,750,000	MasTec, Inc. <sup>(b)</sup>		4.5000	08/15/28	1,670,558
2,000,000	Quanta Services, Inc.		2.9000	10/01/30	1,764,674
					<u>4,839,901</u>
	<b>FORESTRY, PAPER &amp; WOOD PRODUCTS — 0.2%</b>				
1,000,000	Louisiana-Pacific Corporation <sup>(b)</sup>		3.6250	03/15/29	<u>908,322</u>

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 20.6% (Continued)</b>				
	<b>HOME &amp; OFFICE PRODUCTS — 0.5%</b>				
1,910,000	Tempur Sealy International, Inc. <sup>(b)</sup>		4.0000	04/15/29	\$ 1,725,273
	<b>HOME CONSTRUCTION — 0.4%</b>				
1,750,000	M/I Homes, Inc.		3.9500	02/15/30	1,562,033
	<b>INDUSTRIAL SUPPORT SERVICES — 0.4%</b>				
1,700,000	United Rentals North America, Inc.		4.8750	01/15/28	1,648,977
	<b>INSTITUTIONAL FINANCIAL SERVICES — 1.3%</b>				
3,875,000	Morgan Stanley <sup>(f)</sup>	SOFRRATE + 0.745%	0.8640	10/21/25	3,815,426
1,000,000	Nasdaq, Inc.		5.3500	06/28/28	1,009,951
					4,825,377
	<b>INSURANCE — 0.9%</b>				
1,015,000	Aflac, Inc.		1.1250	03/15/26	948,148
500,000	Brown & Brown, Inc.		4.5000	03/15/29	482,571
2,000,000	Pacific Life Global Funding II <sup>(b)</sup>		1.3750	04/14/26	1,868,936
					3,299,655
	<b>MACHINERY — 0.9%</b>				
1,750,000	Mueller Water Products, Inc. <sup>(b)</sup>		4.0000	06/15/29	1,603,951
1,875,000	Xylem, Inc.		1.9500	01/30/28	1,684,165
					3,288,116
	<b>OIL &amp; GAS PRODUCERS — 1.1%</b>				
2,325,000	Cheniere Energy Partners, L.P.		4.5000	10/01/29	2,216,416
1,750,000	Diamondback Energy, Inc.		3.5000	12/01/29	1,615,590
500,000	Diamondback Energy, Inc.		5.1500	01/30/30	497,821
					4,329,827
	<b>REAL ESTATE INVESTMENT TRUSTS — 1.4%</b>				
1,750,000	American Tower Corporation		4.0500	03/15/32	1,603,641
1,000,000	AvalonBay Communities, Inc.		2.0500	01/15/32	820,130
1,750,000	HAT Holdings I, LLC / HAT Holdings II, LLC <sup>(b)</sup>		3.3750	06/15/26	1,652,828
1,500,000	Welltower OP, LLC		2.7000	02/15/27	1,414,265
					5,490,864

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
<b>CORPORATE BONDS — 20.6% (Continued)</b>					
<b>RETAIL - DISCRETIONARY — 1.3%</b>					
1,250,000	Asbury Automotive Group, Inc.		4.5000	03/01/28	\$ 1,186,165
1,450,000	Builders FirstSource, Inc. <sup>(b)</sup>		4.2500	02/01/32	1,283,193
1,600,000	Home Depot, Inc. (The)		4.8750	06/25/27	1,597,497
1,000,000	Patrick Industries, Inc. <sup>(b)</sup>		7.5000	10/15/27	1,011,028
					5,077,883
<b>SEMICONDUCTORS — 1.4%</b>					
1,185,000	Amkor Technology, Inc. <sup>(b)</sup>		6.6250	09/15/27	1,189,005
2,800,000	NXP BV / NXP Funding, LLC / NXP USA, Inc.		2.5000	05/11/31	2,352,064
1,925,000	Synaptics, Inc. <sup>(b)</sup>		4.0000	06/15/29	1,747,588
					5,288,657
<b>SOFTWARE — 0.6%</b>					
1,250,000	Roper Technologies, Inc.		4.2000	09/15/28	1,209,362
1,250,000	Workday, Inc.		3.8000	04/01/32	1,125,698
					2,335,060
<b>TECHNOLOGY SERVICES — 0.4%</b>					
1,500,000	Verisk Analytics, Inc.		5.7500	04/01/33	1,544,508
<b>WHOLESALE - CONSUMER STAPLES — 0.6%</b>					
2,775,000	Sysco Corporation		2.4000	02/15/30	2,407,486
					78,264,016

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
<b>MUNICIPAL BONDS — 4.3%</b>				
<b>COMBINED UTILITIES — 0.4%</b>				
1,475,000	City of Tacoma, WA Electric System Revenue	5.6410	01/01/27	1,489,643
<b>COUNTY — 0.0%<sup>(g)</sup></b>				
150,000	City & County of Honolulu, HI	2.5180	10/01/26	142,629
<b>MISCELLANEOUS TAX — 0.5%</b>				
2,050,000	Commonwealth of Massachusetts	3.6390	07/15/24	2,048,552

See accompanying notes to financial statements.



**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>MUNICIPAL BONDS — 4.3% (Continued)</b>			
	<b>MULTI-FAMILY HOUSING — 0.0%<sup>(6)</sup></b>			
100,000	New York State Housing Finance Agency	0.6500	05/01/25	\$ 97,091
	<b>RESOURCE RECOVERY — 0.0%<sup>(6)</sup></b>			
100,000	City of Napa, CA Solid Waste Revenue	2.3300	08/01/25	96,970
	<b>SINGLE-FAMILY HOUSING — 2.7%</b>			
1,700,000	Florida Housing Finance Corporation	5.5610	07/01/49	1,619,617
500,000	Illinois Housing Development Authority	5.2440	04/01/31	504,192
500,000	Illinois Housing Development Authority	5.2940	10/01/31	504,404
2,325,000	Massachusetts Housing Finance Agency	5.8360	12/01/42	2,305,529
2,250,000	Minnesota Housing Finance Agency	5.5880	07/01/39	2,248,801
1,715,000	Virginia Housing Development Authority	4.9140	04/01/30	1,706,878
1,000,000	Virginia Housing Development Authority	5.6620	10/01/39	996,084
				<u>9,885,505</u>
	<b>STATE — 0.2%</b>			
200,000	State of Oregon	0.8950	05/01/25	193,018
500,000	State of Oregon	1.3150	05/01/27	454,900
				<u>647,918</u>
	<b>WATER AND SEWER — 0.5%</b>			
2,000,000	City of Aurora, CO Water Revenue	2.0980	08/01/34	1,586,884
200,000	City of Los Angeles, CA Wastewater System Revenue	3.6940	06/01/32	184,835
				<u>1,771,719</u>
	<b>TOTAL MUNICIPAL BONDS (Cost \$16,960,504)</b>			<u>16,180,027</u>

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>U.S. GOVERNMENT &amp; AGENCIES — 17.9%</b>			
	<b>AGENCY FIXED RATE — 12.7%</b>			
152,085	Fannie Mae Pool MA2915	3.0000	02/01/27	147,968
759,442	Fannie Mae Pool MA4263	1.5000	02/01/31	694,553
585,733	Fannie Mae Pool FM3333	2.0000	06/01/35	519,553
434,152	Fannie Mae Pool MA4095	2.0000	08/01/35	385,096

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Principal Amount (\$)</u>		<u>Coupon Rate (%)</u>	<u>Maturity</u>	<u>Fair Value</u>
<b>U.S. GOVERNMENT &amp; AGENCIES — 17.9% (Continued)</b>				
<b>AGENCY FIXED RATE — 12.7% (Continued)</b>				
410,095	Fannie Mae Pool BM5466	2.5000	10/01/43	\$ 348,471
382,085	Fannie Mae Pool BM5975	3.0000	12/01/45	337,810
340,335	Fannie Mae Pool MA2806	3.0000	11/01/46	297,142
353,875	Fannie Mae Pool BM5976	3.0000	02/01/47	312,936
1,250,514	Fannie Mae Pool MA4096	2.5000	08/01/50	1,033,992
1,631,259	Fannie Mae Pool MA4327	3.0000	05/01/51	1,400,910
2,836,101	Fannie Mae Pool MA4355	2.0000	06/01/51	2,235,932
1,738,857	Fannie Mae Pool MA4356	2.5000	06/01/51	1,433,624
2,104,012	Fannie Mae Pool MA4379	2.5000	07/01/51	1,734,132
3,311,801	Fannie Mae Pool CB2661	3.0000	01/01/52	2,848,105
3,237,193	Fannie Mae Pool MA4600	3.5000	05/01/52	2,874,049
3,053,204	Fannie Mae Pool MA4625	3.5000	06/01/52	2,710,705
3,134,482	Fannie Mae Pool MA4655	4.0000	07/01/52	2,874,680
3,163,683	Fannie Mae Pool MA4805	4.5000	11/01/52	2,990,334
3,092,399	Fannie Mae Pool MA4869	5.5000	01/01/53	3,060,978
3,374,501	Fannie Mae Pool MA4916	4.0000	02/01/53	3,095,152
642,039	Freddie Mac Pool ZS9163	3.0000	09/01/33	601,701
605,698	Freddie Mac Pool ZS9382	3.0000	09/01/43	535,696
1,263,001	Freddie Mac Pool SD8122	2.5000	01/01/51	1,043,774
1,801,591	Freddie Mac Pool RA5696	2.5000	08/01/51	1,483,568
2,858,094	Freddie Mac Pool SD8214	3.5000	05/01/52	2,537,281
2,747,352	Freddie Mac Pool SD8238	4.5000	08/01/52	2,595,811
3,254,553	Freddie Mac Pool SD8288	5.0000	01/01/53	3,155,564
1,906,000	Freddie Mac Pool SD3026	5.0000	06/01/53	1,851,288
2,701,915	Freddie Mac Pool SD8332	6.0000	06/01/53	2,718,583
316,808	Ginnie Mae II Pool MA3375	3.0000	01/20/46	281,257
				48,140,645
<b>GOVERNMENT OWNED, NO GUARANTEE — 2.9%</b>				
1,350,000	Federal Home Loan Mortgage Corporation	5.2500	12/09/24	1,347,497
2,250,000	Federal Home Loan Mortgage Corporation	5.5000	04/08/27	2,245,886
1,500,000	Federal Home Loan Mortgage Corporation	5.0000	09/18/28	1,491,443
2,500,000	Federal Home Loan Mortgage Corporation	6.2500	07/15/32	2,804,507
2,900,000	Federal National Mortgage Association	6.2500	05/15/29	3,136,873
				11,026,206

See accompanying notes to financial statements.

**EVENTIDE BALANCED FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>U.S. GOVERNMENT &amp; AGENCIES — 17.9% (Continued)</b>			
	<b>GOVERNMENT SPONSORED — 2.3%</b>			
2,250,000	Federal Farm Credit Banks Funding Corporation	5.2300	05/20/26	\$ 2,250,071
1,750,000	Federal Farm Credit Banks Funding Corporation	4.3750	02/28/28	1,743,707
2,750,000	Federal Farm Credit Banks Funding Corporation	4.6250	04/05/29	2,778,826
2,000,000	Federal Farm Credit Banks Funding Corporation	4.3750	03/03/33	1,964,524
				<u>8,737,128</u>
	<b>TOTAL U.S. GOVERNMENT &amp; AGENCIES (Cost \$72,567,556)</b>			<u>67,903,979</u>
				<u>111,291</u>
	<b>SHORT-TERM INVESTMENTS — 0.0% <sup>(a)</sup></b>			
	<b>MONEY MARKET FUNDS - 0.0% <sup>(a)</sup></b>			
111,291	Fidelity Money Market Government Portfolio Class I, 5.20% (Cost \$111,291) <sup>(h)</sup>			111,291
				<u>372,988,478</u>
	<b>TOTAL INVESTMENTS — 98.3% (Cost \$330,892,091)</b>			<u>\$ 372,988,478</u>
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES — 1.7%</b>			6,531,305
	<b>NET ASSETS - 100.0%</b>			<u>\$ 379,519,782</u>

LLC - Limited Liability Company  
LP - Limited Partnership  
MSCI - Morgan Stanley Capital International  
PLC - Public Limited Company  
REIT - Real Estate Investment Trust

SOF30A United States 30 Day Average SOFR Secured Overnight Financing Rate  
SOFRRATE United States SOFR Secured Overnight Financing Rate  
TSFR3M CME Term SOFR 3 Month

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2024 the total market value of 144A securities is \$20,509,206 or 5.4% of net assets.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024 was \$3,739,496, representing 1.0% of net assets.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Private investment.

<sup>(f)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

<sup>(g)</sup> Percentage rounds to less than 0.1%.

<sup>(h)</sup> Rate disclosed is the seven day effective yield as of June 30, 2024.

See accompanying notes to financial statements.

**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>ASSET BACKED SECURITIES — 3.0%</b>				
	<b>AUTO LOAN — 1.7%</b>				
1,375,000	CarMax Auto Owner Trust 2020-4 C		1.3000	08/17/26	\$ 1,346,319
1,000,000	CarMax Auto Owner Trust 2021-2 C		1.3400	02/16/27	959,894
					<u>2,306,213</u>
	<b>OTHER ABS — 1.3%</b>				
1,775,000	PFS Financing Corporation Series C A <sup>(a),(b)</sup>	SOFR30A + 0.800%	6.1330	04/17/28	1,778,089
					<u>4,084,302</u>
	<b>TOTAL ASSET BACKED SECURITIES (Cost \$4,156,473)</b>				

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 45.3%</b>				
	<b>AUTOMOTIVE — 0.3%</b>				
500,000	Dana, Inc.		4.2500	09/01/30	436,891
	<b>BANKING — 3.0%</b>				
1,700,000	Bank of America Corporation Series N <sup>(b)</sup>	TSFR3M + 1.132%	2.4560	10/22/25	1,682,507
2,500,000	JPMorgan Chase & Company <sup>(b)</sup>	SOFRRATE + 1.330%	6.0700	10/22/27	2,544,302
					<u>4,226,809</u>
	<b>BIOTECH &amp; PHARMA — 1.2%</b>				
1,750,000	Zoetis, Inc.		3.9000	08/20/28	1,672,227
	<b>COMMERCIAL SUPPORT SERVICES — 1.2%</b>				
1,700,000	Waste Management, Inc.		4.9500	07/03/31	1,688,143
	<b>ELECTRIC UTILITIES — 11.7%</b>				
1,000,000	AES Corporation (The)		5.4500	06/01/28	998,853
1,750,000	Ameren Illinois Company		5.9000	12/01/52	1,815,656
1,750,000	Constellation Energy Generation, LLC		5.7500	03/15/54	1,706,303
2,250,000	DTE Electric Company		3.9500	03/01/49	1,784,208
2,000,000	Duke Energy Florida, LLC		2.5000	12/01/29	1,766,986
650,000	Interstate Power and Light Company		3.5000	09/30/49	460,654
1,750,000	MidAmerican Energy Company		4.2500	07/15/49	1,447,015
1,400,000	National Rural Utilities Cooperative Finance Corporation		1.3500	03/15/31	1,098,521
1,000,000	NextEra Energy Capital Holdings, Inc.		5.0500	02/28/33	973,976

See accompanying notes to financial statements.

**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 45.3% (Continued)</b>				
	<b>ELECTRIC UTILITIES — 11.7% (Continued)</b>				
1,500,000	NextEra Energy Capital Holdings, Inc. <sup>(b)</sup>	US0003M + 2.409%	4.8000	12/01/77	\$ 1,391,050
1,600,000	Public Service Company of Oklahoma		3.1500	08/15/51	1,037,066
2,450,000	Wisconsin Public Service Corporation		2.8500	12/01/51	1,525,397
					16,005,685
	<b>ELECTRICAL EQUIPMENT — 1.3%</b>				
1,800,000	Lennox International, Inc.		5.5000	09/15/28	1,822,156
	<b>ENGINEERING &amp; CONSTRUCTION — 2.7%</b>				
850,000	Installed Building Products, Inc. <sup>(a)</sup>		5.7500	02/01/28	832,034
750,000	MasTec, Inc. <sup>(a)</sup>		4.5000	08/15/28	715,953
2,275,000	Quanta Services, Inc.		2.9000	10/01/30	2,007,318
					3,555,305
	<b>HOME CONSTRUCTION — 0.7%</b>				
1,000,000	M/I Homes, Inc.		3.9500	02/15/30	892,590
	<b>INDUSTRIAL SUPPORT SERVICES — 0.4%</b>				
625,000	United Rentals North America, Inc.		4.8750	01/15/28	606,241
	<b>INSTITUTIONAL FINANCIAL SERVICES — 3.0%</b>				
2,225,000	Morgan Stanley <sup>(b)</sup>	SOFRRATE + 0.745%	0.8640	10/21/25	2,190,792
1,900,000	Nasdaq, Inc.		5.3500	06/28/28	1,918,907
					4,109,699
	<b>INSURANCE — 1.4%</b>				
2,175,000	Brown & Brown, Inc.		4.9500	03/17/52	1,862,203
	<b>MACHINERY — 1.1%</b>				
650,000	Mueller Water Products, Inc. <sup>(a)</sup>		4.0000	06/15/29	595,753
1,000,000	Xylem, Inc./NY		1.9500	01/30/28	898,222
					1,493,975
	<b>OIL &amp; GAS PRODUCERS — 3.8%</b>				
2,025,000	Cheniere Energy Partners, L.P.		4.5000	10/01/29	1,930,426
2,000,000	Diamondback Energy, Inc.		3.5000	12/01/29	1,846,389

See accompanying notes to financial statements.

**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 45.3% (Continued)</b>				
	<b>OIL &amp; GAS PRODUCERS — 3.8% (Continued)</b>				
1,500,000	EQT Corporation		5.7500	02/01/34	\$ 1,487,690
					<u>5,264,505</u>
	<b>REAL ESTATE INVESTMENT TRUSTS — 4.3%</b>				
1,700,000	American Tower Corporation		4.0500	03/15/32	1,557,822
2,000,000	Equinix, Inc.		3.9000	04/15/32	1,823,839
700,000	HAT Holdings I, LLC / HAT Holdings II, LLC <sup>(a)</sup>		3.3750	06/15/26	661,131
2,000,000	Welltower OP, LLC		3.8500	06/15/32	1,805,868
					<u>5,848,660</u>
	<b>RETAIL - DISCRETIONARY — 1.7%</b>				
1,250,000	Builders FirstSource, Inc. <sup>(a)</sup>		4.2500	02/01/32	1,106,201
1,250,000	Home Depot, Inc. (The)		5.3000	06/25/54	1,227,460
					<u>2,333,661</u>
	<b>SEMICONDUCTORS — 2.5%</b>				
1,000,000	KLA Corporation		3.3000	03/01/50	708,558
2,200,000	NXP BV/NXP Funding, LLC/NXP USA, Inc.		2.5000	05/11/31	1,848,050
1,100,000	Synaptics, Inc. <sup>(a)</sup>		4.0000	06/15/29	998,622
					<u>3,555,230</u>
	<b>SOFTWARE — 2.3%</b>				
2,000,000	Roper Technologies, Inc.		4.2000	09/15/28	1,934,980
1,250,000	Workday, Inc.		3.7000	04/01/29	1,173,815
					<u>3,108,795</u>
	<b>TECHNOLOGY SERVICES — 1.5%</b>				
1,950,000	Verisk Analytics, Inc.		5.7500	04/01/33	2,007,860
	<b>WHOLESALE - CONSUMER STAPLES — 1.2%</b>				
1,875,000	Sysco Corporation		2.4000	02/15/30	1,626,680
					<u>62,117,315</u>
	<b>TOTAL CORPORATE BONDS (Cost \$65,070,521)</b>				

See accompanying notes to financial statements.

**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>MUNICIPAL BONDS — 9.6%</b>			
	<b>COMBINED UTILITIES — 0.7%</b>			
1,000,000	City of Tacoma, WA Electric System Revenue	5.6410	01/01/27	\$ 1,009,927
	<b>MISCELLANEOUS TAX — 0.7%</b>			
900,000	Commonwealth of Massachusetts	3.6390	07/15/24	899,364
	<b>MULTI-FAMILY HOUSING — 1.4%</b>			
1,800,000	Florida Housing Finance Corporation	5.5610	07/01/49	1,714,888
250,000	Maine State Housing Authority	0.4000	11/15/24	246,653
100,000	New York State Housing Finance Agency	0.7000	11/01/25	94,986
				<u>2,056,527</u>
	<b>SINGLE-FAMILY HOUSING — 5.2%</b>			
1,000,000	Illinois Housing Development Authority	5.6140	10/01/39	995,367
1,825,000	Massachusetts Housing Finance Agency	5.8360	12/01/42	1,809,717
1,495,000	Minnesota Housing Finance Agency	5.9000	01/01/49	1,495,801
389,199	Minnesota Housing Finance Agency	1.5800	02/01/51	292,450
480,000	Texas Department of Housing & Community Affairs	0.5000	07/01/24	480,000
2,000,000	Virginia Housing Development Authority	5.6620	10/01/39	1,992,167
				<u>7,065,502</u>
	<b>STATE — 0.7%</b>			
1,250,000	State of Oregon	2.3370	11/01/33	1,016,202
	<b>WATER AND SEWER — 0.9%</b>			
1,500,000	City of Aurora, CO Water Revenue	2.6260	08/01/41	1,126,212
	<b>TOTAL MUNICIPAL BONDS (Cost \$14,148,754)</b>			<u>13,173,734</u>

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>U.S. GOVERNMENT &amp; AGENCIES — 39.4%</b>			
	<b>AGENCY FIXED RATE — 26.6%</b>			
798,350	Fannie Mae Pool BO9355	3.0000	03/01/50	690,218
1,812,552	Fannie Mae Pool MA4120	2.5000	09/01/50	1,498,717
695,517	Fannie Mae Pool FM4720	3.0000	10/01/50	600,953
1,822,463	Fannie Mae Pool CA8256	2.5000	12/01/50	1,498,198

See accompanying notes to financial statements.

**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Principal Amount (\$)</u>		<u>Coupon Rate (%)</u>	<u>Maturity</u>	<u>Fair Value</u>
<b>U.S. GOVERNMENT &amp; AGENCIES — 39.4% (Continued)</b>				
<b>AGENCY FIXED RATE — 26.6% (Continued)</b>				
1,930,722	Fannie Mae Pool CB0199	3.0000	04/01/51	\$ 1,654,085
651,948	Fannie Mae Pool MA4307	3.0000	04/01/51	559,742
3,049,811	Fannie Mae Pool MA4355	2.0000	06/01/51	2,404,417
1,576,096	Fannie Mae Pool MA4379	2.5000	07/01/51	1,299,022
1,312,376	Fannie Mae Pool MA4600	3.5000	05/01/52	1,165,155
2,118,076	Fannie Mae Pool MA4625	3.5000	06/01/52	1,880,477
2,146,651	Fannie Mae Pool MA4700	4.0000	08/01/52	1,969,697
2,367,072	Fannie Mae Pool MA4805	4.5000	11/01/52	2,237,372
2,275,122	Fannie Mae Pool MA4869	5.5000	01/01/53	2,252,005
1,201,877	Fannie Mae Pool MA4916	4.0000	02/01/53	1,102,383
1,511,991	Freddie Mac Pool SD8090	2.0000	09/01/50	1,197,964
1,675,403	Freddie Mac Pool SD8128	2.0000	02/01/51	1,320,295
1,032,372	Freddie Mac Pool RA5696	2.5000	08/01/51	850,134
1,972,191	Freddie Mac Pool SD8206	3.0000	04/01/52	1,684,043
2,255,038	Freddie Mac Pool RA7587	3.5000	06/01/52	2,015,507
2,046,032	Freddie Mac Pool SD8237	4.0000	08/01/52	1,876,788
2,547,948	Freddie Mac Pool SD8238	4.5000	08/01/52	2,407,405
2,298,670	Freddie Mac Pool SD8288	5.0000	01/01/53	2,228,756
1,143,600	Freddie Mac Pool SD3026	5.0000	06/01/53	1,110,773
1,125,798	Freddie Mac Pool SD8332	6.0000	06/01/53	1,132,743
				36,636,849
<b>GOVERNMENT OWNED, NO GUARANTEE — 5.5%</b>				
1,250,000	Federal Home Loan Mortgage Corporation	5.5000	04/08/27	1,247,714
2,250,000	Federal Home Loan Mortgage Corporation	6.2500	07/15/32	2,524,056
2,300,000	Federal National Mortgage Association	6.2500	05/15/29	2,487,865
1,200,000	Federal National Mortgage Association	5.6250	07/15/37	1,320,631
				7,580,266
<b>GOVERNMENT SPONSORED — 7.3%</b>				
1,250,000	Federal Farm Credit Banks Funding Corporation	5.2300	05/20/26	1,250,040
1,750,000	Federal Farm Credit Banks Funding Corporation	4.3750	02/28/28	1,743,707
1,520,000	Federal Farm Credit Banks Funding Corporation	4.8750	11/01/28	1,547,360
1,500,000	Federal Farm Credit Banks Funding Corporation	4.2500	12/15/28	1,490,918
1,425,000	Federal Farm Credit Banks Funding Corporation	4.5000	03/09/29	1,433,333
1,500,000	Federal Farm Credit Banks Funding Corporation	4.1250	07/05/29	1,483,682

See accompanying notes to financial statements.



**EVENTIDE CORE BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>U.S. GOVERNMENT &amp; AGENCIES — 39.4% (Continued)</b>			
	<b>GOVERNMENT SPONSORED — 7.3% (Continued)</b>			
1,000,000	Federal Farm Credit Banks Funding Corporation	4.3750	10/24/29	\$ 998,346
				<u>9,947,386</u>
	<b>TOTAL U.S. GOVERNMENT &amp; AGENCIES (Cost \$55,757,142)</b>			<u>54,164,501</u>
	<b>TOTAL INVESTMENTS - 97.3% (Cost \$139,132,890)</b>			\$ 133,539,852
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 2.7%</b>			<u>3,765,040</u>
	<b>NET ASSETS - 100.0%</b>			<u>\$ 137,304,892</u>

LLC - Limited Liability Company  
L.P. - Limited Partnership

SOFR30A United States 30 Day Average SOFR Secured Overnight Financing Rate  
SOFRRATE United States SOFR Secured Overnight Financing Rate  
TSFR3M CME Term SOFR 3 Month  
US0003M ICE LIBOR USD 3 Month

- <sup>(a)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2024 the total market value of 144A securities is \$6,687,783 or 4.9% of net assets.
- <sup>(b)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

See accompanying notes to financial statements.

**EVENTIDE DIVIDEND OPPORTUNITIES FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

<u>Shares</u>		<u>Fair Value</u>
	<b>COMMON STOCKS — 97.9%</b>	
	<b>BANKING - 0.9%</b>	
45,077	Pinnacle Financial Partners, Inc.	\$ 3,607,963
95,715	Synovus Financial Corporation	3,846,786
		<u>7,454,749</u>
	<b>BIOTECH &amp; PHARMA - 1.5%</b>	
494,331	Royalty Pharma plc, Class A	<u>13,035,508</u>
	<b>CHEMICALS - 5.5%</b>	
82,851	Cabot Corporation	7,613,178
714,806	Element Solutions, Inc.	19,385,539
69,679	Sherwin-Williams Company (The)	20,794,304
		<u>47,793,021</u>
	<b>COMMERCIAL SUPPORT SERVICES - 1.7%</b>	
302,995	Rollins, Inc.	<u>14,783,126</u>
	<b>CONTAINERS &amp; PACKAGING - 1.2%</b>	
234,998	International Paper Company	<u>10,140,164</u>
	<b>DIVERSIFIED INDUSTRIALS - 2.2%</b>	
252,396	Pentair PLC	<u>19,351,201</u>
	<b>ELECTRIC UTILITIES - 8.2%</b>	
99,796	CMS Energy Corporation	5,940,856
39,229	Constellation Energy Corporation	7,856,392
208,040	Public Service Enterprise Group, Inc.	15,332,548
62,311	Sempra Energy	4,739,375
206,700	Southern Company (The)	16,033,719
240,016	Vistra Corporation	20,636,575
		<u>70,539,465</u>
	<b>ELECTRICAL EQUIPMENT - 10.4%</b>	
571,481	nVent Electric PLC	43,781,159
142,594	Trane Technologies PLC	46,903,444
		<u>90,684,603</u>

See accompanying notes to financial statements.

**EVENTIDE DIVIDEND OPPORTUNITIES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 97.9% (Continued)</b>	
	<b>HOME CONSTRUCTION - 2.4%</b>	
146,785	DR Horton, Inc.	\$ 20,686,410
	<b>INDUSTRIAL REIT - 2.5%</b>	
125,157	EastGroup Properties, Inc.	21,289,206
	<b>INDUSTRIAL SUPPORT SERVICES - 4.9%</b>	
63,870	Applied Industrial Technologies, Inc.	12,390,780
152,690	Ferguson PLC	29,568,419
		<u>41,959,199</u>
	<b>INSTITUTIONAL FINANCIAL SERVICES - 2.7%</b>	
171,711	Houlihan Lokey, Inc.	23,156,945
	<b>INSURANCE - 5.3%</b>	
151,582	Arthur J Gallagher & Company	39,306,729
52,192	RLI Corporation	7,342,892
		<u>46,649,621</u>
	<b>MACHINERY - 1.4%</b>	
58,759	IDEX Corporation	11,822,311
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 5.1%</b>	
131,085	Bruker Corporation	8,364,534
8,189	Mettler-Toledo International, Inc. <sup>(a)</sup>	11,444,865
108,899	STERIS plc	23,907,686
		<u>43,717,085</u>
	<b>OIL &amp; GAS PRODUCERS - 8.4%</b>	
324,473	Coterra Energy, Inc.	8,653,695
30,486	Diamondback Energy, Inc.	6,102,992
236,648	Targa Resources Corporation	30,475,530
641,394	Williams Companies, Inc. (The)	27,259,245
		<u>72,491,462</u>
	<b>RESIDENTIAL REIT - 2.3%</b>	
95,317	AvalonBay Communities, Inc.	19,720,134

See accompanying notes to financial statements.

**EVENTIDE DIVIDEND OPPORTUNITIES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 97.9% (Continued)</b>	
	<b>RETAIL - DISCRETIONARY - 2.8%</b>	
28,434	Group 1 Automotive, Inc.	\$ 8,452,860
60,453	Lithia Motors, Inc.	15,261,359
		<u>23,714,219</u>
	<b>SEMICONDUCTORS - 5.1%</b>	
42,009	KLA Corporation	34,636,841
8,744	Lam Research Corporation	9,311,048
		<u>43,947,889</u>
	<b>SOFTWARE - 7.0%</b>	
66,992	Roper Technologies, Inc.	37,760,711
38,514	Synopsys, Inc. <sup>(a)</sup>	22,918,141
		<u>60,678,852</u>
	<b>SPECIALTY REITS - 2.4%</b>	
239,429	Iron Mountain, Inc.	21,457,627
		<u>21,457,627</u>
	<b>TECHNOLOGY HARDWARE - 2.0%</b>	
133,873	NetApp, Inc.	17,242,842
		<u>17,242,842</u>
	<b>TECHNOLOGY SERVICES - 7.7%</b>	
157,143	CDW Corporation	35,174,889
26,775	MSCI, Inc.	12,898,856
68,709	Verisk Analytics, Inc.	18,520,511
		<u>66,594,256</u>
	<b>TRANSPORTATION &amp; LOGISTICS - 2.0%</b>	
98,400	Old Dominion Freight Line, Inc.	17,377,440
		<u>17,377,440</u>
	<b>WHOLESALE - CONSUMER STAPLES - 0.8%</b>	
94,105	Sysco Corporation	6,718,156
		<u>6,718,156</u>
	<b>WHOLESALE - DISCRETIONARY - 1.5%</b>	
42,791	Pool Corporation	13,150,958
		<u>13,150,958</u>
	<b>TOTAL COMMON STOCKS (Cost \$671,210,649)</b>	<u>846,156,449</u>

See accompanying notes to financial statements.

**EVENTIDE DIVIDEND OPPORTUNITIES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Principal Amount (\$)</u>		<u>Coupon Rate (%)</u>	<u>Maturity</u>	<u>Fair Value</u>
	<b>CORPORATE BONDS — 0.4%</b>			
	<b>ASSET MANAGEMENT — 0.4%</b>			
3,250,000	Vision Fund International <sup>(b),(c),(d)</sup>	5.2600	11/30/25	\$ 3,214,663
	<b>TOTAL CORPORATE BONDS (Cost \$3,250,000)</b>			<u>3,214,663</u>
<u>Shares</u>				<u>Fair Value</u>
	<b>SHORT-TERM INVESTMENTS — 0.0%<sup>(e)</sup></b>			
	<b>MONEY MARKET FUNDS - 0.0% <sup>(e)</sup></b>			
111,652	Fidelity Money Market Government Portfolio, Class I, 5.20% <sup>(f)</sup> (Cost \$111,652)			<u>111,652</u>
	<b>TOTAL INVESTMENTS - 98.3% (Cost \$674,572,301)</b>			<u>\$ 849,482,764</u>
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 1.7%</b>			<u>14,430,906</u>
	<b>NET ASSETS - 100.0%</b>			<u>\$ 863,913,670</u>

MSCI - Morgan Stanley Capital International  
PLC - Public Limited Company  
REIT - Real Estate Investment Trust

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024, was \$3,214,663, representing 0.4% of net assets.

<sup>(c)</sup> Private investment.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> Percentage rounds to less than 0.1%.

<sup>(f)</sup> Rate disclosed is the seven day effective yield as of June 30, 2024.

See accompanying notes to financial statements.

**EVENTIDE EXPONENTIAL TECHNOLOGIES FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 94.7%</b>	
	<b>ADVERTISING &amp; MARKETING - 4.8%</b>	
56,535	Trade Desk, Inc. (The), Class A <sup>(a)</sup>	\$ 5,521,773
	<b>BIOTECH &amp; PHARMA - 3.9%</b>	
29,919	TransMedics Group, Inc. <sup>(a)</sup>	4,506,400
	<b>ELECTRICAL EQUIPMENT - 3.0%</b>	
75,055	NEXTracker, Inc. <sup>(a)</sup>	3,518,578
	<b>INDUSTRIAL INTERMEDIATE PROD - 4.3%</b>	
429,173	Xometry, Inc. <sup>(a)</sup>	4,961,240
	<b>RENEWABLE ENERGY - 1.0%</b>	
4,932	First Solar, Inc. <sup>(a)</sup>	1,111,969
	<b>SEMICONDUCTORS - 19.3%</b>	
27,356	Entegris, Inc.	3,704,002
5,560	KLA Corporation	4,584,276
5,125	Lam Research Corporation	5,457,356
42,313	Lattice Semiconductor Corporation <sup>(a)</sup>	2,453,731
7,448	Monolithic Power Systems, Inc.	6,119,873
		<b>22,319,238</b>
	<b>SOFTWARE - 48.9%</b>	
348,774	Arteris, Inc. <sup>(a)</sup>	2,619,293
1,934	Constellation Software, Inc.	5,547,021
6,475	Crowdstrike Holdings, Inc., Class A <sup>(a)</sup>	2,481,155
47,941	Datadog, Inc., Class A <sup>(a)</sup>	6,217,469
142,791	DoubleVerify Holdings, Inc. <sup>(a)</sup>	2,780,141
212,031	Flywire Corporation <sup>(a)</sup>	3,475,188
67,677	Gitlab, Inc. <sup>(a)</sup>	3,364,900
60,335	Global-e Online Ltd. <sup>(a)</sup>	2,188,350
4,301	HubSpot, Inc. <sup>(a)</sup>	2,536,687
41,693	Mobileye Global, Inc., Class A <sup>(a)</sup>	1,170,948
26,893	Monday.com Ltd. <sup>(a)</sup>	6,474,760
8,967	MongoDB, Inc. <sup>(a)</sup>	2,241,391

See accompanying notes to financial statements.

**EVENTIDE EXPONENTIAL TECHNOLOGIES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 94.7% (Continued)</b>	
	<b>SOFTWARE - 48.9% (Continued)</b>	
44,628	Nutanix, Inc., Class A <sup>(a)</sup>	\$ 2,537,102
11,344	Palo Alto Networks, Inc. <sup>(a)</sup>	3,845,729
47,673	Procore Technologies, Inc. <sup>(a)</sup>	3,161,197
9,887	Synopsys, Inc. <sup>(a)</sup>	5,883,358
		<u>56,524,689</u>
	<b>TECHNOLOGY SERVICES - 9.5%</b>	
279,597	Adyen N.V. - ADR <sup>(a)</sup>	3,318,816
87,502	Nayax Ltd. <sup>(a)</sup>	1,872,543
130,105	Remitly Global, Inc. <sup>(a)</sup>	1,576,873
159,765	Toast, Inc., Class A <sup>(a)</sup>	4,117,143
		<u>10,885,375</u>
	<b>TOTAL COMMON STOCKS (Cost \$82,985,474)</b>	<u>109,349,262</u>

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 0.6%</b>			
	<b>ASSET MANAGEMENT — 0.6%</b>			
750,000	Vision Fund International <sup>(b),(c),(d)</sup>	5.2600	11/30/25	741,845
	<b>TOTAL CORPORATE BONDS (Cost \$750,000)</b>			<u>741,845</u>

Shares		Fair Value
	<b>WARRANT — 0.0%<sup>(f)</sup></b>	
	<b>SOFTWARE - 0.0%<sup>(f)</sup></b>	
1,934	Constellation Software, Inc. (Canada) <sup>(a),(b),(e)</sup>	—
	<b>TOTAL WARRANT (Cost \$—)</b>	<u>—</u>

Shares		Fair Value
	<b>SHORT-TERM INVESTMENTS — 0.0%<sup>(f)</sup></b>	
	<b>MONEY MARKET FUNDS - 0.0%<sup>(f)</sup></b>	
12,517	Fidelity Money Market Government Portfolio, Class I, 5.20% <sup>(g)</sup> (Cost \$12,517)	12,517
		<u>12,517</u>

See accompanying notes to financial statements.

**EVENTIDE EXPONENTIAL TECHNOLOGIES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Contracts<sup>(h)</sup></u>		<u>Counterparty</u>	<u>Expiration Date</u>	<u>Exercise Price</u>	<u>Notional Value</u>	<u>Fair Value</u>
	<b>EQUITY OPTIONS PURCHASED - 0.0%</b> <sup>(f)</sup>					
	<b>CALL OPTIONS PURCHASED - 0.0%</b> <sup>(f)</sup>					
320	Five9, Inc.	IB	07/19/2024	\$ 70	\$ 1,411,200	\$ 4,000
	<b>TOTAL CALL OPTIONS PURCHASED</b> (Cost - \$143,936)					
	<b>TOTAL EQUITY OPTIONS PURCHASED</b> (Cost - \$143,936)					4,000
	<b>TOTAL INVESTMENTS - 95.3%</b> (Cost \$83,891,927)				\$ 110,107,624	
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES - 4.7%</b>					5,378,882
	<b>NET ASSETS - 100.0%</b>				\$ 115,486,506	

ADR - American Depositary Receipt  
 IB - Interactive Brokers  
 LTD - Limited Company  
 N.V. - Naamioze Vennootschap

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024 was \$741,845, representing 0.6% of net assets.

<sup>(c)</sup> Private investment.

<sup>(d)</sup> Restricted security. See Note 6 for additional details.

<sup>(e)</sup> The value of this security has been determined in good faith under policies of the Board of Trustees.

<sup>(f)</sup> Percentage rounds to less than 0.1%.

<sup>(g)</sup> Rate disclosed is the seven day effective yield as of June 30, 2024.

<sup>(h)</sup> Each option contract allows the holder of the option to purchase or sell 100 shares of the underlying security.

See accompanying notes to financial statements.



**EVENTIDE GILEAD FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 97.0%</b>	
	<b>ADVERTISING &amp; MARKETING - 3.6%</b>	
1,223,047	Trade Desk, Inc. (The), Class A <sup>(a)</sup>	\$ 119,455,000
	<b>AUTOMOTIVE - 1.4%</b>	
249,790	Aptiv PLC <sup>(a)</sup>	17,590,212
265,593	Autoliv, Inc.	28,415,795
		<u>46,006,007</u>
	<b>BIOTECH &amp; PHARMA – 15.7%</b>	
2,568,543	Ardelyx, Inc. <sup>(a)</sup>	19,032,904
155,276	Argenx S.E. - ADR <sup>(a)</sup>	66,774,891
439,573	Axsome Therapeutics, Inc. <sup>(a)</sup>	35,385,626
1,759,475	Celldex Therapeutics, Inc. <sup>(a)</sup>	65,118,169
1,344,376	Collegium Pharmaceutical, Inc. <sup>(a)</sup>	43,288,907
1,306,685	Dynavax Technologies Corporation <sup>(a)</sup>	14,674,073
2,299,237	Guardant Health, Inc. <sup>(a)</sup>	66,401,964
1,542,961	Mirum Pharmaceuticals, Inc. <sup>(a)</sup>	52,753,837
1,382,242	Scholar Rock Holding Corporation <sup>(a)</sup>	11,514,076
898,059	TransMedics Group, Inc. <sup>(a)</sup>	135,265,646
3,584,309	Zentalis Pharmaceuticals, Inc. <sup>(a),(b)</sup>	14,659,824
		<u>524,869,917</u>
	<b>COMMERCIAL SUPPORT SERVICES - 6.2%</b>	
1,339,752	Rollins, Inc.	65,366,500
804,000	Waste Connections, Inc.	140,989,440
		<u>206,355,940</u>
	<b>ELECTRIC UTILITIES - 0.5%</b>	
192,155	Vistra Corporation	16,521,487
	<b>ELECTRICAL EQUIPMENT - 7.6%</b>	
703,258	NEXTracker, Inc. <sup>(a)</sup>	32,968,735
125,900	Novanta, Inc. <sup>(a)</sup>	20,535,549
613,600	Trane Technologies PLC	201,831,448
		<u>255,335,732</u>

See accompanying notes to financial statements.

**EVENTIDE GILEAD FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Shares</u>		<u>Fair Value</u>
	<b>COMMON STOCKS — 97.0% (Continued)</b>	
	<b>ENGINEERING &amp; CONSTRUCTION - 1.0%</b>	
125,405	Quanta Services, Inc.	\$ 31,864,156
	<b>FORESTRY, PAPER &amp; WOOD PRODUCTS - 1.4%</b>	
654,102	Trex Company, Inc. <sup>(a)</sup>	48,482,040
	<b>HOME CONSTRUCTION - 2.6%</b>	
622,000	DR Horton, Inc.	87,658,460
	<b>INDUSTRIAL INTERMEDIATE PROD - 1.9%</b>	
5,568,096	Xometry, Inc. <sup>(a),(b)</sup>	64,367,190
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 7.3%</b>	
663,539	Exact Sciences Corporation <sup>(a)</sup>	28,034,523
187,567	IDEXX Laboratories, Inc. <sup>(a)</sup>	91,382,642
75,000	Intuitive Surgical, Inc. <sup>(a)</sup>	33,363,750
63,357	Mettler-Toledo International, Inc. <sup>(a)</sup>	88,547,110
		<u>241,328,025</u>
	<b>OIL &amp; GAS PRODUCERS - 0.9%</b>	
214,336	Targa Resources Corporation	27,602,190
	<b>RENEWABLE ENERGY - 0.3%</b>	
50,261	First Solar, Inc. <sup>(a)</sup>	11,331,845
	<b>RETAIL - DISCRETIONARY - 3.9%</b>	
171,076	Lithia Motors, Inc.	43,188,136
251,791	Lowe's Companies, Inc.	55,509,844
30,033	O'Reilly Automotive, Inc. <sup>(a)</sup>	31,716,650
		<u>130,414,630</u>
	<b>SEMICONDUCTORS - 9.0%</b>	
59,873	ASML Holding N.V.	61,233,913
397,941	Entegris, Inc.	53,881,211
79,558	Lam Research Corporation	84,717,337
512,605	Lattice Semiconductor Corporation <sup>(a)</sup>	29,725,964

See accompanying notes to financial statements.

**EVENTIDE GILEAD FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 97.0% (Continued)</b>	
	<b>SEMICONDUCTORS - 9.0% (Continued)</b>	
90,818	Monolithic Power Systems, Inc.	\$ 74,623,334
		<u>304,181,759</u>
	<b>SOFTWARE — 23.7%</b>	
242,465	CrowdStrike Holdings, Inc., Class A <sup>(a)</sup>	92,910,164
954,252	Datadog, Inc., Class A <sup>(a)</sup>	123,756,943
1,162,238	DoubleVerify Holdings, Inc. <sup>(a)</sup>	22,628,774
2,284,740	Evolent Health, Inc., Class A <sup>(a)</sup>	43,684,229
577,271	Five9, Inc. <sup>(a)</sup>	25,457,651
2,848,666	Flywire Corporation <sup>(a)</sup>	46,689,636
909,349	Gitlab, Inc. <sup>(a)</sup>	45,212,832
918,794	Global-e Online Ltd. <sup>(a)</sup>	33,324,658
112,234	HubSpot, Inc. <sup>(a)</sup>	66,194,491
629,209	Mobileye Global, Inc., Class A <sup>(a)</sup>	17,671,335
290,798	Monday.com Ltd. <sup>(a)</sup>	70,012,526
537,718	Nutanix, Inc., Class A <sup>(a)</sup>	30,569,268
203,208	Palo Alto Networks, Inc. <sup>(a)</sup>	68,889,544
159,400	Roper Technologies, Inc.	89,847,405
89,331	Workday, Inc., Class A <sup>(a)</sup>	19,970,838
		<u>796,820,294</u>
	<b>TECHNOLOGY SERVICES - 3.1%</b>	
9,100	Adyen N.V. <sup>(a)</sup>	10,851,762
1,132,371	Remitly Global, Inc. <sup>(a)</sup>	13,724,337
3,063,288	Toast, Inc., Class A <sup>(a)</sup>	78,940,931
		<u>103,517,030</u>
	<b>TRANSPORTATION &amp; LOGISTICS - 3.6%</b>	
220,000	GXO Logistics, Inc. <sup>(a)</sup>	11,110,000
618,706	Old Dominion Freight Line, Inc.	109,263,480
		<u>120,373,480</u>

See accompanying notes to financial statements.

**EVENTIDE GILEAD FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 97.0% (Continued)</b>	
	<b>WHOLESALE - DISCRETIONARY - 3.3%</b>	
710,725	Copart, Inc. <sup>(a)</sup>	\$ 38,492,866
237,000	Pool Corporation	72,837,210
		<u>111,330,076</u>
	<b>TOTAL COMMON STOCKS (Cost \$2,044,787,707)</b>	<u>3,247,815,258</u>

Shares		Fair Value
	<b>CONTINGENT VALUE RIGHTS — 0.1%</b>	
	<b>BIOTECH &amp; PHARMA - 0.1%</b>	
3,982,940	Peloton Therapeutics, Inc. - CVR <sup>(a),(c),(d),(e),(f)</sup>	3,365,186
		<u>3,365,186</u>
	<b>TOTAL CONTINGENT VALUE RIGHTS (Cost \$--)</b>	<u>3,365,186</u>

Shares		Fair Value
	<b>PRIVATE INVESTMENTS — 1.2%</b>	
	<b>BIOTECH &amp; PHARMA — 0.2%</b>	
228,572	Mirum Pharmaceuticals, Inc. PIPE <sup>(a),(b),(c),(f)</sup>	7,814,877
		<u>7,814,877</u>
	<b>MEDICAL EQUIPMENT &amp; DEVICES — 1.0%</b>	
1,881,321	Beta Bionics, Inc. Series B <sup>(a),(b),(c),(d),(e),(f)</sup>	14,072,281
665,474	Beta Bionics, Inc. Series B2 <sup>(a),(b),(c),(d),(e),(f)</sup>	5,064,257
964,052	Beta Bionics, Inc. Series C <sup>(a),(b),(c),(d),(e),(f)</sup>	7,133,985
714,286	Beta Bionics, Inc. Series D <sup>(a),(b),(c),(d),(e),(f)</sup>	6,621,431
		<u>32,891,954</u>
	<b>TOTAL PRIVATE INVESTMENTS (Cost \$49,399,904)</b>	<u>40,706,831</u>

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 1.2%</b>			
	<b>ASSET MANAGEMENT — 1.2%</b>			
12,000,000	Calvert Impact Capital, Inc. <sup>(c)</sup>	1.5000	11/15/24	12,000,000
2,000,000	Hope Global International <sup>(c),(e),(f)</sup>	4.0000	01/07/28	1,868,542
5,000,000	Vision Fund International <sup>(c),(e),(f)</sup>	5.9030	09/19/25	4,988,200
9,000,000	Vision Fund International <sup>(c),(e),(f)</sup>	5.2600	11/30/25	8,902,143
5,000,000	Vision Fund International <sup>(c),(e),(f)</sup>	3.1500	12/15/25	4,796,460

See accompanying notes to financial statements.

**EVENTIDE GILEAD FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Principal Amount (\$)</u>		<u>Coupon Rate (%)</u>	<u>Maturity</u>	<u>Fair Value</u>
	<b>CORPORATE BONDS — 1.2% (Continued)</b>			
	<b>ASSET MANAGEMENT — 1.2% (Continued)</b>			
5,000,000	Vision Fund International <sup>(c),(e),(f)</sup>	3.2230	12/15/26	\$ 4,681,510
5,000,000	Vision Fund International <sup>(c),(e),(f)</sup>	4.7400	05/16/25	4,941,120
				<u>42,177,975</u>
	<b>TOTAL CORPORATE BONDS (Cost \$43,000,000)</b>			<u>42,177,975</u>
				<u>Fair Value</u>
	<b>WARRANT — 0.2%</b>			
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 0.2%</b>			
241,013	Beta Bionics, Inc. Series C Warrant <sup>(a),(b),(c),(d),(e),(f)</sup>			1,783,496
500,000	Beta Bionics, Inc. Series D Warrant <sup>(a),(b),(c),(d),(e),(f)</sup>			3,350,000
				<u>5,133,496</u>
	<b>TOTAL WARRANT (Cost \$-)</b>			<u>5,133,496</u>
				<u>Fair Value</u>
	<b>SHORT-TERM INVESTMENTS — 0.2%</b>			
	<b>MONEY MARKET FUNDS - 0.2%</b>			
5,197,620	Fidelity Money Market Government Portfolio, Class I, 5.20% <sup>(g)</sup> (Cost \$5,197,620)			5,197,620
				<u>5,197,620</u>
	<b>TOTAL INVESTMENTS - 99.9% (Cost \$2,142,385,231)</b>			\$ 3,344,396,366
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 0.1%</b>			4,940,764
	<b>NET ASSETS - 100.0%</b>			<u>\$ 3,349,337,130</u>

ADR	- American Depositary Receipt
CVR	- Contingent Value Rights
LTD	- Limited Company
NV	- Naamioze Vennootschap
PIPE	- Private Investment in Public Equity
PLC	- Public Limited Company

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Affiliated Company – Eventide Gilead Fund holds in excess of 5% of outstanding voting securities of this security.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024 was \$91,383,488, representing 2.7% of net assets.

<sup>(d)</sup> The value of this security has been determined in good faith under policies of the Board of Trustees.

<sup>(e)</sup> Private investment.

<sup>(f)</sup> Restricted security. See Note 6 for additional details.

<sup>(g)</sup> Rate disclosed is the seven day effective yield as of June 30, 2024.

See accompanying notes to financial statements.

**EVENTIDE HEALTHCARE & LIFE SCIENCES FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 88.9%</b>	
	<b>BIOTECH &amp; PHARMA — 74.6%</b>	
881,157	4D Molecular Therapeutics, Inc. <sup>(a)</sup>	\$ 18,495,485
87,000	Alnylam Pharmaceuticals, Inc. <sup>(a)</sup>	21,141,000
568,324	AnaptysBio, Inc. <sup>(a)</sup>	14,242,199
209,794	Apellis Pharmaceuticals, Inc. <sup>(a)</sup>	8,047,698
4,087,881	Ardelyx, Inc. <sup>(a)</sup>	30,291,198
63,059	Argenx S.E. - ADR <sup>(a)</sup>	27,117,893
463,894	Arrowhead Pharmaceuticals, Inc. <sup>(a)</sup>	12,056,605
5,802,682	Aura Biosciences, Inc. <sup>(a),(b)</sup>	43,868,276
375,924	Avidity Biosciences, Inc. <sup>(a)</sup>	15,356,495
497,354	Axsome Therapeutics, Inc. <sup>(a)</sup>	40,036,997
634,664	Biohaven Ltd. <sup>(a)</sup>	22,029,187
231,685	Blueprint Medicines Corporation <sup>(a)</sup>	24,971,009
579,414	Bridgebio Pharma, Inc. <sup>(a)</sup>	14,676,557
1,560,598	Celldex Therapeutics, Inc. <sup>(a)</sup>	57,757,731
490,000	Cerevel Therapeutics Holdings, Inc. <sup>(a)</sup>	20,036,100
1,398,992	Cogent Biosciences, Inc. <sup>(a)</sup>	11,793,503
1,285,217	Collegium Pharmaceutical, Inc. <sup>(a)</sup>	41,383,987
735,088	Crinetics Pharmaceuticals, Inc. <sup>(a)</sup>	32,924,592
254,148	Cytokinetics, Inc. <sup>(a)</sup>	13,769,739
1,585,771	Dynavax Technologies Corporation <sup>(a)</sup>	17,808,208
485,000	Dyne Therapeutics, Inc. <sup>(a)</sup>	17,115,650
6,356,182	Geron Corporation <sup>(a)</sup>	26,950,212
1,452,334	Guardant Health, Inc. <sup>(a)</sup>	41,943,406
335,000	Ideaya Biosciences, Inc. <sup>(a)</sup>	11,761,850
3,936,220	Inozyme Pharma, Inc. <sup>(a),(b)</sup>	17,555,541
675,185	Insmmed, Inc. <sup>(a)</sup>	45,237,395
499,208	Keros Therapeutics, Inc. <sup>(a)</sup>	22,813,806
160,047	Korro Bio, Inc. <sup>(a)</sup>	5,420,792
136,485	Krystal Biotech, Inc. <sup>(a)</sup>	25,064,105
462,099	Kymera Therapeutics, Inc. <sup>(a)</sup>	13,793,655

See accompanying notes to financial statements.

**EVENTIDE HEALTHCARE & LIFE SCIENCES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 88.9% (Continued)</b>	
	<b>BIOTECH &amp; PHARMA — 74.6% (Continued)</b>	
2,081,301	Lexeo Therapeutics, Inc. <sup>(a),(b)</sup>	\$ 33,384,068
133,333	Metagenomi, Inc. <sup>(a)</sup>	543,999
1,684,814	Mirum Pharmaceuticals, Inc. <sup>(a)</sup>	57,603,790
7,529,096	Nektar Therapeutics <sup>(a)</sup>	9,336,079
2,378	Ocular Therapeutix, Inc. <sup>(a)</sup>	16,266
50,000	Rapport Therapeutics, Inc. <sup>(a)</sup>	1,163,000
650,826	REVOLUTION Medicines, Inc. <sup>(a)</sup>	25,258,557
770,691	Rocket Pharmaceuticals, Inc. <sup>(a)</sup>	16,592,977
228,529	Sarepta Therapeutics, Inc. <sup>(a)</sup>	36,107,582
1,686,602	Scholar Rock Holding Corporation <sup>(a)</sup>	14,049,395
718,814	TG Therapeutics, Inc. <sup>(a)</sup>	12,787,701
214,000	TransMedics Group, Inc. <sup>(a)</sup>	32,232,680
458,317	Turnstone Biologics Corporation <sup>(a)</sup>	1,200,791
67,825	United Therapeutics Corporation <sup>(a)</sup>	21,605,654
739,153	Vaxcyte, Inc. <sup>(a)</sup>	55,813,443
527,781	Verona Pharma plc - ADR <sup>(a)</sup>	7,631,713
252,969	Viking Therapeutics, Inc. <sup>(a)</sup>	13,409,887
4,948,595	Zentalis Pharmaceuticals, Inc. <sup>(a),(b)</sup>	20,239,754
		<u>1,074,438,207</u>
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 11.1%</b>	
1,535,000	Celcuity, Inc. <sup>(a)</sup>	25,143,300
565,546	Exact Sciences Corporation <sup>(a)</sup>	23,894,319
63,542	Glaukos Corporation <sup>(a)</sup>	7,520,196
619,649	Inari Medical, Inc. <sup>(a)</sup>	29,836,098
125,090	Inspire Medical Systems, Inc. <sup>(a)</sup>	16,740,795
272,092	iRhythm Technologies, Inc. <sup>(a)</sup>	29,287,983
119,000	Repligen Corporation <sup>(a)</sup>	15,001,140
564,000	Veracyte, Inc. <sup>(a)</sup>	12,221,880
		<u>159,645,711</u>

See accompanying notes to financial statements.

**EVENTIDE HEALTHCARE & LIFE SCIENCES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 88.9% (Continued)</b>	
	<b>SOFTWARE - 3.2%</b>	
1,445,064	Evotent Health, Inc., Class A <sup>(a)</sup>	\$ 27,629,623
76,207	Privia Health Group, Inc. <sup>(a)</sup>	1,324,478
1,375,980	R1 RCM, Inc. <sup>(a)</sup>	17,282,309
		<u>46,236,410</u>
	<b>TOTAL COMMON STOCKS (Cost \$1,150,698,424)</b>	<u>1,280,320,328</u>
Shares		Fair Value
	<b>CONTINGENT VALUE RIGHTS — 0.1%</b>	
	<b>BIOTECH &amp; PHARMA - 0.1%</b>	
1,528,871	Peloton Therapeutics, Inc. - CVR <sup>(a),(c),(d),(e),(f)</sup>	1,291,743
		<u>1,291,743</u>
	<b>TOTAL CONTINGENT VALUE RIGHTS (Cost \$—)</b>	<u>1,291,743</u>
Shares		Fair Value
	<b>PRIVATE INVESTMENTS — 7.2%</b>	
	<b>BIOTECH &amp; PHARMA — 5.7%</b>	
4,643,043	Arch Oncology, Inc. Series C1 <sup>(a),(c),(d),(e),(f)</sup>	128,798
20,482,289	Avalyn Pharma Inc. Series C1 <sup>(a),(c),(d),(e),(f)</sup>	15,000,000
295,276	BioSplice Therapeutics, Inc. Series B-1 <sup>(a),(c),(d),(e),(f)</sup>	—
137,513	Bridgebio Pharma Inc. PIPE <sup>(a),(c),(e),(f),(g)</sup>	3,483,204
5,000,000	Casma Therapeutics, Inc. Series B1 <sup>(a),(b),(c),(d),(e),(f)</sup>	1,046,500
5,000,000	Casma Therapeutics, Inc. Series B2 <sup>(a),(b),(c),(d),(e),(f)</sup>	1,046,500
1,820,413	Casma Therapeutics, Inc. Series C1 <sup>(a),(b),(c),(d),(e),(f)</sup>	381,013
1,979,882	Casma Therapeutics, Inc. Series C2 <sup>(a),(b),(c),(d),(e),(f)</sup>	414,389
1,017,770	Evida BioSciences, Inc. <sup>(a),(b),(c),(d),(e),(f)</sup>	702,261
1,097,561	Flare Therapeutics, Inc. Series A <sup>(a),(c),(d),(e),(f)</sup>	1,320,366
902,439	Flare Therapeutics, Inc. Series A2 <sup>(a),(c),(d),(e),(f)</sup>	1,085,634
1,952,962	Flare Therapeutics, Inc. Series B <sup>(a),(c),(d),(e),(f)</sup>	2,349,413
930,436	Freenome Holdings, Inc. Series D <sup>(a),(c),(d),(e),(f)</sup>	1,526,101
133,941	Freenome Holdings, Inc. Series F <sup>(a),(c),(d),(e),(f)</sup>	219,690
5,000,000	Goldfinch Biopharma, Inc. Series A <sup>(a),(b),(c),(d),(e),(f)</sup>	—
8,474,576	Goldfinch Biopharma, Inc. Series B <sup>(a),(b),(c),(d),(e),(f)</sup>	—
4,237,288	Goldfinch Biopharma, Inc. Series B2 <sup>(a),(b),(c),(d),(e),(f)</sup>	—

See accompanying notes to financial statements.



**EVENTIDE HEALTHCARE & LIFE SCIENCES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Shares</u>				<u>Fair Value</u>
	<b>PRIVATE INVESTMENTS — 7.2% (Continued)</b>			
	<b>BIOTECH &amp; PHARMA — 5.7% (Continued)</b>			
763,319	Kojin Therapeutics, Inc. Series A-1 <sup>(a),(c),(d),(e),(f)</sup>			\$ 467,228
763,319	Kojin Therapeutics, Inc. Series A-2 <sup>(a),(c),(d),(e),(f)</sup>			467,228
369,108	Korro Bio, Inc. <sup>(a),(b),(c),(f)</sup>			12,501,688
1,287,846	Lexeo Therapeutics, Inc. <sup>(a),(b),(c),(f)</sup>			20,657,050
449,708	Metagenomi, Inc. <sup>(a),(c),(f)</sup>			1,834,809
152,381	Mirum Pharmaceuticals, Inc. PIPE <sup>(a),(b),(c),(e),(f)</sup>			5,209,906
1,489,958	Shoreline Biosciences Series B <sup>(a),(c),(d),(e),(f)</sup>			12,673,435
				<u>82,515,213</u>
	<b>MEDICAL EQUIPMENT &amp; DEVICES — 1.5%</b>			
940,660	Beta Bionics, Inc. Series B <sup>(a),(b),(c),(d),(e),(f)</sup>			7,036,136
809,360	Beta Bionics, Inc. Series B2 <sup>(a),(b),(c),(d),(e),(f)</sup>			6,159,230
482,026	Beta Bionics, Inc. Series C <sup>(a),(b),(c),(d),(e),(f)</sup>			3,566,992
476,190	Beta Bionics, Inc. Series D <sup>(a),(b),(c),(d),(e),(f)</sup>			4,414,281
				<u>21,176,639</u>
	<b>TOTAL PRIVATE INVESTMENTS (Cost \$181,463,490)</b>			<u>103,691,852</u>
<u>Principal Amount (\$)</u>		<u>Coupon Rate (%)</u>	<u>Maturity</u>	<u>Fair Value</u>
	<b>CONVERTIBLE BONDS — 0.0%<sup>(h)</sup></b>			
	<b>BIOTECH &amp; PHARMA — 0.0%<sup>(h)</sup></b>			
3,500,000	Biosplice Therapeutics, Inc. Series C PIK <sup>(c),(d),(e),(f)</sup>	1.0500	03/12/25	394,520
	<b>TOTAL CONVERTIBLE BONDS (Cost \$3,500,000)</b>			<u>394,520</u>
<u>Shares</u>				<u>Fair Value</u>
	<b>WARRANT — 0.2%</b>			
	<b>BIOTECH &amp; PHARMA - 0.0%<sup>(h)</sup></b>			
103,150	Biosplice Therapeutics, Inc. Series C Warrant <sup>(a),(c),(d),(e),(f)</sup>			—

See accompanying notes to financial statements.

**EVENTIDE HEALTHCARE & LIFE SCIENCES FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>WARRANT — 0.2% (Continued)</b>	
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 0.2%</b>	
120,500	Beta Bionics, Inc. Series C Warrant <sup>(a),(b),(c),(d),(e),(f)</sup>	\$ 891,700
333,333	Beta Bionics, Inc. Series D Warrant <sup>(a),(b),(c),(d),(e),(f)</sup>	2,233,331
		<u>3,125,031</u>
	<b>TOTAL WARRANT (Cost \$-)</b>	<u>3,125,031</u>
	<b>SHORT-TERM INVESTMENTS — 0.3%</b>	
	<b>MONEY MARKET FUNDS – 0.3%</b>	
3,394,275	Fidelity Money Market Government Portfolio, Class I, 5.20% <sup>(i)</sup> (Cost \$3,394,275)	<u>3,394,275</u>
	<b>TOTAL INVESTMENTS – 96.7% (Cost \$1,339,056,189)</b>	\$ 1,392,217,749
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 3.3%</b>	<u>47,698,000</u>
	<b>NET ASSETS - 100.0%</b>	<u>\$ 1,439,915,749</u>

ADR	- American Depositary Receipt
CVR	- Contingent Value Rights
LLC	- Limited Liability Company
LTD	- Limited Company
PIK	- Payment in Kind
PIPE	- Private Investment in Public Equity
PLC	- Public Limited Company

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Affiliated Company – Eventide Healthcare & Life Sciences Fund holds in excess of 5% of outstanding voting securities of this security.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024 was \$108,503,146, representing 7.5% of net assets.

<sup>(d)</sup> The value of this security has been determined in good faith under policies of the Board of Trustees.

<sup>(e)</sup> Private investment.

<sup>(f)</sup> Restricted security. See Note 6 for additional details.

<sup>(g)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2024 the total market value of 144A securities is \$3,483,204 or 0.2% of net assets.

<sup>(h)</sup> Percentage rounds to less than 0.1%.

<sup>(i)</sup> Rate disclosed is the seven day effective yield as of June 30, 2024.

See accompanying notes to financial statements.

**EVENTIDE LARGE CAP FOCUS FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 96.8%</b>	
	<b>ADVERTISING &amp; MARKETING - 1.7%</b>	
18,781	Trade Desk, Inc. (The), Class A <sup>(a)</sup>	\$ 1,834,340
	<b>BIOTECH &amp; PHARMA - 6.2%</b>	
7,150	Amgen, Inc.	2,234,018
1,180	Eli Lilly & Company	1,068,348
122,989	Royalty Pharma plc, Class A	3,243,220
		<u>6,545,586</u>
	<b>CHEMICALS - 8.8%</b>	
13,363	Linde plc	5,863,818
11,842	Sherwin-Williams Company (The)	3,534,008
		<u>9,397,826</u>
	<b>COMMERCIAL SUPPORT SERVICES - 1.5%</b>	
8,124	Republic Services, Inc.	1,578,818
	<b>CONTAINERS &amp; PACKAGING - 0.9%</b>	
22,018	International Paper Company	950,077
	<b>ELECTRIC UTILITIES - 6.0%</b>	
6,474	Constellation Energy Corporation	1,296,548
22,140	Public Service Enterprise Group, Inc.	1,631,718
44,200	Southern Company (The)	3,428,594
		<u>6,356,860</u>
	<b>ELECTRICAL EQUIPMENT - 5.6%</b>	
30,420	Otis Worldwide Corporation	2,928,229
9,077	Trane Technologies PLC	2,985,697
		<u>5,913,926</u>
	<b>HOME CONSTRUCTION - 3.2%</b>	
24,279	DR Horton, Inc.	3,421,639
	<b>INDUSTRIAL SUPPORT SERVICES - 3.4%</b>	
18,835	Ferguson PLC	3,647,398

See accompanying notes to financial statements.

**EVENTIDE LARGE CAP FOCUS FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

<u>Shares</u>		<u>Fair Value</u>
	<b>COMMON STOCKS — 96.8% (Continued)</b>	
	<b>INSTITUTIONAL FINANCIAL SERVICES - 2.3%</b>	
18,211	Houlihan Lokey, Inc.	\$ 2,455,935
	<b>INSURANCE - 1.9%</b>	
7,931	Arthur J Gallagher & Company	2,056,588
	<b>MEDICAL EQUIPMENT &amp; DEVICES - 2.3%</b>	
1,781	Mettler-Toledo International, Inc. <sup>(a)</sup>	2,489,108
	<b>OIL &amp; GAS PRODUCERS - 5.8%</b>	
21,238	EOG Resources, Inc.	2,673,227
81,412	Williams Companies, Inc. (The)	3,460,010
		<u>6,133,237</u>
	<b>RETAIL - DISCRETIONARY - 9.6%</b>	
5,955	Group 1 Automotive, Inc.	1,770,302
5,267	Home Depot, Inc. (The)	1,813,112
5,338	Lithia Motors, Inc.	1,347,578
7,991	Lowe's Companies, Inc.	1,761,696
3,282	O'Reilly Automotive, Inc. <sup>(a)</sup>	3,465,990
		<u>10,158,678</u>
	<b>SEMICONDUCTORS - 14.2%</b>	
2,547	KLA Corporation	2,100,027
5,010	Lam Research Corporation	5,334,899
8,482	Micron Technology, Inc.	1,115,637
17,819	NVIDIA Corporation	2,201,359
24,688	Taiwan Semiconductor Manufacturing Company Ltd. - ADR	4,291,021
		<u>15,042,943</u>
	<b>SOFTWARE - 13.5%</b>	
15,183	Datadog, Inc., Class A <sup>(a)</sup>	1,969,083
3,573	Intuit, Inc.	2,348,211
35,717	Nutanix, Inc., Class A <sup>(a)</sup>	2,030,511
5,751	Roper Technologies, Inc.	3,241,610
2,117	ServiceNow, Inc. <sup>(a)</sup>	1,665,380
2,412	Synopsys, Inc. <sup>(a)</sup>	1,435,285

See accompanying notes to financial statements.

**EVENTIDE LARGE CAP FOCUS FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Shares		Fair Value
	<b>COMMON STOCKS — 96.8% (Continued)</b>	
	<b>SOFTWARE - 13.5% (Continued)</b>	
7,112	Workday, Inc., Class A <sup>(a)</sup>	\$ 1,589,959
		<u>14,280,039</u>
	<b>TECHNOLOGY HARDWARE - 2.0%</b>	
16,400	NetApp, Inc.	<u>2,112,320</u>
	<b>TECHNOLOGY SERVICES - 5.6%</b>	
4,477	CDW Corporation	1,002,132
11,146	S&P Global, Inc.	4,971,116
		<u>5,973,248</u>
	<b>TRANSPORTATION &amp; LOGISTICS - 2.3%</b>	
5,349	Old Dominion Freight Line, Inc.	944,633
6,628	Union Pacific Corporation	1,499,652
		<u>2,444,285</u>
	<b>TOTAL COMMON STOCKS (Cost \$95,268,290)</b>	<u>102,792,851</u>
	<b>WARRANT — 0.0%<sup>(b)</sup></b>	
	<b>SOFTWARE - 0.0%<sup>(b)</sup></b>	
252	Constellation Software, Inc. (Canada) <sup>(a),(c),(d)</sup>	—
	<b>TOTAL WARRANT (Cost \$—)</b>	<u>—</u>
	<b>TOTAL INVESTMENTS - 96.8% (Cost \$95,268,290)</b>	\$ 102,792,851
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 3.2%</b>	<u>3,390,332</u>
	<b>NET ASSETS - 100.0%</b>	<u>\$ 106,183,183</u>

ADR - American Depositary Receipt  
LTD - Limited Company  
PLC - Public Limited Company

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Percentage rounds to less than 0.1%.

<sup>(c)</sup> Illiquid security. The total fair value of these securities as of June 30, 2024, was \$0, representing 0.0% of net assets.

<sup>(d)</sup> The value of this security has been determined in good faith under policies of the Board of Trustees.

See accompanying notes to financial statements.

**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>ASSET BACKED SECURITIES — 4.7%</b>				
	<b>AUTO LOAN — 3.3%</b>				
2,600,000	CarMax Auto Owner Trust Series 2020-4 C		1.3000	08/17/26	\$ 2,545,766
1,000,000	CarMax Auto Owner Trust Series 2021-2 C		1.3400	02/16/27	959,894
1,500,000	CarMax Auto Owner Trust Series 2021-2 D		1.5500	10/15/27	1,438,868
					4,944,528
	<b>OTHER ABS — 1.4%</b>				
1,975,000	PFS Financing Corporation Series C A <sup>(a),(b)</sup>	SOFR30A + 0.800%	6.1330	04/17/28	1,978,437
	<b>TOTAL ASSET BACKED SECURITIES (Cost \$7,085,146)</b>				
					6,922,965

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 63.0%</b>				
	<b>AUTOMOTIVE — 1.8%</b>				
1,250,000	Dana, Inc.		4.2500	09/01/30	1,092,228
1,500,000	Honda Motor Company Ltd.		2.2710	03/10/25	1,467,233
					2,559,461
	<b>BANKING — 5.9%</b>				
3,000,000	Bank of America Corporation Series N <sup>(b)</sup>	TSFR3M + 1.132%	2.4560	10/22/25	2,969,129
2,975,000	JPMorgan Chase & Company <sup>(b)</sup>	SOFRRATE + 1.330%	6.0700	10/22/27	3,027,722
2,750,000	Royal Bank of Canada		1.1500	07/14/26	2,535,245
					8,532,096
	<b>BIOTECH &amp; PHARMA — 1.3%</b>				
2,000,000	Zoetis, Inc.		3.9000	08/20/28	1,911,116
	<b>CONSTRUCTION MATERIALS — 0.9%</b>				
1,350,000	Advanced Drainage Systems, Inc. <sup>(a)</sup>		5.0000	09/30/27	1,321,812
	<b>ELECTRIC UTILITIES — 11.4%</b>				
2,000,000	AES Corporation (The)		1.3750	01/15/26	1,874,887
1,500,000	Avangrid, Inc.		3.1500	12/01/24	1,483,702
2,000,000	Constellation Energy Generation, LLC		5.6000	03/01/28	2,027,490
2,500,000	Duke Energy Florida, LLC		2.5000	12/01/29	2,208,733
1,525,000	Georgia Power Company Series 2016-A		3.2500	04/01/26	1,474,713
2,650,000	MidAmerican Energy Company		3.1000	05/01/27	2,529,189

See accompanying notes to financial statements.

**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 63.0% (Continued)</b>				
	<b>ELECTRIC UTILITIES — 11.4% (Continued)</b>				
2,500,000	National Rural Utilities Cooperative Finance		4.8500	02/07/29	\$ 2,486,943
1,000,000	NextEra Energy Capital Holdings, Inc.		4.9000	02/28/28	991,214
1,650,000	NextEra Energy Capital Holdings, Inc. <sup>(b)</sup>	US0003M + 2.409%	4.8000	12/01/77	1,530,155
					16,607,026
	<b>ELECTRICAL EQUIPMENT — 1.6%</b>				
2,350,000	Lennox International, Inc.		5.5000	09/15/28	2,378,926
	<b>ENGINEERING &amp; CONSTRUCTION — 3.7%</b>				
1,425,000	Installed Building Products, Inc. <sup>(a)</sup>		5.7500	02/01/28	1,394,881
1,850,000	MasTec, Inc. <sup>(a)</sup>		4.5000	08/15/28	1,766,018
1,500,000	Quanta Services, Inc.		0.9500	10/01/24	1,480,822
825,000	Quanta Services, Inc.		2.9000	10/01/30	727,928
					5,369,649
	<b>FORESTRY, PAPER &amp; WOOD PRODUCTS — 0.9%</b>				
1,375,000	Louisiana-Pacific Corporation <sup>(a)</sup>		3.6250	03/15/29	1,248,943
	<b>HOME &amp; OFFICE PRODUCTS — 0.8%</b>				
1,250,000	Tempur Sealy International, Inc. <sup>(a)</sup>		4.0000	04/15/29	1,129,106
	<b>HOME CONSTRUCTION — 1.0%</b>				
1,500,000	M/I Homes, Inc.		4.9500	02/01/28	1,448,084
	<b>INDUSTRIAL SUPPORT SERVICES — 0.9%</b>				
1,450,000	United Rentals North America, Inc.		3.8750	11/15/27	1,370,919
	<b>INSTITUTIONAL FINANCIAL SERVICES — 3.8%</b>				
3,000,000	Morgan Stanley <sup>(b)</sup>	SOFRRATE + 0.745%	0.8640	10/21/25	2,953,878
2,500,000	Nasdaq, Inc.		5.3500	06/28/28	2,524,877
					5,478,755
	<b>INSURANCE — 4.2%</b>				
2,750,000	Aflac, Inc.		1.1250	03/15/26	2,568,873
2,300,000	Brown & Brown, Inc.		4.2000	09/15/24	2,290,535

See accompanying notes to financial statements.

**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 63.0% (Continued)</b>				
	<b>INSURANCE — 4.2% (Continued)</b>				
1,425,000	Pacific Life Global Funding II <sup>(a)</sup>		1.3750	04/14/26	\$ 1,331,617
					<u>6,191,025</u>
	<b>MACHINERY — 2.3%</b>				
1,500,000	Mueller Water Products, Inc. <sup>(a)</sup>		4.0000	06/15/29	1,374,815
2,250,000	Xylem, Inc./NY		1.9500	01/30/28	2,020,998
					<u>3,395,813</u>
	<b>OIL &amp; GAS PRODUCERS — 3.9%</b>				
2,200,000	Cheniere Energy Partners, L.P.		4.5000	10/01/29	2,097,253
2,400,000	Diamondback Energy, Inc.		3.5000	12/01/29	2,215,667
1,400,000	EQT Corporation		5.7000	04/01/28	1,414,734
					<u>5,727,654</u>
	<b>REAL ESTATE INVESTMENT TRUSTS — 6.5%</b>				
1,675,000	Alexandria Real Estate Equities, Inc.		3.8000	04/15/26	1,628,395
2,000,000	American Tower Corporation		5.2500	07/15/28	1,997,634
2,250,000	Equinix, Inc.		1.5500	03/15/28	1,969,432
1,650,000	HAT Holdings I, LLC / HAT Holdings II, LLC <sup>(a)</sup>		3.3750	06/15/26	1,558,381
2,500,000	Welltower OP, LLC		2.7000	02/15/27	2,357,109
					<u>9,510,951</u>
	<b>RETAIL - DISCRETIONARY — 5.5%</b>				
1,500,000	Asbury Automotive Group, Inc.		4.5000	03/01/28	1,423,398
2,500,000	AutoZone, Inc.		4.5000	02/01/28	2,446,812
1,500,000	Builders FirstSource, Inc. <sup>(a)</sup>		5.0000	03/01/30	1,421,002
1,650,000	Home Depot, Inc. (The)		4.8750	06/25/27	1,647,418
1,000,000	Patrick Industries, Inc. <sup>(a)</sup>		7.5000	10/15/27	1,011,028
					<u>7,949,658</u>
	<b>SEMICONDUCTORS — 2.0%</b>				
1,725,000	NXP BV / NXP Funding, LLC / NXP USA, Inc.		2.5000	05/11/31	1,449,039
1,625,000	Synaptics, Inc. <sup>(a)</sup>		4.0000	06/15/29	1,475,237
					<u>2,924,276</u>
	<b>SOFTWARE — 3.0%</b>				
2,550,000	Roper Technologies, Inc.		4.2000	09/15/28	2,467,099
2,000,000	Workday, Inc.		3.5000	04/01/27	1,914,154
					<u>4,381,253</u>

See accompanying notes to financial statements.



**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>CORPORATE BONDS — 63.0% (Continued)</b>				
	<b>TECHNOLOGY SERVICES — 0.2%</b>				
281,000	Verisk Analytics, Inc.		4.0000	06/15/25	\$ 276,456
	<b>WHOLESALE - CONSUMER STAPLES — 1.4%</b>				
1,000,000	Sysco Corporation		3.7500	10/01/25	979,246
1,250,000	Sysco Corporation		2.4000	02/15/30	1,084,453
					<u>2,063,699</u>
	<b>TOTAL CORPORATE BONDS (Cost \$93,860,673)</b>				<u>91,776,678</u>

Principal Amount (\$)			Coupon Rate (%)	Maturity	Fair Value
	<b>MUNICIPAL BONDS — 7.9%</b>				
	<b>COMBINED UTILITIES — 1.1%</b>				
1,525,000	City of Tacoma, WA Electric System Revenue		5.6410	01/01/27	1,540,139
	<b>COUNTY — 0.7%</b>				
1,115,000	City & County of Honolulu, HI		2.5180	10/01/26	1,060,211
	<b>MISCELLANEOUS TAX — 1.4%</b>				
2,050,000	Commonwealth of Massachusetts		3.6390	07/15/24	2,048,552
	<b>MULTI-FAMILY HOUSING — 0.2%</b>				
250,000	New York State Housing Finance Agency		2.2000	11/01/24	247,300
	<b>SINGLE-FAMILY HOUSING — 2.7%</b>				
305,000	Illinois Housing Development Authority		5.0940	04/01/30	306,657
1,000,000	Illinois Housing Development Authority		5.2440	04/01/31	1,008,384
35,000	Maryland Community Development Administration		3.2420	09/01/48	34,124
2,150,000	Virginia Housing Development Authority		4.8570	10/01/29	2,138,999
500,000	Virginia Housing Development Authority		4.9140	04/01/30	497,632
					<u>3,985,796</u>
	<b>STATE — 0.5%</b>				
500,000	State of Oregon		0.8120	11/01/24	492,510
300,000	State of Oregon		0.8950	05/01/25	289,527
					<u>782,037</u>

See accompanying notes to financial statements.

**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Coupon Rate (%)	Maturity	Fair Value	
	<b>MUNICIPAL BONDS — 7.9% (Continued)</b>				
	<b>WATER AND SEWER — 1.3%</b>				
2,000,000	Boston Water & Sewer Commission	0.9650	11/01/25	\$ 1,895,288	
				<hr/>	
	<b>TOTAL MUNICIPAL BONDS (Cost \$11,866,163)</b>			<hr/> 11,559,323 <hr/>	
Principal Amount (\$)	Spread	Coupon Rate (%)	Maturity	Fair Value	
	<b>U.S. GOVERNMENT &amp; AGENCIES — 21.7%</b>				
	<b>AGENCY FIXED RATE — 4.6%</b>				
2,048,428	Fannie Mae Pool MA4805	4.5000	11/01/52	1,936,187	
1,591,358	Freddie Mac Pool SD8237	4.0000	08/01/52	1,459,724	
2,322,881	Freddie Mac Pool SD8258	5.0000	10/01/52	2,254,576	
1,138,408	Ginnie Mae II Pool MA7107	2.5000	01/20/36	1,032,584	
				<hr/>	
				6,683,071	
	<b>AGENCY HYBRID ARMS — 0.0%<sup>(c)</sup></b>				
5,804	Ginnie Mae II Pool 82903 <sup>(b)</sup>	H15T1Y + 1.500%	3.6250	08/20/41	5,803
				<hr/>	
	<b>ARMS — 0.0%<sup>(d)</sup></b>				
1,652	Fannie Mae Pool 791573 <sup>(b)</sup>	H15T1Y + 2.170%	6.1700	08/01/34	1,678
26	Ginnie Mae II Pool 8502 <sup>(b)</sup>	H15T1Y + 1.500%	3.6250	09/20/24	26
35	Ginnie Mae II Pool 8503 <sup>(b)</sup>	H15T1Y + 1.500%	3.6250	09/20/24	35
81	Ginnie Mae II Pool 8565 <sup>(b)</sup>	H15T1Y + 1.500%	4.0000	12/20/24	81
242	Ginnie Mae II Pool 8567 <sup>(b)</sup>	H15T1Y + 1.500%	4.5000	12/20/24	241
686	Ginnie Mae II Pool 8595 <sup>(b)</sup>	H15T1Y + 1.500%	4.6250	02/20/25	681
253	Ginnie Mae II Pool 8660 <sup>(b)</sup>	H15T1Y + 1.500%	3.6250	07/20/25	251
10,709	Ginnie Mae II Pool 80569 <sup>(b)</sup>	H15T1Y + 1.500%	4.6250	01/20/32	10,645
1,414	Ginnie Mae II Pool 80659 <sup>(b)</sup>	H15T1Y + 1.500%	3.7500	12/20/32	1,397
				<hr/>	
				15,035	
	<b>GOVERNMENT OWNED, NO GUARANTEE — 9.8%</b>				
1,500,000	Federal Home Loan Mortgage Corporation	5.2500	12/09/24	1,497,219	
1,250,000	Federal Home Loan Mortgage Corporation	5.6000	03/06/26	1,249,499	
2,000,000	Federal Home Loan Mortgage Corporation	5.3750	04/09/26	1,996,723	
2,000,000	Federal Home Loan Mortgage Corporation	5.5000	04/08/27	1,996,343	
1,500,000	Federal Home Loan Mortgage Corporation	5.6250	06/11/27	1,500,581	
1,250,000	Federal Home Loan Mortgage Corporation	5.0000	09/18/28	1,242,869	

See accompanying notes to financial statements.

**EVENTIDE LIMITED-TERM BOND FUND**  
**SCHEDULE OF INVESTMENTS (Continued)**  
**June 30, 2024**

Principal Amount (\$)		Spread	Coupon Rate (%)	Maturity	Fair Value
	<b>U.S. GOVERNMENT &amp; AGENCIES — 21.7% (Continued)</b>				
	<b>GOVERNMENT OWNED, NO GUARANTEE — 9.8% (Continued)</b>				
2,000,000	Federal National Mortgage Association		4.1250	08/28/25	\$ 1,980,280
2,575,000	Federal National Mortgage Association		6.2500	05/15/29	2,785,327
					<u>14,248,841</u>
	<b>GOVERNMENT SPONSORED — 7.3%</b>				
2,250,000	Federal Farm Credit Banks Funding Corporation		5.2300	05/20/26	2,250,072
1,500,000	Federal Farm Credit Banks Funding Corporation		5.3000	10/19/26	1,495,739
1,750,000	Federal Farm Credit Banks Funding Corporation		4.5000	03/26/27	1,746,769
2,250,000	Federal Farm Credit Banks Funding Corporation		4.3750	02/28/28	2,241,909
1,500,000	Federal Farm Credit Banks Funding Corporation		3.7800	06/08/28	1,450,837
1,500,000	Federal Farm Credit Banks Funding Corporation		4.2500	12/15/28	1,490,918
					<u>10,676,244</u>
	<b>TOTAL U.S. GOVERNMENT &amp; AGENCIES (Cost \$31,889,825)</b>				<u>31,628,994</u>
	<b>TOTAL INVESTMENTS - 97.3% (Cost \$144,701,807)</b>				\$ 141,887,960
	<b>OTHER ASSETS IN EXCESS OF LIABILITIES- 2.7%</b>				<u>3,937,579</u>
	<b>NET ASSETS - 100.0%</b>				<u>\$ 145,825,539</u>

LLC - Limited Liability Company  
LP - Limited Partnership  
LTD - Limited Company

H15T1Y US Treasury Yield Curve Rate T Note Constant Maturity 1 Year  
SOFR30A United States 30 Day Average SOFR Secured Overnight Financing Rate  
SOFRRATE United States SOFR Secured Overnight Financing Rate  
TSFR3M CME Term SOFR 3 Month  
US0003M ICE LIBOR USD 3 Month

<sup>(a)</sup> Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of June 30, 2024 the total market value of 144A securities is \$17,011,277 or 11.7% of net assets.

<sup>(b)</sup> Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.

<sup>(c)</sup> Percentage rounds to less than 0.1%.

See accompanying notes to financial statements.

**Eventide Funds**  
**STATEMENTS OF ASSETS AND LIABILITIES**  
June 30, 2024

	Eventide Balanced	Eventide Core Bond Fund	Eventide Dividend Opportunities Fund	Eventide Exponential Technologies Fund	Eventide Gilead Fund
<b>ASSETS</b>					
Investment securities:					
Unaffiliated investments at cost	\$ 330,892,091	\$ 139,132,890	\$ 674,572,301	\$ 83,891,927	\$ 1,904,951,716
Affiliated investments at cost	-	-	-	-	237,433,515
Total Investments at cost	<u>330,892,091</u>	<u>139,132,890</u>	<u>674,572,301</u>	<u>83,891,927</u>	<u>2,142,385,231</u>
Unaffiliated investments at value	\$ 372,988,478	\$ 133,539,852	\$ 849,482,764	\$ 110,107,624	\$ 3,219,529,025
Affiliated investments at value	-	-	-	-	124,867,341
Total investments at value	<u>372,988,478</u>	<u>133,539,852</u>	<u>849,482,764</u>	<u>110,107,624</u>	<u>3,344,396,366</u>
Cash held at custodian	7,277,373	5,209,554	13,911,906	5,298,307	11,911,477
Cash held at broker	111,764	-	107,871	256,352	165,237
Receivable for Fund shares sold	357,216	80,294	2,246,670	95,216	1,568,125
Dividends and interest receivable	1,551,956	1,162,295	788,907	44,835	1,158,948
Prepaid expenses and other assets	73,592	1,314	113,803	40,200	206,009
<b>TOTAL ASSETS</b>	<u><u>\$ 382,360,379</u></u>	<u><u>\$ 139,993,309</u></u>	<u><u>\$ 866,651,921</u></u>	<u><u>\$ 115,842,534</u></u>	<u><u>\$ 3,359,406,162</u></u>
<b>LIABILITIES</b>					
Payable for investments purchased	1,991,608	2,509,353	992,081	-	-
Payable for Fund shares repurchased	320,358	122,642	907,257	189,037	6,222,417
Advisory fees payable	207,736	3,349	437,594	83,361	2,708,645
Distribution (12b-1) fees payable	85,533	8,579	124,611	31,121	85,406
Payable to related parties	103,863	17,503	113,564	13,668	372,663
Accrued expenses and other liabilities	131,499	26,991	163,144	38,841	679,901
<b>TOTAL LIABILITIES</b>	<u>2,840,597</u>	<u>2,688,417</u>	<u>2,738,251</u>	<u>356,028</u>	<u>10,069,032</u>
<b>NET ASSETS</b>	<u><u>\$ 379,519,782</u></u>	<u><u>\$ 137,304,892</u></u>	<u><u>\$ 863,913,670</u></u>	<u><u>\$ 115,486,506</u></u>	<u><u>\$ 3,349,337,130</u></u>
<b>Composition of Net Assets:</b>					
Paid in capital	\$ 348,154,578	\$ 156,700,975	\$ 719,115,243	\$ 148,039,352	\$ 2,234,462,249
Accumulated earnings (losses)	31,365,204	(19,396,083)	144,798,427	(32,552,846)	1,114,874,881
<b>NET ASSETS</b>	<u><u>\$ 379,519,782</u></u>	<u><u>\$ 137,304,892</u></u>	<u><u>\$ 863,913,670</u></u>	<u><u>\$ 115,486,506</u></u>	<u><u>\$ 3,349,337,130</u></u>

See accompanying notes to financial statements.

**Eventide Funds**  
**STATEMENTS OF ASSETS AND LIABILITIES (Continued)**  
June 30, 2024

	Eventide Balanced	Eventide Core Bond Fund	Eventide Dividend Opportunities Fund	Eventide Exponential Technologies Fund	Eventide Gilead Fund
<b>Net Asset Value Per Share:</b>					
Class N Shares:					
Net Assets	\$ 22,307,683	\$ 35,466,640	\$ 87,873,034	\$ 19,201,126	\$ 427,767,621
Shares of beneficial interest outstanding (a)	1,619,083	4,387,636	4,958,310	1,604,843	8,884,473
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 13.78</u>	<u>\$ 8.08</u>	<u>\$ 17.72</u>	<u>\$ 11.96</u>	<u>\$ 48.15</u>
Class A Shares:					
Net Assets	\$ 30,175,063	\$ 607,819	\$ 50,563,172	\$ 8,420,726	\$ 320,982,747
Shares of beneficial interest outstanding (a)	2,185,751	74,876	2,851,251	704,003	6,715,500
Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share	<u>\$ 13.81</u>	<u>\$ 8.12</u>	<u>\$ 17.73</u>	<u>\$ 11.96</u>	<u>\$ 47.80</u>
Maximum offering price per share (net asset value plus maximum sales charge of 5.75%)	<u>\$ 14.65</u>	<u>\$ 8.62</u>	<u>\$ 18.81</u>	<u>\$ 12.69</u>	<u>\$ 50.72</u>
Class C Shares:					
Net Assets	\$ 16,019,944	\$ 492,228	\$ 19,564,095	\$ 2,549,521	\$ 166,155,034
Shares of beneficial interest outstanding (a)	1,169,322	61,261	1,116,858	219,649	3,983,444
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 13.70</u>	<u>\$ 8.03</u>	<u>\$ 17.52</u>	<u>\$ 11.61</u>	<u>\$ 41.71</u>
Class I Shares:					
Net Assets	\$ 311,017,092	\$ 100,738,205	\$ 705,913,369	\$ 85,315,133	\$ 2,434,431,728
Shares of beneficial interest outstanding (a)	22,569,529	12,461,634	39,794,478	7,069,477	48,881,636
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 13.78</u>	<u>\$ 8.08</u>	<u>\$ 17.74</u>	<u>\$ 12.07</u>	<u>\$ 49.80</u>

(a) Unlimited number of shares of beneficial interest authorized, no par value.

**Eventide Funds**  
**STATEMENTS OF ASSETS AND LIABILITIES (Continued)**  
June 30, 2024

	<b>Eventide Healthcare &amp; Life Sciences Fund</b>	<b>Eventide Large Cap Focus Fund</b>	<b>Eventide Limited-Term Bond Fund</b>
<b>ASSETS</b>			
Investment securities:			
Unaffiliated investments at cost	\$ 1,042,769,725	\$ 95,268,290	\$ 144,701,807
Affiliated investments at cost	296,286,464	-	-
Investments at cost	1,339,056,189	95,268,290	144,701,807
Unaffiliated investments at value	\$ 1,210,909,133	\$ 102,792,851	\$ 141,887,960
Affiliated investments at value	181,308,616	-	-
Total investments at value	1,392,217,749	102,792,851	141,887,960
Cash held at custodian	60,855,823	3,934,741	2,699,553
Cash held at broker	116,470	-	-
Receivable for Fund shares sold	1,469,791	238,852	214,002
Dividends and interest receivable	611,682	54,474	1,293,116
Prepaid expenses and other assets	105,690	66,875	45,057
<b>TOTAL ASSETS</b>	<b>1,455,377,205</b>	<b>107,087,793</b>	<b>146,139,688</b>
<b>LIABILITIES</b>			
Payable for investments purchased	10,813,492	756,004	-
Payable for Fund shares repurchased	2,760,867	99,198	100,238
Advisory fees payable	1,298,739	39,539	73,470
Distribution (12b-1) fees payable	90,738	-	2,390
Payable to related parties	165,566	3,114	71,558
Accrued expenses and other liabilities	332,054	6,755	66,493
<b>TOTAL LIABILITIES</b>	<b>15,461,456</b>	<b>904,610</b>	<b>314,149</b>
<b>NET ASSETS</b>	<b>\$ 1,439,915,749</b>	<b>\$ 106,183,183</b>	<b>\$ 145,825,539</b>
<b>Composition of Net Assets:</b>			
Paid in capital	\$ 1,421,894,332	\$ 95,317,684	\$ 157,158,771
Accumulated earnings (losses)	18,021,417	10,865,499	(11,333,232)
<b>NET ASSETS</b>	<b>\$ 1,439,915,749</b>	<b>\$ 106,183,183</b>	<b>\$ 145,825,539</b>

See accompanying notes to financial statements.

**Eventide Funds**  
**STATEMENTS OF ASSETS AND LIABILITIES (Continued)**  
June 30, 2024

	<b>Eventide Healthcare &amp; Life Sciences Fund</b>	<b>Eventide Large Cap Focus Fund</b>	<b>Eventide Limited-Term Bond Fund</b>
<b>Net Asset Value Per Share:</b>			
Class N Shares:			
Net Assets	\$ 93,026,982	\$ 13,096,696	\$ 17,948,798
Shares of beneficial interest outstanding (a)	2,793,716	934,677	1,815,024
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 33.30</u>	<u>\$ 14.01</u>	<u>\$ 9.89</u>
Class A Shares:			
Net Assets	\$ 122,422,635	\$ 1,835,642	\$ 4,611,924
Shares of beneficial interest outstanding (a)	3,705,496	131,244	465,212
Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share	<u>\$ 33.04</u>	<u>\$ 13.99</u>	<u>\$ 9.91</u>
Maximum offering price per share (net asset value plus maximum sales charge of 5.75%)	<u>\$ 35.06</u>	<u>\$ 14.84</u>	<u>\$ 10.51</u>
Class C Shares:			
Net Assets	\$ 55,660,694	\$ 292,203	\$ 1,563,685
Shares of beneficial interest outstanding (a)	1,848,407	21,183	158,859
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 30.11</u>	<u>\$ 13.79</u>	<u>\$ 9.84</u>
Class I Shares:			
Net Assets	\$ 1,168,805,438	\$ 90,958,642	\$ 121,701,132
Shares of beneficial interest outstanding (a)	34,285,245	6,476,960	11,988,852
Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share	<u>\$ 34.09</u>	<u>\$ 14.04</u>	<u>\$ 10.15</u>

(a) Unlimited number of shares of beneficial interest authorized, no par value.

**Eventide Funds**  
**STATEMENTS OF OPERATIONS**  
For the Year Ended June 30, 2024

	Eventide Balanced	Eventide Core Bond Fund	Eventide Dividend Opportunities Fund	Eventide Exponential Technologies Fund	Eventide Gilead Fund
<b>INVESTMENT INCOME</b>					
Dividend income	\$ 2,592,564	\$ -	\$ 9,580,578	\$ 128,816	\$ 13,102,859
Interest	6,211,262	4,542,298	1,044,018	195,142	7,865,582
Less: Foreign dividend withholding taxes	-	-	(149)	(1,208)	(406,650)
<b>TOTAL INVESTMENT INCOME</b>	<b>8,803,826</b>	<b>4,542,298</b>	<b>10,624,447</b>	<b>322,750</b>	<b>20,561,791</b>
<b>EXPENSES</b>					
Investment advisory fees	2,076,679	357,352	4,974,202	1,314,480	35,349,592
Distribution (12b-1) fees:					
Class N	55,029	70,040	179,530	43,010	980,046
Class A	66,748	1,008	106,232	21,675	860,598
Class C	157,808	2,535	164,320	27,085	1,912,191
Shareholder servicing fees	398,937	118,068	794,673	164,657	3,834,102
Printing and postage expenses	129,932	27,595	157,369	39,705	368,639
Financial administration/fund accounting fees	132,355	53,769	195,182	49,994	1,023,544
Registration fees	100,650	67,710	110,750	70,024	146,450
Legal administration/management services fees	71,477	21,649	140,604	24,657	753,401
Transfer agent fees	46,072	17,223	67,779	33,001	309,461
Custodian fees	23,395	6,540	38,550	15,678	205,809
Legal fees	23,404	21,112	21,860	20,714	31,826
Compliance officer fees	17,132	11,304	23,545	9,813	99,011
Audit fees	22,982	16,288	19,000	12,829	45,001
Trustees fees and expenses	15,598	15,637	15,611	15,598	15,698
Insurance expense	12,810	3,660	15,450	2,568	109,850
Other expenses	4,457	4,002	3,897	3,944	4,503
<b>TOTAL EXPENSES</b>	<b>3,355,465</b>	<b>815,492</b>	<b>7,028,554</b>	<b>1,869,432</b>	<b>46,049,722</b>
Less: Fees waived/reimbursed by the Advisor	(236,729)	(131,361)	(97,498)	(68,862)	-
<b>NET EXPENSES</b>	<b>3,118,736</b>	<b>684,131</b>	<b>6,931,056</b>	<b>1,800,570</b>	<b>46,049,722</b>
<b>NET INVESTMENT INCOME (LOSS)</b>	<b>5,685,090</b>	<b>3,858,167</b>	<b>3,693,391</b>	<b>(1,477,820)</b>	<b>(25,487,931)</b>
<b>REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS</b>					
Net realized gain (loss) from:					
Unaffiliated investments	3,359,942	(2,770,122)	14,015,615	(1,693,620)	43,126,125
Affiliated investments (See Note 5)	-	-	-	-	(55,517,695)
Securities sold short	-	-	-	(478,620)	(753,126)
Foreign currency transactions	-	-	-	(1,910)	(12,798)
Distributions of long term capital gains from underlying investment companies	2,982	-	68,490	-	-
<b>Net realized gain (loss):</b>	<b>3,362,924</b>	<b>(2,770,122)</b>	<b>14,084,105</b>	<b>(2,174,150)</b>	<b>(13,157,494)</b>
Net change in unrealized appreciation on:					
Unaffiliated investments	32,146,544	2,371,706	117,234,972	3,599,272	83,517,835
Affiliated investments (See Note 5)	-	-	-	-	(55,980,935)
<b>Net change in unrealized appreciation:</b>	<b>32,146,544</b>	<b>2,371,706</b>	<b>117,234,972</b>	<b>3,599,272</b>	<b>27,536,900</b>
<b>NET REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS</b>	<b>35,509,468</b>	<b>(398,416)</b>	<b>131,319,077</b>	<b>1,425,122</b>	<b>14,379,406</b>
<b>NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS</b>	<b>\$ 41,194,558</b>	<b>\$ 3,459,751</b>	<b>\$ 135,012,468</b>	<b>\$ (52,698)</b>	<b>\$ (11,108,525)</b>

See accompanying notes to financial statements.



**Eventide Funds**  
**STATEMENTS OF OPERATIONS (Continued)**  
For Year Ended June 30, 2024

	Eventide Healthcare & Life Sciences Fund	Eventide Large Cap Focus Fund	Eventide Limited-Term Bond Fund
<b>INVESTMENT INCOME</b>			
Dividend income	\$ -	\$ 386,143	\$ -
Interest	4,473,968	134,747	4,951,366
Less: Foreign dividend withholding taxes	(45,115)	(6,575)	-
<b>TOTAL INVESTMENT INCOME</b>	<u>4,428,853</u>	<u>514,315</u>	<u>4,951,366</u>
<b>EXPENSES</b>			
Investment advisory fees	17,506,668	319,467	422,673
Distribution (12b-1) fees:			
Class N	222,274	12,769	35,466
Class A	340,157	1,865	27,175
Class C	644,059	1,009	14,455
Shareholder servicing fees	1,724,492	35,285	179,197
Financial administration/fund accounting fees	472,135	22,501	80,849
Legal administration/management services fees	328,420	8,996	28,166
Transfer agent fees	195,414	15,480	24,818
Printing and postage expenses	290,408	8,059	65,954
Registration fees	128,100	36,750	65,920
Audit fees	91,940	13,579	17,051
Custodian fees	101,247	12,061	9,152
Insurance expense	53,070	370	5,490
Compliance officer fees	47,437	7,789	11,994
Legal fees	25,278	15,215	22,058
Trustees fees and expenses	15,602	15,603	15,597
Other expenses	3,981	4,014	3,596
<b>TOTAL EXPENSES</b>	<u>22,190,682</u>	<u>530,812</u>	<u>1,029,611</u>
Less: Fees waived/reimbursed by the Advisor	-	(101,331)	(202,441)
<b>NET EXPENSES</b>	<u>22,190,682</u>	<u>429,481</u>	<u>827,170</u>
<b>NET INVESTMENT INCOME (LOSS)</b>	<u>(17,761,829)</u>	<u>84,834</u>	<u>4,124,196</u>
<b>REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS</b>			
Net realized gain (loss) from:			
Unaffiliated investments	79,239,923	3,919,159	(995,253)
Affiliated investments (See Note 5)	(50,453,063)	-	-
<b>Net realized gain (loss):</b>	<u>28,786,860</u>	<u>3,919,159</u>	<u>(995,253)</u>
Net change in unrealized appreciation (depreciation) on:			
Unaffiliated investments	(69,227,944)	5,840,777	3,826,483
Affiliated investments (See Note 5)	(102,478,691)	-	-
<b>Net change in unrealized appreciation (depreciation):</b>	<u>(171,706,635)</u>	<u>5,840,777</u>	<u>3,826,483</u>
<b>NET REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS</b>	<u>(142,919,775)</u>	<u>9,759,936</u>	<u>2,831,230</u>
<b>NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS</b>	<u>\$ (160,681,604)</u>	<u>\$ 9,844,770</u>	<u>\$ 6,955,426</u>

**Eventide Balanced Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment income	\$ 5,685,090	\$ 5,151,980
Net realized gain (loss)	3,359,942	(14,479,724)
Distributions of long term capital gains from underlying investment companies	2,982	-
Net change in unrealized appreciation	32,146,544	26,607,153
Net increase in net assets resulting from operations	41,194,558	17,279,409
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
From Accumulated Earnings		
Class N	(422,597)	(1,025,429)
Class A	(408,420)	(587,205)
Class C	(129,472)	(258,344)
Class I	(4,928,123)	(6,650,735)
Return of Capital		
Class N	-	(123,456)
Class A	-	(77,622)
Class C	-	(50,944)
Class I	-	(787,757)
Total distributions to shareholders	(5,888,612)	(9,561,492)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	9,079,352	49,176,092
Class A	7,382,970	4,205,289
Class C	2,465,144	2,132,876
Class I	99,214,636	75,332,706
Net asset value of shares issued in reinvestment of distributions:		
Class N	399,727	1,104,953
Class A	363,434	591,647
Class C	120,546	289,078
Class I	4,513,376	6,830,607
Payments for shares repurchased:		
Class N	(20,672,373)	(54,627,872)
Class A	(5,867,639)	(5,644,099)
Class C	(4,339,723)	(4,809,955)
Class I	(81,509,861)	(97,402,343)
Net increase (decrease) in net assets from shares of beneficial interest	11,149,589	(22,821,021)
<b>TOTAL INCREASE (DECREASE) IN NET ASSETS</b>	46,455,535	(15,103,104)
<b>NET ASSETS</b>		
Beginning of Year	333,064,247	348,167,351
End of Year	\$ 379,519,782	\$ 333,064,247

See accompanying notes to financial statements.

**Eventide Balanced Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	702,251	4,036,342
Shares Reinvested	30,806	91,129
Shares Repurchased	(1,575,339)	(4,542,574)
Net decrease in shares of beneficial interest outstanding	<u>(842,282)</u>	<u>(415,103)</u>
Class A:		
Shares Sold	556,790	342,410
Shares Reinvested	27,746	48,591
Shares Repurchased	(450,768)	(459,232)
Net increase (decrease) in shares of beneficial interest outstanding	<u>133,768</u>	<u>(68,231)</u>
Class C:		
Shares Sold	189,180	175,582
Shares Reinvested	9,284	23,934
Shares Repurchased	(336,562)	(397,078)
Net decrease in shares of beneficial interest outstanding	<u>(138,098)</u>	<u>(197,562)</u>
Class I:		
Shares Sold	7,563,324	6,177,662
Shares Reinvested	345,405	561,831
Shares Repurchased	(6,292,309)	(8,014,650)
Net increase (decrease) in shares of beneficial interest outstanding	<u>1,616,420</u>	<u>(1,275,157)</u>

**Eventide Core Bond Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment income	\$ 3,858,167	\$ 1,497,137
Net realized loss	(2,770,122)	(3,797,575)
Net change in unrealized appreciation	2,371,706	1,383,710
Net increase (decrease) in net assets resulting from operations	3,459,751	(916,728)
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
From Accumulated Earnings		
Class N	(1,109,828)	(791,346)
Class A	(14,181)	(6,663)
Class C	(7,752)	(3,378)
Class I	(2,637,606)	(735,595)
Total distributions to shareholders	(3,769,367)	(1,536,982)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	7,288,166	19,475,162
Class A	392,447	246,372
Class C	324,177	34,274
Class I	96,894,042	34,388,084
Net asset value of shares issued in reinvestment of distributions:		
Class N	1,106,587	790,735
Class A	14,053	6,663
Class C	7,478	3,364
Class I	1,570,467	615,819
Payments for shares repurchased:		
Class N	(10,033,040)	(39,413,830)
Class A	(206,432)	(30,999)
Class C	(57,303)	(33,678)
Class I	(37,064,233)	(8,715,146)
Net increase in net assets from shares of beneficial interest	60,236,409	7,366,820
<b>TOTAL INCREASE IN NET ASSETS</b>	59,926,793	4,913,110
<b>NET ASSETS</b>		
Beginning of Year	77,378,099	42,646,989
End of Year	\$ 137,304,892	\$ 77,378,099

**Eventide Core Bond Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	896,472	2,362,456
Shares Reinvested	136,943	97,444
Shares Repurchased	(1,241,562)	(4,782,659)
Net decrease in shares of beneficial interest outstanding	<u>(208,147)</u>	<u>(2,322,759)</u>
Class A:		
Shares Sold	47,998	29,981
Shares Reinvested	1,728	816
Shares Repurchased	(25,196)	(3,796)
Net increase in shares of beneficial interest outstanding	<u>24,530</u>	<u>27,001</u>
Class C:		
Shares Sold	40,205	4,110
Shares Reinvested	929	416
Shares Repurchased	(7,073)	(4,147)
Net increase in shares of beneficial interest outstanding	<u>34,061</u>	<u>379</u>
Class I:		
Shares Sold	12,040,793	4,159,816
Shares Reinvested	193,765	75,784
Shares Repurchased	(4,596,461)	(1,062,677)
Net increase in shares of beneficial interest outstanding	<u>7,638,097</u>	<u>3,172,923</u>

**Eventide Dividend Opportunities Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment income	\$ 3,693,391	\$ 4,442,752
Net realized gain (loss)	14,015,615	(44,373,084)
Distributions of long term capital gains from underlying investment companies	68,490	-
Net change in unrealized appreciation	117,234,972	90,497,053
Net increase in net assets resulting from operations	135,012,468	50,566,721
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
From Accumulated Earnings		
Class N	(334,756)	(1,203,965)
Class A	(147,401)	(378,484)
Class C	-	(76,849)
Class I	(3,216,856)	(5,200,706)
Return of Capital		
Class N	-	(92,962)
Class A	-	(102,479)
Class C	-	(9,900)
Class I	-	(908,635)
Total distributions to shareholders	(3,699,013)	(7,973,980)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	29,519,252	42,168,215
Class A	12,265,171	13,780,142
Class C	5,169,491	6,546,046
Class I	334,215,421	232,281,533
Net asset value of shares issued in reinvestment of distributions:		
Class N	324,923	1,267,578
Class A	141,369	463,082
Class C	-	84,188
Class I	2,894,360	5,504,373
Payments for shares repurchased:		
Class N	(50,762,173)	(33,157,570)
Class A	(6,831,786)	(9,749,781)
Class C	(3,551,445)	(2,812,230)
Class I	(164,593,403)	(145,117,850)
Net increase in net assets from shares of beneficial interest	158,791,180	111,257,726
<b>TOTAL INCREASE IN NET ASSETS</b>	290,104,635	153,850,467
<b>NET ASSETS</b>		
Beginning of Year	573,809,035	419,958,568
End of Year	\$ 863,913,670	\$ 573,809,035

**Eventide Dividend Opportunities Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	For the Year Ended June 30, 2024	For the Year Ended June 30, 2023
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	1,807,676	3,006,122
Shares Reinvested	19,929	92,382
Shares Repurchased	(3,142,435)	(2,406,922)
Net increase (decrease) in shares of beneficial interest outstanding	<u>(1,314,830)</u>	<u>691,582</u>
Class A:		
Shares Sold	762,040	985,242
Shares Reinvested	8,574	33,666
Shares Repurchased	(424,470)	(691,004)
Net increase in shares of beneficial interest outstanding	<u>346,144</u>	<u>327,904</u>
Class C:		
Shares Sold	319,457	475,330
Shares Reinvested	-	6,152
Shares Repurchased	(226,340)	(205,600)
Net increase in shares of beneficial interest outstanding	<u>93,117</u>	<u>275,882</u>
Class I:		
Shares Sold	20,550,743	16,642,155
Shares Reinvested	174,089	400,250
Shares Repurchased	(10,273,314)	(10,457,863)
Net increase in shares of beneficial interest outstanding	<u>10,451,518</u>	<u>6,584,542</u>

**Eventide Exponential Technologies Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment loss	\$ (1,477,820)	\$ (1,082,795)
Net realized loss	(2,174,150)	(25,591,542)
Net change in unrealized appreciation	3,599,272	35,911,605
Net increase (decrease) in net assets resulting from operations	(52,698)	9,237,268
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	6,027,041	13,244,258
Class A	1,869,118	1,781,643
Class C	542,067	628,624
Class I	32,629,726	47,180,850
Redemption fee proceeds:		
Class N	-	17,663
Class A	-	9,414
Class C	-	3,021
Class I	-	92,427
Payments for shares repurchased:		
Class N	(8,987,032)	(5,852,092)
Class A	(1,673,077)	(1,638,384)
Class C	(611,792)	(627,686)
Class I	(30,069,547)	(43,109,040)
Net increase (decrease) in net assets from shares of beneficial interest	(273,496)	11,730,698
<b>TOTAL INCREASE (DECREASE) IN NET ASSETS</b>	<b>(326,194)</b>	<b>20,967,966</b>
<b>NET ASSETS</b>		
Beginning of Year	115,812,700	94,844,734
End of Year	<b>\$ 115,486,506</b>	<b>\$ 115,812,700</b>



**Eventide Exponential Technologies Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	488,743	1,258,489
Shares Repurchased	(732,729)	(551,922)
Net increase (decrease) in shares of beneficial interest outstanding	(243,986)	706,567
Class A:		
Shares Sold	152,030	162,981
Shares Repurchased	(135,986)	(149,936)
Net increase in shares of beneficial interest outstanding	16,044	13,045
Class C:		
Shares Sold	45,554	58,336
Shares Repurchased	(50,461)	(58,741)
Net decrease in shares of beneficial interest outstanding	(4,907)	(405)
Class I:		
Shares Sold	2,640,341	4,159,896
Shares Repurchased	(2,419,872)	(3,923,676)
Net increase in shares of beneficial interest outstanding	220,469	236,220

**Eventide Gilead Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment loss	\$ (25,487,931)	\$ (18,202,004)
Net realized loss	(13,157,494)	(50,832,143)
Net change in unrealized appreciation	27,536,900	575,636,075
Net increase (decrease) in net assets resulting from operations	(11,108,525)	506,601,928
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
Class N	-	(26,502,428)
Class A	-	(15,537,719)
Class C	-	(13,038,729)
Class I	-	(117,168,110)
Total distributions to shareholders	-	(172,246,986)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	73,774,173	88,745,999
Class A	43,406,603	55,727,869
Class C	10,231,757	14,904,069
Class I	642,713,540	640,408,718
Net asset value of shares issued in reinvestment of distributions:		
Class N	-	25,204,656
Class A	-	14,252,437
Class C	-	12,562,355
Class I	-	103,966,493
Payments for shares repurchased:		
Class N	(172,318,771)	(163,362,221)
Class A	(73,157,162)	(50,748,542)
Class C	(60,256,585)	(61,602,217)
Class I	(864,585,791)	(730,773,548)
Net decrease in net assets from shares of beneficial interest	(400,192,236)	(50,713,932)
<b>TOTAL INCREASE (DECREASE) IN NET ASSETS</b>	(411,300,761)	283,641,010
<b>NET ASSETS</b>		
Beginning of Year	3,760,637,891	3,476,996,881
End of Year	<b>\$ 3,349,337,130</b>	<b>\$ 3,760,637,891</b>

See accompanying notes to financial statements.

**Eventide Gilead Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	1,518,597	1,959,635
Shares Reinvested	-	594,029
Shares Repurchased	(3,552,489)	(3,651,814)
Net decrease in shares of beneficial interest outstanding	(2,033,892)	(1,098,150)
Class A:		
Shares Sold	908,469	1,244,030
Shares Reinvested	-	338,136
Shares Repurchased	(1,533,665)	(1,135,497)
Net increase (decrease) in shares of beneficial interest outstanding	(625,196)	446,669
Class C:		
Shares Sold	243,481	372,502
Shares Reinvested	-	337,607
Shares Repurchased	(1,439,695)	(1,566,252)
Net decrease in shares of beneficial interest outstanding	(1,196,214)	(856,143)
Class I:		
Shares Sold	12,826,677	13,786,761
Shares Reinvested	-	2,376,377
Shares Repurchased	(17,409,071)	(15,809,021)
Net increase (decrease) in shares of beneficial interest outstanding	(4,582,394)	354,117

**Eventide Healthcare & Life Sciences Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment loss	\$ (17,761,829)	\$ (16,468,559)
Net realized gain	28,786,860	87,672,175
Net change in unrealized appreciation (depreciation)	(171,706,635)	429,893,252
Net increase (decrease) in net assets resulting from operations	(160,681,604)	501,096,868
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	27,610,590	24,795,762
Class A	18,327,882	24,063,154
Class C	5,931,902	6,812,105
Class I	338,891,051	410,248,708
Payments for shares repurchased:		
Class N	(56,522,523)	(48,550,846)
Class A	(33,663,932)	(30,091,421)
Class C	(19,891,812)	(19,599,460)
Class I	(483,248,261)	(387,178,463)
Net decrease in net assets from shares of beneficial interest	(202,565,103)	(19,500,461)
<b>TOTAL INCREASE (DECREASE) IN NET ASSETS</b>	(363,246,707)	481,596,407
<b>NET ASSETS</b>		
Beginning of Year	1,803,162,456	1,321,566,049
End of Year	\$ 1,439,915,749	\$ 1,803,162,456

**Eventide Healthcare & Life Sciences Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	808,352	761,278
Shares Repurchased	(1,645,670)	(1,502,705)
Net decrease in shares of beneficial interest outstanding	<u>(837,318)</u>	<u>(741,427)</u>
Class A:		
Shares Sold	533,812	747,325
Shares Repurchased	(1,004,391)	(923,751)
Net decrease in shares of beneficial interest outstanding	<u>(470,579)</u>	<u>(176,426)</u>
Class C:		
Shares Sold	189,732	232,446
Shares Repurchased	(643,139)	(661,200)
Net decrease in shares of beneficial interest outstanding	<u>(453,407)</u>	<u>(428,754)</u>
Class I:		
Shares Sold	9,731,634	12,546,799
Shares Repurchased	(13,939,231)	(11,930,781)
Net increase (decrease) in shares of beneficial interest outstanding	<u>(4,207,597)</u>	<u>616,018</u>

**Eventide Large Cap Focus Fund**  
**STATEMENT OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023 <sup>(1)</sup></b>
<b>FROM OPERATIONS</b>		
Net investment income	\$ 84,834	\$ 4,324
Net realized gain (loss)	3,919,159	(308,679)
Net change in unrealized appreciation	5,840,777	1,683,784
Net increase in net assets resulting from operations	9,844,770	1,379,429
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
From Accumulated Earnings		
Class I	-	(4,107)
Return of Capital		
Class N	-	(35)
Class A	-	(36)
Class I	-	(5,720)
Total distributions to shareholders	-	(9,898)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	13,208,513	524,748
Class A	1,618,697	249,063
Class C	250,508	24,480
Class I	80,767,005	15,266,218
Net asset value of shares issued in reinvestment of distributions:		
Class N	-	27
Class A	-	36
Class I	-	9,440
Payments for shares repurchased:		
Class N	(2,227,146)	(224,466)
Class A	(129,860)	(79,745)
Class C	(2,696)	-
Class I	(10,501,346)	(3,784,594)
Net increase in net assets from shares of beneficial interest	82,983,675	11,985,207
<b>TOTAL INCREASE IN NET ASSETS</b>	92,828,445	13,354,738
<b>NET ASSETS</b>		
Beginning of Period/Year	13,354,738	-
End of Period/Year	\$ 106,183,183	\$ 13,354,738

(1) Eventide Large Cap Focus Fund commenced operations on June 30, 2022.

**Eventide Large Cap Focus Fund**  
**STATEMENT OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023 <sup>(1)</sup></b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	1,073,482	50,682
Shares Reinvested	-	3
Shares Repurchased	(167,698)	(21,792)
Net increase in shares of beneficial interest outstanding	905,784	28,893
Class A:		
Shares Sold	124,512	24,367
Shares Reinvested	-	3
Shares Repurchased	(9,870)	(7,768)
Net increase in shares of beneficial interest outstanding	114,642	16,602
Class C:		
Shares Sold	19,051	2,338
Shares Repurchased	(206)	-
Net increase in shares of beneficial interest outstanding	18,845	2,338
Class I:		
Shares Sold	6,219,032	1,487,132
Shares Reinvested	-	923
Shares Repurchased	(861,446)	(368,681)
Net increase in shares of beneficial interest outstanding	5,357,586	1,119,374

(1) Eventide Large Cap Focus Fund commenced operations on June 30, 2022.

**Eventide Limited-Term Bond Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>FROM OPERATIONS</b>		
Net investment income	\$ 4,124,196	\$ 2,571,717
Net realized loss	(995,253)	(5,299,246)
Net change in unrealized appreciation	3,826,483	4,451,387
Net increase in net assets resulting from operations	6,955,426	1,723,858
<b>DISTRIBUTIONS TO SHAREHOLDERS</b>		
From Accumulated Earnings		
Class N	(515,651)	(283,263)
Class A	(282,483)	(302,006)
Class C	(30,364)	(15,268)
Class I	(3,275,627)	(2,074,932)
Return of Capital		
Class N	-	(4,462)
Class A	-	(5,259)
Class C	-	(487)
Class I	-	(32,214)
Total distributions to shareholders	(4,104,125)	(2,717,891)
<b>FROM SHARES OF BENEFICIAL INTEREST</b>		
Proceeds from shares sold:		
Class N	5,325,751	21,519,104
Class A	5,593,337	9,487,414
Class C	517,636	1,005,560
Class I	71,435,949	73,533,124
Net asset value of shares issued in reinvestment of distributions:		
Class N	514,104	286,917
Class A	278,766	304,810
Class C	30,364	15,678
Class I	3,066,017	1,847,368
Payments for shares repurchased:		
Class N	(5,935,269)	(9,928,344)
Class A	(20,858,904)	(12,462,801)
Class C	(632,265)	(1,078,599)
Class I	(43,733,461)	(138,219,235)
Net increase (decrease) in net assets from shares of beneficial interest	15,602,025	(53,689,004)
<b>TOTAL INCREASE (DECREASE) IN NET ASSETS</b>	18,453,326	(54,683,037)
<b>NET ASSETS</b>		
Beginning of Year	127,372,213	182,055,250
End of Year	\$ 145,825,539	\$ 127,372,213



**Eventide Limited-Term Bond Fund**  
**STATEMENTS OF CHANGES IN NET ASSETS (Continued)**

	<b>For the Year Ended June 30, 2024</b>	<b>For the Year Ended June 30, 2023</b>
<b>SHARE ACTIVITY</b>		
Class N:		
Shares Sold	540,489	2,245,504
Shares Reinvested	52,457	29,697
Shares Repurchased	(605,720)	(1,025,667)
Net increase (decrease) in shares of beneficial interest outstanding	<u>(12,774)</u>	<u>1,249,534</u>
Class A:		
Shares Sold	572,186	979,448
Shares Reinvested	28,422	31,459
Shares Repurchased	(2,133,393)	(1,291,906)
Net decrease in shares of beneficial interest outstanding	<u>(1,532,785)</u>	<u>(280,999)</u>
Class C:		
Shares Sold	52,892	105,013
Shares Reinvested	3,112	1,629
Shares Repurchased	(64,985)	(112,068)
Net decrease in shares of beneficial interest outstanding	<u>(8,981)</u>	<u>(5,426)</u>
Class I:		
Shares Sold	7,107,542	7,407,748
Shares Reinvested	304,804	186,484
Shares Repurchased	(4,351,992)	(13,969,448)
Net increase (decrease) in shares of beneficial interest outstanding	<u>3,060,354</u>	<u>(6,375,216)</u>

## Eventide Balanced Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class N				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 12.44	\$ 12.12	\$ 14.21	\$ 11.38	\$ 10.90
Activity from investment operations:					
Net investment income (1)	0.19	0.16	0.10	0.08	0.16
Net realized and unrealized gain (loss) on investments	1.35	0.47	(1.35)	2.95	0.60
Total from investment operations	1.54	0.63	(1.25)	3.03	0.76
Less distributions from:					
Net investment income	(0.20)	(0.15)	(0.21)	(0.18)	(0.14)
Net realized gains	-	(0.12)	(0.63)	(0.02)	-
Return of capital	-	(0.04)	-	-	(0.14)
Total distributions	(0.20)	(0.31)	(0.84)	(0.20)	(0.28)
Net asset value, end of year	\$ 13.78	\$ 12.44	\$ 12.12	\$ 14.21	\$ 11.38
Total return (2)	12.52%	5.35%	(9.58)%	26.81%	7.03%
Net assets, at end of year (000s)	\$ 22,308	\$ 30,618	\$ 34,856	\$ 39,947	\$ 19,454
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.09%	1.10%	1.01%	1.05%	1.19%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.02%	1.02%	1.02%	1.02%	1.10%
Ratio of net investment income to average net assets (4)(5)	1.51%	1.34%	0.69%	0.59%	1.44%
Portfolio Turnover Rate	43%	48%	66%	73%	107%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Balanced Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class A				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 12.46	\$ 12.14	\$ 14.22	\$ 11.38	\$ 10.89
Activity from investment operations:					
Net investment income (1)	0.19	0.16	0.09	0.07	0.15
Net realized and unrealized gain (loss) on investments	1.36	0.47	(1.33)	2.96	0.61
Total from investment operations	1.55	0.63	(1.24)	3.03	0.76
Less distributions from:					
Net investment income	(0.20)	(0.15)	(0.21)	(0.17)	(0.13)
Net realized gains	-	(0.12)	(0.63)	(0.02)	-
Return of capital	-	(0.04)	-	-	(0.14)
Total distributions	(0.20)	(0.31)	(0.84)	(0.19)	(0.27)
Net asset value, end of year	<u>\$ 13.81</u>	<u>\$ 12.46</u>	<u>\$ 12.14</u>	<u>\$ 14.22</u>	<u>\$ 11.38</u>
Total return (2)	<u>12.53% (6)</u>	<u>5.29%</u>	<u>(9.55)%</u>	<u>26.84%</u>	<u>7.07%</u>
Net assets, at end of year (000s)	<u>\$ 30,175</u>	<u>\$ 25,577</u>	<u>\$ 25,744</u>	<u>\$ 23,139</u>	<u>\$ 10,659</u>
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.14%	1.15%	1.06%	1.10%	1.24%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.07%	1.07%	1.07%	1.07%	1.15%
Ratio of net investment income to average net assets (4)(5)	1.47%	1.32%	0.65%	0.55%	1.39%
Portfolio Turnover Rate	43%	48%	66%	73%	107%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Balanced Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class C				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 12.38	\$ 12.06	\$ 14.15	\$ 11.34	\$ 10.86
Activity from investment operations:					
Net investment income (loss) (1)	0.09	0.07	(0.01)	(0.03)	0.07
Net realized and unrealized gain (loss) on investments	1.34	0.47	(1.35)	2.95	0.60
Total from investment operations	1.43	0.54	(1.36)	2.92	0.67
Less distributions from:					
Net investment income	(0.11)	(0.06)	(0.10)	(0.09)	(0.09)
Net realized gains	-	(0.12)	(0.63)	(0.02)	-
Return of capital	-	(0.04)	-	-	(0.10)
Total distributions	(0.11)	(0.22)	(0.73)	(0.11)	(0.19)
Net asset value, end of year	\$ 13.70	\$ 12.38	\$ 12.06	\$ 14.15	\$ 11.34
Total return (2)	11.58%	4.54%	(10.33)%	25.85%	6.23%
Net assets, at end of year (000s)	\$ 16,020	\$ 16,181	\$ 18,146	\$ 18,883	\$ 8,091
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.89%	1.90%	1.81%	1.85%	1.99%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.82%	1.82%	1.82%	1.82%	1.90%
Ratio of net investment income (loss) to average net assets (4)(5)	0.72%	0.56%	(0.10)%	(0.21)%	0.64%
Portfolio Turnover Rate	43%	48%	66%	73%	107%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income (loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Balanced Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class I				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 12.44	\$ 12.12	\$ 14.22	\$ 11.38	\$ 10.90
Activity from investment operations:					
Net investment income (1)	0.22	0.19	0.12	0.11	0.18
Net realized and unrealized gain (loss) on investments	1.35	0.47	(1.35)	2.95	0.60
Total from investment operations	1.57	0.66	(1.23)	3.06	0.78
Less distributions from:					
Net investment income	(0.23)	(0.18)	(0.24)	(0.20)	(0.15)
Net realized gains	-	(0.12)	(0.63)	(0.02)	-
Return of capital	-	(0.04)	-	-	(0.15)
Total distributions	(0.23)	(0.34)	(0.87)	(0.22)	(0.30)
Net asset value, end of year	\$ 13.78	\$ 12.44	\$ 12.12	\$ 14.22	\$ 11.38
Total return (2)	12.75%	5.57%	(9.46)%	27.12%	7.23%
Net assets, at end of year (000s)	\$ 311,017	\$ 260,688	\$ 269,421	\$ 279,142	\$ 110,295
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	0.89%	0.90%	0.81%	0.85%	0.99%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	0.82%	0.82%	0.82%	0.82%	0.90%
Ratio of net investment income to average net assets (4)(5)	1.72%	1.57%	0.90%	0.81%	1.65%
Portfolio Turnover Rate	43%	48%	66%	73%	107%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Core Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

	Class N			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Period Ended June 30, 2021 *
Net asset value, beginning of period/year	\$ 8.15	\$ 8.41	\$ 9.66	\$ 10.00
Activity from investment operations:				
Net investment income (1)	0.28	0.17	0.08	0.05
Net realized and unrealized gain (loss) on investments	(0.09)	(0.25)	(1.20)	(0.29)
Total from investment operations	0.19	(0.08)	(1.12)	(0.24)
Less distributions from:				
Net investment income	(0.26)	(0.18)	(0.11)	(0.05)
Return of capital	-	-	(0.02)	(0.05)
Total distributions	(0.26)	(0.18)	(0.13)	(0.10)
Net asset value, end of period/year	\$ 8.08	\$ 8.15	\$ 8.41	\$ 9.66
Total return (2)	2.34%	(0.89)%	(11.69)%	(2.39)% (6)
Net assets, at end of period/year (000s)	\$ 35,467	\$ 37,445	\$ 58,166	\$ 56,644
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.90%	1.01%	0.96%	0.89% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	0.78%	0.78%	0.78%	0.78% (7)
Ratio of net investment income to average net assets (4)(5)	3.46%	2.09%	0.88%	0.53% (7)
Portfolio Turnover Rate	33%	57%	56%	52% (6)

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

## Eventide Core Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

	Class A			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Period Ended June 30, 2021 *
Net asset value, beginning of year/period	\$ 8.18	\$ 8.44	\$ 9.71	\$ 10.00
Activity from investment operations:				
Net investment income (1)	0.28	0.18	0.07	0.05
Net realized and unrealized gain (loss) on investments	(0.09)	(0.26)	(1.22)	(0.27)
Total from investment operations	0.19	(0.08)	(1.15)	(0.22)
Less distributions from:				
Net investment income	(0.25)	(0.18)	(0.10)	(0.02)
Return of capital	-	-	(0.02)	(0.05)
Total distributions	(0.25)	(0.18)	(0.12)	(0.07)
Net asset value, end of year/period	\$ 8.12	\$ 8.18	\$ 8.44	\$ 9.71
Total return (2)	2.42%	(0.90)%	(11.91)%	(2.28)% (6)
Net assets, at end of year/period (000s)	\$ 608	\$ 412	\$ 197	\$ 384
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.95%	1.06%	1.01%	0.94% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	0.83%	0.83%	0.83%	0.83% (7)
Ratio of net investment income to average net assets (4)(5)	3.47%	2.19%	0.78%	0.51% (7)
Portfolio Turnover Rate	33%	57%	56%	52% (6)

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

## Eventide Core Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

	Class C			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Period Ended June 30, 2021 *
Net asset value, beginning of year/period	\$ 8.11	\$ 8.37	\$ 9.63	\$ 10.00
Activity from investment operations:				
Net investment income (loss) (1)	0.22	0.11	0.01	(0.02)
Net realized and unrealized gain (loss) on investments	(0.09)	(0.25)	(1.20)	(0.28)
Total from investment operations	0.13	(0.14)	(1.19)	(0.30)
Less distributions from:				
Net investment income	(0.21)	(0.12)	(0.06)	(0.02)
Return of capital	-	-	(0.01)	(0.05)
Total distributions	(0.21)	(0.12)	(0.07)	(0.07)
Net asset value, end of year/period	\$ 8.03	\$ 8.11	\$ 8.37	\$ 9.63
Total return (2)	1.53%	(1.67)%	(12.37)%	(3.02)% (6)
Net assets, at end of year/period (000s)	\$ 492	\$ 221	\$ 224	\$ 163
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.70%	1.81%	1.76%	1.69% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	1.58%	1.58%	1.58%	1.58% (7)
Ratio of net investment income (loss) to average net assets (4)(5)	2.74%	1.35%	0.09%	(0.20)% (7)
Portfolio Turnover Rate	33%	57%	56%	52% (6)

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.



## Eventide Core Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Periods or Years Presented

	Class I			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Period Ended June 30, 2021 *
Net asset value, beginning of year/period	\$ 8.15	\$ 8.41	\$ 9.66	\$ 10.00
Activity from investment operations:				
Net investment income (1)	0.30	0.20	0.09	0.07
Net realized and unrealized gain (loss) on investments	(0.10)	(0.26)	(1.19)	(0.29)
Total from investment operations	0.20	(0.06)	(1.10)	(0.22)
Less distributions from:				
Net investment income	(0.27)	(0.20)	(0.13)	(0.07)
Return of capital	-	-	(0.02)	(0.05)
Total distributions	(0.27)	(0.20)	(0.15)	(0.12)
Net asset value, end of year/period	\$ 8.08	\$ 8.15	\$ 8.41	\$ 9.66
Total return (2)	2.54%	(0.67)%	(11.51)%	(2.24)% (6)
Net assets, at end of year/period (000s)	\$ 100,738	\$ 39,300	\$ 13,877	\$ 64,377
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.70%	0.81%	0.76%	0.69% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	0.58%	0.58%	0.58%	0.58% (7)
Ratio of net investment income to average net assets (4)(5)	3.77%	2.45%	1.00%	0.80% (7)
Portfolio Turnover Rate	33%	57%	56%	52% (6)

\* Eventide Core Bond Fund commenced operations on July 31, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Not annualized.

(7) Annualized.

## Eventide Dividend Opportunities Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class N				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 14.65	\$ 13.43	\$ 15.86	\$ 10.88	\$ 10.37
Activity from investment operations:					
Net investment income (1)	0.06	0.11	0.05	0.04	0.11
Net realized and unrealized gain (loss) on investments	3.07	1.31	(2.01)	5.08	0.57
Total from investment operations	3.13	1.42	(1.96)	5.12	0.68
Less distributions from:					
Net investment income	(0.06)	(0.10)	(0.18)	(0.14)	(0.10)
Net realized gains	-	(0.09)	(0.29)	-	-
Return of capital	-	(0.01)	-	-	(0.07)
Total distributions	(0.06)	(0.20)	(0.47)	(0.14)	(0.17)
Net asset value, end of year	\$ 17.72	\$ 14.65	\$ 13.43	\$ 15.86	\$ 10.88
Total return (2)	21.40%	10.66%	(12.90)%	47.21%	6.60%
Net assets, at end of year (000s)	\$ 87,873	\$ 91,912	\$ 74,940	\$ 70,566	\$ 18,576
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.16%	1.23%	1.14%	1.19%	1.50%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.15%	1.15%	1.15%	1.15%	1.15%
Ratio of net investment income to average net assets (4)(5)	0.40%	0.75%	0.34%	0.27%	1.01%
Portfolio Turnover Rate	38%	50%	50%	35%	90%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Dividend Opportunities Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class A				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 14.66	\$ 13.43	\$ 15.85	\$ 10.87	\$ 10.36
Activity from investment operations:					
Net investment income (1)	0.05	0.10	0.05	0.03	0.10
Net realized and unrealized gain (loss) on investments	3.07	1.32	(2.01)	5.08	0.57
Total from investment operations	3.12	1.42	(1.96)	5.11	0.67
Less distributions from:					
Net investment income	(0.05)	(0.06)	(0.17)	(0.13)	(0.09)
Net realized gains	-	(0.09)	(0.29)	-	-
Return of capital	-	(0.04)	-	-	(0.07)
Total distributions	(0.05)	(0.19)	(0.46)	(0.13)	(0.16)
Net asset value, end of year	\$ 17.73	\$ 14.66	\$ 13.43	\$ 15.85	\$ 10.87
Total return (2)	21.35%	10.68%	(12.88)%	47.22%	6.55%
Net assets, at end of year (000s)	\$ 50,563	\$ 36,722	\$ 29,243	\$ 17,865	\$ 3,184
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.21%	1.28%	1.19%	1.24%	1.55%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.20%	1.20%	1.20%	1.20%	1.20%
Ratio of net investment income to average net assets (4)(5)	0.34%	0.69%	0.31%	0.22%	0.89%
Portfolio Turnover Rate	38%	50%	50%	35%	90%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Dividend Opportunities Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class C				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 14.54	\$ 13.34	\$ 15.77	\$ 10.86	\$ 10.35
Activity from investment operations:					
Net investment income (loss) (1)	(0.06) (6)	(0.01)	(0.07)	(0.08)	0.03
Net realized and unrealized gain (loss) on investments	3.04	1.31	(2.00)	5.06	0.56
Total from investment operations	2.98	1.30	(2.07)	4.98	0.59
Less distributions from:					
Net investment income	-	-	(0.07)	(0.07)	(0.05)
Net realized gains	-	(0.09)	(0.29)	-	-
Return of capital	-	(0.01)	-	-	(0.03)
Total distributions	-	(0.10)	(0.36)	(0.07)	(0.08)
Net asset value, end of year	\$ 17.52	\$ 14.54	\$ 13.34	\$ 15.77	\$ 10.86
Total return (2)	20.50%	9.78%	(13.57)%	45.93%	5.78%
Net assets, at end of year (000s)	\$ 19,564	\$ 14,889	\$ 9,975	\$ 4,508	\$ 824
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	1.96%	2.03%	1.94%	1.99%	2.30%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	1.95%	1.95%	1.95%	1.95%	1.95%
Ratio of net investment income (loss) to average net assets (4)(5)	(0.40)%	(0.05)%	(0.42)%	(0.53)%	0.25%
Portfolio Turnover Rate	38%	50%	50%	35%	90%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the year ended June 30, 2024, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

## Eventide Dividend Opportunities Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class I				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 14.66	\$ 13.44	\$ 15.87	\$ 10.88	\$ 10.37
Activity from investment operations:					
Net investment income (1)	0.09	0.13	0.09	0.07	0.12
Net realized and unrealized gain (loss) on investments	3.08	1.32	(2.02)	5.07	0.57
Total from investment operations	3.17	1.45	(1.93)	5.14	0.69
Less distributions from:					
Net investment income	(0.09)	(0.11)	(0.21)	(0.15)	(0.10)
Net realized gains	-	(0.09)	(0.29)	-	-
Return of capital	-	(0.03)	-	-	(0.08)
Total distributions	(0.09)	(0.23)	(0.50)	(0.15)	(0.18)
Net asset value, end of year	\$ 17.74	\$ 14.66	\$ 13.44	\$ 15.87	\$ 10.88
Total return (2)	21.70%	10.87%	(12.72)%	47.49%	6.79%
Net assets, at end of year (000s)	\$ 705,913	\$ 430,286	\$ 305,801	\$ 237,256	\$ 45,034
Ratio of gross expenses to average net assets before expense reimbursement/recapture (3)(4)	0.96%	1.03%	0.94%	0.99%	1.30%
Ratio of net expenses to average net assets after expense reimbursement/recapture (4)	0.95%	0.95%	0.95%	0.95%	0.95%
Ratio of net investment income to average net assets (4)(5)	0.61%	0.96%	0.55%	0.48%	1.16%
Portfolio Turnover Rate	38%	50%	50%	35%	90%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower/higher.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Exponential Technologies Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented

	Class N			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021 *
Net asset value, beginning of period/year	\$ 12.00	\$ 10.92	\$ 19.08	\$ 10.00
Activity from investment operations:				
Net investment loss (1)	(0.17)	(0.13)	(0.25)	(0.25)
Net realized and unrealized gain (loss) on investments	0.13	1.20	(7.69)	9.33
Total from investment operations	(0.04)	1.07	(7.94)	9.08
Less distributions from:				
Net realized gains	-	-	(0.23)	(0.02)
Total distributions	-	-	(0.23)	(0.02)
Paid-in-capital from redemption fees (1)	-	0.01	0.01	0.02
Net asset value, end of period/year	\$ 11.96	\$ 12.00	\$ 10.92	\$ 19.08
Total return (2)	(0.33)%	9.89%	(42.00)%	91.00%
Net assets, at end of period/year (000s)	\$ 19,201	\$ 22,186	\$ 12,479	\$ 15,730
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.69%	1.70%	1.63%	1.73%
Ratio of net expenses to average net assets after expense reimbursement (4)	1.63%	1.63%	1.63%	1.63%
Ratio of net investment loss to average net assets (4)(5)	(1.36)%	(1.23)%	(1.54)%	(1.50)%
Portfolio Turnover Rate	70%	80%	69%	60%

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Exponential Technologies Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented

	Class A			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021 *
Net asset value, beginning of period/year	\$ 12.00	\$ 10.93	\$ 19.08	\$ 10.00
Activity from investment operations:				
Net investment loss (1)	(0.17)	(0.14)	(0.25)	(0.26)
Net realized and unrealized gain (loss) on investments	0.13	1.20	(7.68)	9.34
Total from investment operations	(0.04)	1.06	(7.93)	9.08
Less distributions from:				
Net realized gains	-	-	(0.23)	(0.02)
Total distributions	-	-	(0.23)	(0.02)
Paid-in-capital from redemption fees (1)	-	0.01	0.01	0.02
Net asset value, end of period/year	<u>\$ 11.96</u>	<u>\$ 12.00</u>	<u>\$ 10.93</u>	<u>\$ 19.08</u>
Total return (2)	<u>(0.33)%</u>	<u>9.79%</u>	<u>(41.95)%</u>	<u>91.00%</u>
Net assets, at end of period/year (000s)	<u>\$ 8,421</u>	<u>\$ 8,257</u>	<u>\$ 7,377</u>	<u>\$ 7,662</u>
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.74%	1.75%	1.68%	1.78%
Ratio of net expenses to average net assets after expense reimbursement (4)	1.68%	1.68%	1.68%	1.68%
Ratio of net investment loss to average net assets (4)(5)	(1.41)%	(1.28)%	(1.58)%	(1.55)%
Portfolio Turnover Rate	70%	80%	69%	60%

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Exponential Technologies Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented

	Class C			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021 *
Net asset value, beginning of period/year	\$ 11.74	\$ 10.77	\$ 18.96	\$ 10.00
Activity from investment operations:				
Net investment loss (1)	(0.25)	(0.21)	(0.37)	(0.38)
Net realized and unrealized gain (loss) on investments	0.12	1.17	(7.60)	9.35
Total from investment operations	(0.13)	0.96	(7.97)	8.97
Less distributions from:				
Net realized gains	-	-	(0.23)	(0.02)
Total distributions	-	-	(0.23)	(0.02)
Paid-in-capital from redemption fees (1)	-	0.01	0.01	0.01
Net asset value, end of period/year	\$ 11.61	\$ 11.74	\$ 10.77	\$ 18.96
Total return (2)	(1.11)%	9.01%	(42.43)%	89.80%
Net assets, at end of period/year (000s)	\$ 2,550	\$ 2,635	\$ 2,422	\$ 2,065
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	2.49%	2.50%	2.43%	2.53%
Ratio of net expenses to average net assets after expense reimbursement (4)	2.43%	2.43%	2.43%	2.43%
Ratio of net investment loss to average net assets (4)(5)	(2.16)%	(2.03)%	(2.33)%	(2.30)%
Portfolio Turnover Rate	70%	80%	69%	60%

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.



## Eventide Exponential Technologies Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Period or Years Presented

	Class I			
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021 *
Net asset value, beginning of period/year	\$ 12.08	\$ 10.97	\$ 19.12	\$ 10.00
Activity from investment operations:				
Net investment loss (1)	(0.14)	(0.11)	(0.22)	(0.22)
Net realized and unrealized gain (loss) on investments	0.13	1.21	(7.71)	9.34
Total from investment operations	(0.01)	1.10	(7.93)	9.12
Less distributions from:				
Net realized gains	-	-	(0.23)	(0.02)
Total distributions	-	-	(0.23)	(0.02)
Paid-in-capital from redemption fees (1)	-	0.01	0.01	0.02
Net asset value, end of period/year	\$ 12.07	\$ 12.08	\$ 10.97	\$ 19.12
Total return (2)	(0.08)%	10.12%	(41.86)%	91.40%
Net assets, at end of period/year (000s)	\$ 85,315	\$ 82,735	\$ 72,567	\$ 96,821
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.49%	1.50%	1.43%	1.53%
Ratio of net expenses to average net assets after expense reimbursement (4)	1.43%	1.43%	1.43%	1.43%
Ratio of net investment loss to average net assets (4)(5)	(1.16)%	(1.02)%	(1.33)%	(1.30)%
Portfolio Turnover Rate	70%	80%	69%	60%

\* Eventide Exponential Technologies Fund commenced operations on June 30, 2020.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

## Eventide Gilead Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class N				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 48.25	\$ 44.10	\$ 69.91	\$ 47.16	\$ 41.75
Activity from investment operations:					
Net investment loss (1)	(0.38)	(0.27)	(0.53)	(0.51)	(0.25)
Net realized and unrealized gain (loss) on investments	0.28	6.70	(21.01)	23.77	6.98
Total from investment operations	(0.10)	6.43	(21.54)	23.26	6.73
Less distributions from:					
Net realized gains	-	(2.28)	(4.27)	(0.51)	(1.32)
Total distributions	-	(2.28)	(4.27)	(0.51)	(1.32)
Net asset value, end of year	\$ 48.15	\$ 48.25	\$ 44.10	\$ 69.91	\$ 47.16
Total return (2)	(0.21)% (5)	15.29% (5)	(32.65)%	49.43%	16.66%
Net assets, at end of year (000s)	\$ 427,768	\$ 526,825	\$ 529,869	\$ 827,811	\$ 549,944
Ratio of net expenses to average net assets (3)	1.36%	1.38%	1.31%	1.31%	1.38%
Ratio of net investment loss to average net assets (3)(4)	(0.79)%	(0.59)%	(0.86)%	(0.85)%	(0.63)%
Portfolio Turnover Rate	36%	34%	27%	19%	35%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Gilead Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class A				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 47.94	\$ 43.83	\$ 69.53	\$ 46.92	\$ 41.57
Activity from investment operations:					
Net investment loss (1)	(0.41)	(0.29)	(0.55)	(0.54)	(0.27)
Net realized and unrealized gain (loss) on investments	0.27	6.68	(20.88)	23.66	6.94
Total from investment operations	(0.14)	6.39	(21.43)	23.12	6.67
Less distributions from:					
Net realized gains	-	(2.28)	(4.27)	(0.51)	(1.32)
Total distributions	-	(2.28)	(4.27)	(0.51)	(1.32)
Net asset value, end of year	\$ 47.80	\$ 47.94	\$ 43.83	\$ 69.53	\$ 46.92
Total return (2)	(0.29)% (5)	15.30% (5)	(32.67)%	49.39%	16.58%
Net assets, at end of year (000s)	\$ 320,983	\$ 351,924	\$ 302,171	\$ 458,726	\$ 301,013
Ratio of net expenses to average net assets (3)	1.41%	1.43%	1.36%	1.36%	1.43%
Ratio of net investment loss to average net assets (3)(4)	(0.85)%	(0.65)%	(0.91)%	(0.91)%	(0.69)%
Portfolio Turnover Rate	36%	34%	27%	19%	35%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Gilead Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class C				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 42.13	\$ 39.09	\$ 62.97	\$ 42.86	\$ 38.37
Activity from investment operations:					
Net investment loss (1)	(0.67)	(0.55)	(0.91)	(0.89)	(0.53)
Net realized and unrealized gain (loss) on investments	0.25	5.87	(18.70)	21.51	6.34
Total from investment operations	(0.42)	5.32	(19.61)	20.62	5.81
Less distributions from:					
Net realized gains	-	(2.28)	(4.27)	(0.51)	(1.32)
Total distributions	-	(2.28)	(4.27)	(0.51)	(1.32)
Net asset value, end of year	\$ 41.71	\$ 42.13	\$ 39.09	\$ 62.97	\$ 42.86
Total return (2)	(1.00)% (5)	14.38% (5)	(33.21)%	48.23%	15.71%
Net assets, at end of year (000s)	\$ 166,155	\$ 218,201	\$ 235,967	\$ 404,272	\$ 289,242
Ratio of net expenses to average net assets (3)	2.16%	2.18%	2.11%	2.11%	2.18%
Ratio of net investment loss to average net assets (3)(4)	(1.59)%	(1.40)%	(1.67)%	(1.65)%	(1.43)%
Portfolio Turnover Rate	36%	34%	27%	19%	35%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Gilead Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

#### Class I

	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 49.82	\$ 45.36	\$ 71.65	\$ 48.22	\$ 42.59
Activity from investment operations:					
Net investment loss (1)	(0.30)	(0.19)	(0.41)	(0.40)	(0.18)
Net realized and unrealized gain (loss) on investments	0.28	6.93	(21.61)	24.34	7.13
Total from investment operations	(0.02)	6.74	(22.02)	23.94	6.95
Less distributions from:					
Net realized gains	-	(2.28)	(4.27)	(0.51)	(1.32)
Total distributions	-	(2.28)	(4.27)	(0.51)	(1.32)
Net asset value, end of year	\$ 49.80	\$ 49.82	\$ 45.36	\$ 71.65	\$ 48.22
Total return (2)	(0.04)% (5)	15.56% (5)	(32.52)%	49.76%	16.85%
Net assets, at end of year (000s)	\$ 2,434,432	\$ 2,663,688	\$ 2,408,991	\$ 3,522,353	\$ 1,997,163
Ratio of net expenses to average net assets (3)	1.16%	1.18%	1.11%	1.11%	1.18%
Ratio of net investment loss to average net assets (3)(4)	(0.60)%	(0.40)%	(0.66)%	(0.65)%	(0.43)%
Portfolio Turnover Rate	36%	34%	27%	19%	35%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Healthcare & Life Sciences Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class N				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 36.63	\$ 26.52	\$ 46.19	\$ 43.33	\$ 35.51
Activity from investment operations:					
Net investment loss (1)	(0.42)	(0.37)	(0.57)	(0.72)	(0.52)
Net realized and unrealized gain (loss) on investments	(2.91)	10.48	(14.74)	5.52	9.19
Total from investment operations	(3.33)	10.11	(15.31)	4.80	8.67
Less distributions from:					
Net investment income	-	-	(0.63)	-	-
Net realized gains	-	-	(3.73)	(1.94)	(0.87)
Total distributions	-	-	(4.36)	(1.94)	(0.87)
Paid-in-capital from redemption fees (1)	-	-	-	0.00 (5)	0.02
Net asset value, end of year	\$ 33.30	\$ 36.63	\$ 26.52	\$ 46.19	\$ 43.33
Total return (2)	(9.09)% (6)	38.12% (6)	(35.99)% (6)	10.34%	24.68%
Net assets, at end of year (000s)	\$ 93,027	\$ 133,006	\$ 115,954	\$ 227,441	\$ 231,460
Ratio of net expenses to average net assets (3)	1.52%	1.50%	1.50%	1.48%	1.50%
Ratio of net investment loss to average net assets (3)(4)	(1.24)%	(1.14)%	(1.49)%	(1.47)%	(1.44)%
Portfolio Turnover Rate	71%	79%	59%	62%	33%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than \$0.01 per share.

(6) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Healthcare & Life Sciences Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class A				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 36.37	\$ 26.34	\$ 45.91	\$ 43.10	\$ 35.33
Activity from investment operations:					
Net investment loss (1)	(0.44)	(0.38)	(0.58)	(0.74)	(0.53)
Net realized and unrealized gain (loss) on investments	(2.89)	10.41	(14.64)	5.49	9.15
Total from investment operations	(3.33)	10.03	(15.22)	4.75	8.62
Less distributions from:					
Net investment income	-	-	(0.62)	-	-
Net realized gains	-	-	(3.73)	(1.94)	(0.87)
Total distributions	-	-	(4.35)	(1.94)	(0.87)
Paid-in-capital from redemption fees (1)	-	-	-	0.00 (5)	0.02
Net asset value, end of year	\$ 33.04	\$ 36.37	\$ 26.34	\$ 45.91	\$ 43.10
Total return (2)	(9.16)% (6)	38.08% (6)	(36.02)% (6)	10.28%	24.67%
Net assets, at end of year (000s)	\$ 122,423	\$ 151,885	\$ 114,642	\$ 191,709	\$ 175,151
Ratio of net expenses to average net assets (3)	1.57%	1.55%	1.55%	1.53%	1.55%
Ratio of net investment loss to average net assets (3)(4)	(1.29)%	(1.19)%	(1.54)%	(1.52)%	(1.49)%
Portfolio Turnover Rate	71%	79%	59%	62%	33%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than \$0.01 per share.

(6) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Healthcare & Life Sciences Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class C				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 33.39	\$ 24.37	\$ 42.78	\$ 40.56	\$ 33.54
Activity from investment operations:					
Net investment loss (1)	(0.63)	(0.57)	(0.80)	(1.04)	(0.76)
Net realized and unrealized gain (loss) on investments	(2.65)	9.59	(13.60)	5.20	8.63
Total from investment operations	<u>(3.28)</u>	<u>9.02</u>	<u>(14.40)</u>	<u>4.16</u>	<u>7.87</u>
Less distributions from:					
Net investment income	-	-	(0.28)	-	-
Net realized gains	-	-	(3.73)	(1.94)	(0.87)
Total distributions	<u>-</u>	<u>-</u>	<u>(4.01)</u>	<u>(1.94)</u>	<u>(0.87)</u>
Paid-in-capital from redemption fees (1)	<u>-</u>	<u>-</u>	<u>-</u>	0.00 (5)	<u>0.02</u>
Net asset value, end of year	<u>\$ 30.11</u>	<u>\$ 33.39</u>	<u>\$ 24.37</u>	<u>\$ 42.78</u>	<u>\$ 40.56</u>
Total return (2)	<u>(9.82)% (6)</u>	<u>37.01% (6)</u>	<u>(36.51)% (6)</u>	<u>9.45%</u>	<u>23.73%</u>
Net assets, at end of year (000s)	<u>\$ 55,661</u>	<u>\$ 76,849</u>	<u>\$ 66,540</u>	<u>\$ 120,351</u>	<u>\$ 104,202</u>
Ratio of net expenses to average net assets (3)	2.32%	2.30%	2.30%	2.28%	2.30%
Ratio of net investment loss to average net assets (3)(4)	(2.04)%	(1.94)%	(2.29)%	(2.27)%	(2.23)%
Portfolio Turnover Rate	71%	79%	59%	62%	33%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than \$0.01 per share.

(6) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.



## Eventide Healthcare & Life Sciences Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class I				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 37.45	\$ 27.05	\$ 47.04	\$ 44.02	\$ 35.98
Activity from investment operations:					
Net investment loss (1)	(0.37)	(0.31)	(0.49)	(0.64)	(0.46)
Net realized and unrealized gain (loss) on investments	(2.99)	10.71	(15.03)	5.60	9.35
Total from investment operations	(3.36)	10.40	(15.52)	4.96	8.89
Less distributions from:					
Net investment income	-	-	(0.74)	-	-
Net realized gains	-	-	(3.73)	(1.94)	(0.87)
Total distributions	-	-	(4.47)	(1.94)	(0.87)
Paid-in-capital from redemption fees (1)	-	-	-	0.00 (5)	0.02
Net asset value, end of year	\$ 34.09	\$ 37.45	\$ 27.05	\$ 47.04	\$ 44.02
Total return (2)	(8.97)% (6)	38.45% (6)	(35.85)% (6)	10.54%	24.97%
Net assets, at end of year (000s)	\$ 1,168,805	\$ 1,441,422	\$ 1,024,430	\$ 1,573,091	\$ 1,120,862
Ratio of net expenses to average net assets (3)	1.32%	1.30%	1.30%	1.28%	1.30%
Ratio of net investment loss to average net assets (3)(4)	(1.04)%	(0.94)%	(1.29)%	(1.28)%	(1.24)%
Portfolio Turnover Rate	71%	79%	59%	62%	33%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.

(3) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(4) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(5) Amount represents less than \$0.01 per share.

(6) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

## Eventide Large Cap Focus Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period or Year Presented

	Class N	
	Year Ended June 30, 2024	Year Ended June 30, 2023 *
Net asset value, beginning of period/year	\$ 11.44	\$ 10.00
Activity from investment operations:		
Net investment loss (1)	(0.00) (6)(7)	(0.01)
Net realized and unrealized gain on investments	2.57	1.45
Total from investment operations	2.57	1.44
Less distributions from:		
Return of capital	-	(0.00) (6)
Total distributions	-	(0.00) (6)
Net asset value, end of period/year	\$ 14.01	\$ 11.44
Total return (2)	22.47%	14.43%
Net assets, at end of period/year (000s)	\$ 13,097	\$ 330
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.38%	2.84% (8)
Ratio of net expenses to average net assets after expense reimbursement (4)	1.14%	1.15% (8)
Ratio of net investment loss to average net assets (4)(5)	(0.02)%	(0.15)%
Portfolio Turnover Rate	101%	48%

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than \$0.01 per share.

(7) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the year ended June 30, 2024, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

(8) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

## Eventide Large Cap Focus Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period or Year Presented

	Class A	
	Year Ended June 30, 2024	Year Ended June 30, 2023 *
Net asset value, beginning of period/year	\$ 11.42	\$ 10.00
Activity from investment operations:		
Net investment loss (1)	(0.00) (6)(7)	(0.00) (6)
Net realized and unrealized gain on investments	2.57	1.43
Total from investment operations	2.57	1.43
Less distributions from:		
Return of capital	-	(0.01)
Total distributions	-	(0.01)
Net asset value, end of period/year	\$ 13.99	\$ 11.42
Total return (2)	22.50% (8)	14.26%
Net assets, at end of period/year (000s)	\$ 1,836	\$ 190
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.43%	2.89% (9)
Ratio of net expenses to average net assets after expense reimbursement (4)	1.19%	1.20% (9)
Ratio of net investment loss to average net assets (4)(5)	(0.03)%	(0.25)%
Portfolio Turnover Rate	101%	48%

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than \$0.01 per share.

(7) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the year ended June 30, 2024, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.

(8) Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset values for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.

(9) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

## Eventide Large Cap Focus Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period or Year Presented

	Class C	
	Year Ended June 30, 2024	Year Ended June 30, 2023 *
Net asset value, beginning of period/year	\$ 11.36	\$ 10.00
Activity from investment operations:		
Net investment loss (1)	(0.09) (6)	(0.09)
Net realized and unrealized gain on investments	2.52	1.45
Total from investment operations	2.43	1.36
Net asset value, end of period/year	\$ 13.79	\$ 11.36
Total return (2)	21.39%	13.60%
Net assets, at end of period/year (000s)	\$ 292	\$ 27
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	2.18%	3.64% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	1.94%	1.95% (7)
Ratio of net investment loss to average net assets (4)(5)	(0.68)%	(0.93)%
Portfolio Turnover Rate	101%	48%

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

- (1) Per share amounts calculated using the average shares method.
- (2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.
- (3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.
- (4) The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.
- (5) Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.
- (6) As required by SEC standard per share data calculation methodology, this represents a balancing figure derived from the other amounts in the financial highlights tables that captures all other changes affecting net asset value per share. This per share loss amount does not correlate to the aggregate of the net investment income in the Statement of Operations for the year ended June 30, 2024, primarily due to the timing of sales and repurchases of the Fund's shares in relation to underlying income.
- (7) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

## Eventide Large Cap Focus Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period or Year Presented

	Class I	
	Year Ended June 30, 2024	Year Ended June 30, 2023 *
Net asset value, beginning of period/year	\$ 11.44	\$ 10.00
Activity from investment operations:		
Net investment income (1)	0.03	0.01
Net realized and unrealized gain on investments	2.57	1.44
Total from investment operations	2.60	1.45
Less distributions from:		
Net investment income	-	(0.00) (6)
Return of capital	-	(0.01)
Total distributions	-	(0.01)
Net asset value, end of period/year	\$ 14.04	\$ 11.44
Total return (2)	22.73%	14.55%
Net assets, at end of period/year (000s)	\$ 90,959	\$ 12,808
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.18%	2.64% (7)
Ratio of net expenses to average net assets after expense reimbursement (4)	0.94%	0.95% (7)
Ratio of net investment income (loss) to average net assets (4)(5)	0.24%	0.08%
Portfolio Turnover Rate	101%	48%

\* Eventide Large Cap Focus Fund Class N commenced operations on June 30, 2022.

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than \$0.01 per share.

(7) The ratio includes 0.01% for the year ended June 30, 2023 attributed to line of credit fees.

## Eventide Limited-Term Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class N				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 9.68	\$ 9.72	\$ 10.49	\$ 10.62	\$ 10.38
Activity from investment operations:					
Net investment income (1)	0.28	0.16	0.04	0.06	0.15
Net realized and unrealized gain (loss) on investments	0.22	(0.04)	(0.69)	(0.01)	0.30
Total from investment operations	0.50	0.12	(0.65)	0.05	0.45
Less distributions from:					
Net investment income	(0.29)	(0.16)	(0.07)	(0.07)	(0.19)
Net realized gains	-	-	-	(0.07)	-
Return of capital	-	(0.00) (6)	(0.05)	(0.04)	(0.02)
Total distributions	(0.29)	(0.16)	(0.12)	(0.18)	(0.21)
Net asset value, end of year	\$ 9.89	\$ 9.68	\$ 9.72	\$ 10.49	\$ 10.62
Total return (2)	5.18%	1.29%	(6.26)%	0.48%	4.37%
Net assets, at end of year (000s)	\$ 17,949	\$ 17,698	\$ 5,622	\$ 6,906	\$ 37,973
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.89%	0.91%	0.84%	0.86%	1.11%
Ratio of net expenses to average net assets after expense reimbursement (4)	0.75%	0.75%	0.75%	0.75%	0.75%
Ratio of net investment income to average net assets (4)(5)	2.87%	1.66%	0.42%	0.54%	1.44%
Portfolio Turnover Rate	33%	34%	48%	72%	71%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Amount represents less than \$0.01 per share.

## Eventide Limited-Term Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class A				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 9.70	\$ 9.75	\$ 10.51	\$ 10.65	\$ 10.41
Activity from investment operations:					
Net investment income (1)	0.27	0.14	0.04	0.03	0.17
Net realized and unrealized gain (loss) on investments	0.22	(0.03)	(0.69)	0.01 (6)	0.27
Total from investment operations	0.49	0.11	(0.65)	0.04	0.44
Less distributions from:					
Net investment income	(0.28)	(0.16)	(0.06)	(0.07)	(0.18)
Net realized gains	-	-	-	(0.07)	-
Return of capital	-	(0.00) (7)	(0.05)	(0.04)	(0.02)
Total distributions	(0.28)	(0.16)	(0.11)	(0.18)	(0.20)
Paid-in-capital from redemption fees (1)	-	-	-	-	-
Net asset value, end of year	\$ 9.91	\$ 9.70	\$ 9.75	\$ 10.51	\$ 10.65
Total return (2)	5.09%	1.14%	(6.20)%	0.45%	4.30%
Net assets, at end of year (000s)	\$ 4,612	\$ 19,390	\$ 22,210	\$ 29,596	\$ 12,873
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.94%	0.96%	0.89%	0.91%	1.16%
Ratio of net expenses to average net assets after expense reimbursement (4)	0.80%	0.80%	0.80%	0.80%	0.80%
Ratio of net investment income to average net assets (4)(5)	2.70%	1.47%	0.37%	0.27%	1.63%
Portfolio Turnover Rate	33%	34%	48%	72%	71%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.

(7) Amount represents less than \$0.01 per share.

## Eventide Limited-Term Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class C				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 9.64	\$ 9.68	\$ 10.44	\$ 10.60	\$ 10.37
Activity from investment operations:					
Net investment income (loss) (1)	0.20	0.07	(0.04)	(0.05)	(0.01)
Net realized and unrealized gain (loss) on investments	0.21	(0.02)	(0.68)	0.01 (6)	0.37
Total from investment operations	0.41	0.05	(0.72)	(0.04)	0.36
Less distributions from:					
Net investment income	(0.21)	(0.09)	(0.02)	(0.01)	(0.10)
Net realized gains	-	-	-	(0.07)	-
Return of capital	-	(0.00) (7)	(0.02)	(0.04)	(0.03)
Total distributions	(0.21)	(0.09)	(0.04)	(0.12)	(0.13)
Net asset value, end of year	\$ 9.84	\$ 9.64	\$ 9.68	\$ 10.44	\$ 10.60
Total return (2)	4.26%	0.49%	(6.94)%	(0.38)%	3.50%
Net assets, at end of year (000s)	\$ 1,564	\$ 1,618	\$ 1,678	\$ 1,545	\$ 401
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	1.69%	1.71%	1.64%	1.66%	1.91%
Ratio of net expenses to average net assets after expense reimbursement (4)	1.55%	1.55%	1.55%	1.55%	1.55%
Ratio of net investment income (loss) to average net assets (4)(5)	2.05%	0.74%	(0.37)%	(0.50)%	(0.08)%
Portfolio Turnover Rate	33%	34%	48%	72%	71%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.

(7) Amount represents less than \$0.01 per share.



## Eventide Limited-Term Bond Fund

### FINANCIAL HIGHLIGHTS

Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years Presented

	Class I				
	Year Ended June 30, 2024	Year Ended June 30, 2023	Year Ended June 30, 2022	Year Ended June 30, 2021	Year Ended June 30, 2020
Net asset value, beginning of year	\$ 9.93	\$ 9.97	\$ 10.75	\$ 10.89	\$ 10.64
Activity from investment operations:					
Net investment income (1)	0.31	0.16	0.07	0.05	0.17
Net realized and unrealized gain (loss) on investments	0.22	(0.02)	(0.71)	0.01 (6)	0.31
Total from investment operations	0.53	0.14	(0.64)	0.06	0.48
Less distributions from:					
Net investment income	(0.31)	(0.18)	(0.08)	(0.09)	(0.21)
Net realized gains	-	-	-	(0.07)	-
Return of capital	-	(0.00) (7)	(0.06)	(0.04)	(0.02)
Total distributions	(0.31)	(0.18)	(0.14)	(0.20)	(0.23)
Paid-in-capital from redemption fees (1)	-	-	-	-	-
Net asset value, end of year	\$ 10.15	\$ 9.93	\$ 9.97	\$ 10.75	\$ 10.89
Total return (2)	5.35%	1.46%	(6.02)%	0.65%	4.58%
Net assets, at end of year (000s)	\$ 121,701	\$ 88,666	\$ 152,546	\$ 144,089	\$ 28,847
Ratio of gross expenses to average net assets before expense reimbursement (3)(4)	0.69%	0.71%	0.64%	0.66%	0.91%
Ratio of net expenses to average net assets after expense reimbursement (4)	0.55%	0.55%	0.55%	0.55%	0.55%
Ratio of net investment income to average net assets (4)(5)	3.10%	1.68%	0.64%	0.49%	1.58%
Portfolio Turnover Rate	33%	34%	48%	72%	71%

(1) Per share amounts calculated using the average shares method.

(2) Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any. Had the advisor not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.

(3) Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the advisor.

(4) The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.

(5) Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.

(6) Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.

(7) Amount represents less than \$0.01 per share.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS

June 30, 2024

---

### (I) ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Mutual Fund Series Trust (the "**Trust**"), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended ("**1940 Act**"). The Trust currently consists of thirty-five series. These financial statements include the following series: Eventide Balanced Fund (formerly Eventide Multi-Asset Income Fund), Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and the Eventide Limited-Term Bond Fund (each a "**Fund**" or collectively the "**Funds**"). Each Fund except Eventide Exponential Technologies Fund and Eventide Large Cap Focus Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund and Eventide Large Cap Focus Fund are non-diversified series of the Trust. The Funds' investment advisor is Eventide Asset Management, LLC (the "**Advisor**").

Eventide Balanced Fund commenced operations on July 15, 2015. The Fund's investment objective is current income while maintaining the potential for capital appreciation.

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund's investment objective is total return consistent with income generation.

Eventide Dividend Opportunities Fund commenced operations on September 29, 2017. The Fund's investment objectives are dividend income and long-term capital appreciation. The Fund's secondary objective is dividend growth.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund's investment objective is long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund's investment objective is long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund's investment objective is long-term capital appreciation.

Eventide Large Cap Focus Fund commenced operations on June 30, 2022. The Fund's investment objective is long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify (the "**Conversion**") all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the "**Conversion Date**"). On the Conversion Date, each Class C share was reclassified as a Class I shares equal in value to the Class C shares owned by that shareholder. The Eventide Limited-Term Bond Fund's Class N and Class C shares commenced operations December 14, 2018. The Fund changed its fiscal year end from October 31 to June 30. The Fund's investment objective is income.

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with accounting principles generally accepted in the United States of America ("**GAAP**"). The Funds are investment companies and accordingly follow the investment company accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 "Financial Services – Investment Companies" including Accounting Standards Update 2013-08.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

---

a) Securities Valuation - Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (“**NOCP**”). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the “**Board**”) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the “**underlying funds**”). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any closed-end investment company purchased by the Funds will not change. The independent pricing service does not distinguish between smaller-sized bond positions known as “odd lots” and larger institutional-sized bond positions known as “round lots”. The Funds may fair value a particular bond if the Advisor does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund’s holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

The Fund may hold investments, such as private investments, interests in commodity pools, other non-traded securities or temporarily illiquid securities, for which market quotations are not readily available or are determined to be unreliable. These securities are valued using the “fair value” procedures approved by the Board. The Board has designated the Advisor as its valuation designee (the “**Valuation Designee**”) to execute these procedures. The Board may also enlist third party consultants such a valuation specialist at a public accounting firm, valuation consultant or financial officer of a security issuer on an as-needed basis to assist the Valuation Designee in determining a security-specific fair value. The Board is responsible for reviewing and approving fair value methodologies utilized by the Valuation Designee, approval of which shall be based upon whether the Valuation Designee followed the valuation procedures established by the Board.

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

Level 2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Funds’ own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following tables summarize the inputs used as of June 30, 2024 for the Funds' assets measured at fair value:

### Eventide Balanced Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 201,369,881	\$ -	\$ -	\$ 201,369,881
Asset Backed Securities <sup>(a)</sup>	-	6,058,130	-	6,058,130
Collateralized Mortgage Obligations <sup>(a)</sup>	-	1,823,998	-	1,823,998
Convertible Bonds <sup>(a)</sup>	-	1,277,156	-	1,277,156
Corporate Bonds <sup>(a)</sup>	-	78,264,016	-	78,264,016
Municipal Bonds <sup>(a)</sup>	-	16,180,027	-	16,180,027
U.S. Government & Agencies <sup>(a)</sup>	-	67,903,979	-	67,903,979
Short-Term Investments	111,291	-	-	111,291
<b>Total</b>	<b>\$ 201,481,172</b>	<b>\$ 171,507,306</b>	<b>\$ -</b>	<b>\$ 372,988,478</b>

### Eventide Core Bond Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Asset Backed Securities <sup>(a)</sup>	\$ -	\$ 4,084,302	\$ -	\$ 4,084,302
Corporate Bonds <sup>(a)</sup>	-	62,117,315	-	62,117,315
Municipal Bonds <sup>(a)</sup>	-	13,173,734	-	13,173,734
U.S. Government & Agencies <sup>(a)</sup>	-	54,164,501	-	54,164,501
<b>Total</b>	<b>\$ -</b>	<b>\$ 133,539,852</b>	<b>\$ -</b>	<b>\$ 133,539,852</b>

### Eventide Dividend Opportunities Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 846,156,449	\$ -	\$ -	\$ 846,156,449
Corporate Bonds <sup>(a)</sup>	-	3,214,663	-	3,214,663
Short-Term Investments	111,652	-	-	111,652
<b>Total</b>	<b>\$ 846,268,101</b>	<b>\$ 3,214,663</b>	<b>\$ -</b>	<b>\$ 849,482,764</b>

### Eventide Exponential Technologies Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 109,349,262	\$ -	\$ -	\$ 109,349,262
Corporate Bonds <sup>(a)</sup>	-	741,845	-	741,845
Warrant <sup>(a)</sup>	-	-	-	-
Short-Term Investments	12,517	-	-	12,517
Equity Options Purchased	4,000	-	-	4,000
<b>Total</b>	<b>\$ 109,365,779</b>	<b>\$ 741,845</b>	<b>\$ -</b>	<b>\$ 110,107,624</b>

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Gilead Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 3,247,815,258	\$ -	\$ -	\$ 3,247,815,258
Contingent Value Rights <sup>(a)</sup>	-	-	3,365,186	3,365,186
Private Investments <sup>(a)</sup>	7,814,877	-	32,891,954	40,706,831
Corporate Bonds <sup>(a)</sup>	-	42,177,975	-	42,177,975
Warrant <sup>(a)</sup>	-	-	5,133,496	5,133,496
Short-Term Investments	5,197,620	-	-	5,197,620
<b>Total</b>	<b>\$ 3,260,827,755</b>	<b>\$ 42,177,975</b>	<b>\$ 41,390,636</b>	<b>\$ 3,344,396,366</b>

### Eventide Healthcare & Life Sciences Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 1,280,320,328	\$ -	\$ -	\$ 1,280,320,328
Contingent Value Rights <sup>(a)</sup>	-	-	1,291,743	1,291,743
Private Investments <sup>(a)</sup>	43,686,657	-	60,005,195	103,691,852
Convertible Bonds <sup>(a)</sup>	-	-	394,520	394,520
Warrant <sup>(a)</sup>	-	-	3,125,031	3,125,031
Short-Term Investments	3,394,275	-	-	3,394,275
<b>Total</b>	<b>\$ 1,327,401,260</b>	<b>\$ -</b>	<b>\$ 64,816,489</b>	<b>\$ 1,392,217,749</b>

### Eventide Large Cap Focus Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Common Stocks <sup>(a)</sup>	\$ 102,792,851	\$ -	\$ -	\$ 102,792,851
Warrant <sup>(a)</sup>	-	-	-	-
<b>Total</b>	<b>\$ 102,792,851</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 102,792,851</b>

### Eventide Limited-Term Bond Fund

#### Assets

Security Classifications	Level 1	Level 2	Level 3	Totals
Asset Backed Securities <sup>(a)</sup>	\$ -	\$ 6,922,965	\$ -	\$ 6,922,965
Corporate Bonds <sup>(a)</sup>	-	91,776,678	-	91,776,678
Municipal Bonds <sup>(a)</sup>	-	11,559,323	-	11,559,323
U.S. Government & Agencies <sup>(a)</sup>	-	31,628,994	-	31,628,994
<b>Total</b>	<b>\$ -</b>	<b>\$ 141,887,960</b>	<b>\$ -</b>	<b>\$ 141,887,960</b>

<sup>(a)</sup> For a detailed break-out of investments by security classification, please refer to the Schedule of Investments.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

### Eventide Balanced Fund

	Corporate Bonds	Total
Beginning balance 6/30/2023	\$ 3,800,000	\$ 3,800,000
Total realized gain (loss)	-	-
Change in unrealized appreciation (depreciation)	(60,504)	(60,504)
Cost of purchases	-	-
Proceeds from sales	-	-
Net transfers in/out of level 3*	(3,739,496)	(3,739,496)
Ending balance 6/30/2024	\$ -	\$ -

### Eventide Dividend Opportunities Fund

	Corporate Bonds	Total
Beginning balance 6/30/2023	\$ 2,000,000	\$ 2,000,000
Total realized gain (loss)	-	-
Change in unrealized appreciation (depreciation)	(35,337)	(35,337)
Cost of purchases	3,250,000	3,250,000
Proceeds from sales	(2,000,000)	(2,000,000)
Corporate action	-	-
Net transfers in/out of level 3*	(3,214,663)	(3,214,663)
Ending balance 6/30/2024	\$ -	\$ -

### Eventide Exponential Technologies Fund

	Corporate Bonds	Warrant	Total
Beginning balance 6/30/2023	\$ -	\$ -	\$ -
Total realized gain (loss)	-	-	-
Change in unrealized appreciation (depreciation)	(8,155)	-	(8,155)
Cost of purchases	750,000	-	750,000
Proceeds from sales	-	-	-
Net transfers in/out of level 3*	(741,845)	-	(741,845)
Ending balance 6/30/2024	\$ -	\$ -	\$ -

### Eventide Gilead Fund

	Contingent Value Rights	Private Investments	Corporate Bonds	Warrant	Total
Beginning balance 6/30/2023	\$ 3,197,106	\$ 18,653,578	\$ 27,000,000	\$ 1,274,958	\$ 50,125,642
Total realized gain (loss)	-	-	-	-	-
Change in unrealized appreciation (depreciation)	168,080	8,238,374	(690,567)	3,858,538	11,574,425
Cost of purchases	-	6,000,002	9,000,000	-	15,000,002
Proceeds from sales	-	-	(7,000,000)	-	(7,000,000)
Net transfers in/out of level 3*	-	-	(28,309,433)	-	(28,309,433)
Ending balance 6/30/2024	\$ 3,365,186	\$ 32,891,954	\$ -	\$ 5,133,496	\$ 41,390,636

### Eventide Healthcare & Life Sciences Fund

	Contingent Value Rights	Private Investments	Convertible Bonds	Warrants	Total
Beginning balance 6/30/2023	\$ 1,227,225	\$ 93,230,465	\$ 2,818,000	\$ 708,377	\$ 97,984,067
Total realized gain (loss)	-	(16)	-	-	(16)
Change in unrealized appreciation (depreciation)	64,518	824,706	(3,423,480)	2,416,654	(117,602)
Cost of purchases	-	20,340,980	1,000,000	-	21,340,980
Proceeds from sales	-	(54,390,940)	-	-	(54,390,940)
Net transfers in/out of level 3	-	-	-	-	-
Ending balance 6/30/2024	\$ 1,291,743	\$ 60,005,195	\$ 394,520	\$ 3,125,031	\$ 64,816,489

\*Transferred from Level 3 to Level 2 because observable market data became available for the investments.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investments were as follows:

Fund	Description	Valuation Technique(s)	Unobservable Input	Input	Impact to Valuation from an increase in Input <sup>A</sup>
Eventide Healthcare & Life Sciences Fund	Arch Oncology, Inc. Series C I	Residual Value	Net assets	\$540K	Increase
Eventide Healthcare & Life Sciences Fund	Avalyn Pharma Inc. Series C I	Market Approach	Recent transaction price	\$0.73	Increase
Eventide Healthcare & Life Sciences Fund, Eventide Gilead Fund	Beta Bionics, Inc. Series B, Beta Bionics, Inc. Series B2, Beta Bionics, Inc. Series C, Beta Bionics, Inc. Series C Warrant, Beta Bionics, Inc. Series D, Beta Bionics, Inc. Series D Warrant	Probability-Weighted Expected Return Method	Revenue, Revenue multiple, Recovery multiple, Strategic sale, IPO, Downside, Dissolution	\$75.1M, 7.00-8.00x, 0.50x, 30% probability weight, 45% probability weight, 15% probability weight, 10% probability weight	Increase, Increase, Increase, Increase, Decrease, Decrease
Eventide Healthcare & Life Sciences Fund	BioSplice Therapeutics, Inc. Series B-I	Cash Value	Cash	\$14.2M	Increase
Eventide Healthcare & Life Sciences Fund	BioSplice Therapeutics, Inc. Series C Warrant	Cash Value	Cash	\$14.2M	Increase
Eventide Healthcare & Life Sciences Fund	BioSplice Therapeutics, Inc. Series C PIK	Cash Value	Cash	\$14.2M	Increase
Eventide Healthcare & Life Sciences Fund	Casma Therapeutics, Inc. Series B1, Casma Therapeutics, Inc. Series B2, Casma Therapeutics, Inc. Series C1, Casma Therapeutics, Inc. Series C2, Casma Therapeutics, Inc. Series C2 Extension	Discount	Discount, Recent transaction price	54.5%, \$0.46	Decrease, Increase
Eventide Healthcare & Life Sciences Fund	Flare Therapeutics, Inc. Series A, Flare Therapeutics, Inc. Series A2, Flare Therapeutics, Inc. Series B	Market Approach	Recent transaction price	\$1.20	Increase
Eventide Healthcare & Life Sciences Fund	Freenome Holdings, Inc. Series D, Freenome Holdings, Inc. Series F	Cash Value	Cash	\$482M	Increase
Eventide Healthcare & Life Sciences Fund	Goldfinch Biopharma, Inc. Series A, Goldfinch Biopharma, Inc. Series B, Goldfinch Biopharma, Inc. Series B2	Residual Value	Net assets	\$0	Increase
Eventide Healthcare & Life Sciences Fund	Kojin Therapeutics, Inc. Series A-1, Kojin Therapeutics, Inc. Series A-2	Residual Value	Net assets	\$19M	Increase
Eventide Healthcare & Life Sciences Fund	Peloton Therapeutics, Inc. - CRV	Present Value	Discount rate, Probability of success, Milestone payments,	10%, 2.5%-75%, \$50M-\$1.1B	Decrease, Increase, Increase, Decrease
Eventide Healthcare & Life Sciences Fund	Evida BioSciences, Inc.	Market Approach	Recent transaction price	\$0.69	Increase
Eventide Healthcare & Life Sciences Fund	Shoreline Biosciences Series B	Option Pricing Model/Back solve	Risk free rate, Time to expiration, Volatility, Market Equity Adjustment	1.01% -4.30%, 4.19 years, 75.64% - 77.54%, -15.91%	Decrease, Increase, Increase, Increase

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

<sup>A</sup> Represents the directional change in the fair value of the Level 3 investments that could have resulted from an increase in the corresponding input as of period end. A decrease to the unobservable input would have had the opposite effect. Significant changes in these inputs may have resulted in a significantly higher or lower fair value measurement at period end.

The total change in unrealized appreciation or depreciation included in the Statements of Operations attributable to Level 3 investments still held at June 30, 2024 was \$0, \$0, \$0, \$12,264,972 and \$(3,551,01) for the Eventide Balanced Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, respectively.

b) Accounting for Options - When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

The Advisor may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the manager believes adverse market, political or other conditions are likely. The Advisor may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as “straddles,” “collars” or “spreads”) or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds (“ETFs”)) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

The notional value of the derivative instruments outstanding as of June 30, 2024 as disclosed in the Schedules of Investments and the amounts realized and changes in unrealized gains and losses on derivative instruments during the year as disclosed above and within the Statements of Operations serve as indicators of the volume of derivative activity of the Funds.

The effect of derivative instruments on the Statements of Assets & Liabilities for the year ended June 30, 2024 was as follows:

### Eventide Exponential Technologies Fund

Derivative	Primary Risk Exposure	Location of Derivative on Statements of Assets and Liabilities	Fair Value of Asset Derivative
Call Options Purchased	Equity Risk	Unaffiliated investments at value	\$ 4,000
Total			\$ 4,000

The effect of derivative instruments on the Statements of Operations for the year ended June 30, 2024 was as follows:

### Eventide Exponential Technologies Fund

Derivatives Not Accounted for as Hedging Instruments under GAAP	Primary Risk Exposure	Location of Gain (Loss) on Derivatives Recognized in Statements of Operations	Realized and Unrealized Gain (Loss) on Asset Derivatives Recognized in Income
Options Purchased	Equity Risk	Net realized loss from unaffiliated investments	\$ 13,411
Options Purchased	Equity Risk	Net change in unrealized appreciation on unaffiliated investments	(139,936)
Total			\$ (126,525)



# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

---

c) Short Sales - The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

d) Federal Income Tax - The Funds have qualified and intend to continue to qualify as regulated investment companies and to comply with the applicable provisions of the Internal Revenue Code of 1986, as amended, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income or excise tax provisions are required.

As of and during the year ended June 30, 2024, the Funds did not have a liability for any unrecognized tax expense. The Funds recognize interest and penalties, if any, related to unrecognized tax expense as income tax expense in the Statements of Operations. As of June 30, 2024, the Funds did not incur any interest or penalties. The Trust's officers have analyzed the Funds' tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years ended June 30, 2021, to June 30, 2023, or expected to be taken in the Funds' June 30, 2024, year-end tax return.

e) Distributions to Shareholders - Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all of its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains, interest and dividend income. Each Fund may make distributions of its net realized capital gains (after any reductions for capital loss carry forwards) annually except for the Balanced Fund which is monthly. The Funds intend to make quarterly distributions if applicable.

f) Multiple Class Allocations - Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

g) Security Transactions and Investment Income - Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the specific identified cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds' understanding of the applicable country's tax rules and rates. Distributions received from a Fund's investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available. Distribution from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available.

h) Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) Indemnification - The Trust indemnifies its officers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds' maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

j) Redemption Fees and Sales Charges (loads) - A \$15 fee may be charged for redemptions made by wire. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds. The maximum deferred sales charge of 1.00% on Class A shares applies only to purchases of \$1 million or more made without an initial sales charge and applies to shares sold within 18 months of purchase. The maximum deferred sales charge of 1.00% on Class C shares applies to shares sold within 12 months of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the year ended June 30, 2024, there were the following redemption fees paid to the Funds and CDSC fees paid to the distributor:

Fund	Redemption Fees	CDSC Fees	
		Class A	Class C
Eventide Balanced Fund	\$ -	\$ -	\$ 200
Eventide Core Bond Fund	-	-	30
Eventide Dividend Opportunities Fund	-	-	4,167
Eventide Exponential Technologies Fund	-	-	29
Eventide Gilead Fund	-	1,415	2,066
Eventide Healthcare & Life Sciences Fund	-	-	471
Eventide Large Cap Focus Fund	-	-	8
Eventide Limited-Term Bond Fund	-	-	131

k) Cash and cash equivalents - Cash and cash equivalents are held with a financial institution. Cash and cash equivalents of the Funds may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation ("FDIC") insurance limits. The FDIC insures deposit accounts up to \$250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Funds place deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

### (2) INVESTMENT TRANSACTIONS

For the year ended June 30, 2024, aggregate purchases and proceeds from sales of investment securities (excluding short-term investments) for the Funds were as follows:

#### Eventide Balanced Fund

Purchases	Sales
\$ 173,752,372	\$ 162,512,863

#### Eventide Core Bond Fund

Purchases	Sales
\$ 97,392,549	\$ 39,231,139

#### Eventide Dividend Opportunities Fund

Purchases	Sales
\$ 426,298,730	\$ 258,647,533

#### Eventide Exponential Technologies Fund

Purchases	Sales
\$ 82,067,200	\$ 83,931,002

#### Eventide Gilead Fund

Purchases	Sales
\$ 1,282,739,032	\$ 1,582,936,830

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Healthcare & Life Sciences Fund

Purchases	Sales
\$ 1,138,494,960	\$ 1,265,849,410

### Eventide Large Cap Focus Fund

Purchases	Sales
\$ 123,965,482	\$ 43,633,846

### Eventide Limited-Term Bond Fund

Purchases	Sales
\$ 59,283,909	\$ 45,464,348

### (3) INVESTMENT ADVISORY AGREEMENT AND TRANSACTIONS WITH RELATED PARTIES

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of an investment advisory agreement between the Advisor and the Trust (the “**Advisory Agreement**”). Boyd Watterson Asset Management, LLC serves as sub-advisor to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Balanced Fund’s portfolio. Under the terms of the Advisory Agreement, the Advisor manages the investment operations of the Funds in accordance with the Funds’ investment policies and restrictions. The Advisor provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. The fees paid by the Funds to the Advisor are described in greater detail below. The Advisor pays expenses incurred by it in connection with acting as investment manager to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Advisory Agreement). The Advisor pays for all employees, office space and facilities required by it to provide services under the Advisory Agreement, with the exception of specific items of expense (as detailed in the Advisory Agreement). For the year ended June 30, 2024, advisory fees of \$2,076,679, \$357,352, \$4,974,202, \$1,314,480, \$35,349,592, \$17,506,668, \$319,467 and \$422,673 were incurred by the Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund, respectively, before the waivers and reimbursements described below.

Each Fund is authorized to pay the Advisor an annual fee based on its average daily net assets. The advisory fee is paid monthly. The Advisor has contractually agreed to waive fees and/or reimburse expenses, but only to the extent necessary to maintain each Fund’s total annual operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at a certain level through October 31, 2024. This agreement may be terminated by the Board only on 60 days’ written notice to the Advisor and upon the termination of the Advisory Agreement between the Trust and the Advisor. Fee waivers and expense reimbursements are subject to possible recoupment by the Advisor from the Funds in future years on a rolling three-year basis (within the three years after the fees have been waived or reimbursed) if, after the recoupment is taken into account, such recoupment can be achieved within the lesser of the expense limitation in place at the time of waiver/reimbursement and the expense limitation in place at the time of recapture. Each waiver or reimbursement by the Advisor is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The following table lists the contractual advisory fee and the expense limitation for each Fund.

Fund	Contractual Advisory Fee	Expense Limitation
Eventide Balanced Fund	0.60%	Class N: 1.02% Class A: 1.07% Class C: 1.82% Class I: 0.82%
Eventide Core Bond Fund	0.34% *	Class N: 0.78% Class A: 0.83% Class C: 1.58% Class I: 0.58%
Eventide Dividend Opportunities Fund	0.73%	Class N: 1.15% Class A: 1.20% Class C: 1.95% Class I: 0.95%
Eventide Exponential Technologies Fund	1.10%	Class N: 1.63% Class A: 1.68% Class C: 2.43% Class I: 1.43%
Eventide Gilead Fund	1.00% of the first \$2 billion; 0.95% on the next \$1 billion; 0.90% on the next \$1 billion; and 0.85% thereafter	Class N: 1.62% Class A: 1.67% Class C: 2.42% Class I: 1.42%
Eventide Healthcare & Life Sciences Fund	1.10%	Class N: 1.63% Class A: 1.68% Class C: 2.43% Class I: 1.43%
Eventide Large Cap Focus Fund	0.73%	Class N: 1.14% Class A: 1.19% Class C: 1.94% Class I: 0.94%
Eventide Limited-Term Bond Fund	0.31% *	Class N: 0.75% Class A: 0.80% Class C: 1.55% Class I: 0.55%

\* Effective May 31, 2023, the contractual advisory fees of Eventide Core Bond Fund and Eventide Limited-Term Bond Fund were reduced from 0.36% to 0.34% and 0.33% to 0.31%, respectively.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

For the year ended June 30, 2024, the Manager waived no advisory fees from Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund and waived fees of \$236,729, \$131,361, \$97,498, \$68,862, \$101,331 and \$202,441 from the Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Exponential Technologies Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund, respectively. As of June 30, 2024, the Advisor has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

	2025	2026	2027
Eventide Balanced Fund	\$ -	\$276,044	\$236,729
Eventide Core Bond Fund	201,020	164,775	131,361
Eventide Dividend Opportunities Fund	-	391,061	97,498
Eventide Exponential Technologies Fund	-	69,721	68,862
Eventide Large Cap Focus Fund	-	107,732	101,331
Eventide Limited-Term Bond Fund	165,476	243,710	202,441

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund do not have any expenses previously waived by the Advisor that are subject to recapture and did not waive any further expenses during the year ended June 30, 2024.

Pursuant to the Management Services Agreement between the Trust and MFund Services, LLC (“MFund”), MFund provides the Funds with management and legal administrative services (the “Management Services Agreement”). For these services, the Funds pay MFund an annual asset-based fee in accordance with the following schedule applied at the Fund family level (i.e., all the Funds in the Trust advised by the Advisor): 0.10% of net assets up to \$50 million; 0.07% of net assets from \$50 million to \$100 million; 0.05% of net assets from \$100 million to \$250 million; 0.04% of net assets from \$250 million to \$500 million; 0.03% of net assets from \$500 million to \$1 billion; 0.02% of net assets from \$1 billion to \$5 billion; and 0.01% of assets from \$5 billion and above. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Management Services Agreement. The amounts due to MFund for the Management Services Agreement are listed in the Statements of Assets and Liabilities under “Payable to related parties” and the amounts accrued for the year are shown in the Statements of Operations under “Legal administration fees/Management service fees.”

Pursuant to the Compliance Services Agreement, MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund \$1,200 per month for the first fund in the fund family and \$400 each additional fund; \$400 for each adviser and sub-adviser; and .0025% of the assets of each Fund. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Compliance Services Agreement.

There are no amounts due to MFund for chief compliance officer services as of June 30, 2024 and the amounts accrued for the year are shown in the Statements of Operations under “Compliance officer fees.”

A trustee of the Trust is also the controlling member of MFund and the investment advisers to other series of the Trust and is not paid any fees directly by the Trust for serving in such capacities. Trustees who are not “interested persons” as that term is defined in the 1940 Act, are paid a quarterly retainer and receive compensation for each special Board meeting and Risk and Compliance Committee meeting attended. The fees paid to the Independent Trustees for attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust, the Chairman of the Trust’s Audit Committee and the Chairman of the Risk and Compliance Committee receive an additional quarterly retainer. The “interested persons” of the Trust receive no compensation from the Funds. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

Ultimus Fund Solutions, LLC (“UFS”), an affiliate of the distributor, provides administrative, fund accounting, and transfer agency services to the Funds pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (“Blu Giant”), an affiliate of UFS and the distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

The Trust’s officers are not paid any fees directly by the Trust for serving in such capacity except for the chief compliance officer.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The Trust has adopted a Master Distribution Plan Pursuant to Rule 12b-1 (the “Plan”) under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC (the “**Distributor**”) and the Manager for distribution related expenses.

For the year ended June 30, 2024, the Distributor received \$43,616, \$1,911, \$53,742, \$11,798, \$125,122, \$50,717, \$6,656 and \$2,416 in underwriter commissions from the sale of Class A shares of the Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund, respectively.

### (4) DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL

The following table represents aggregate cost for federal tax purposes, including options written, for the Funds as of June 30, 2024 and differs from market value by net unrealized appreciation/depreciation which consisted of:

Fund	Cost for		Tax Net	
	Federal Tax purposes	Unrealized Appreciation	Unrealized Depreciation	Unrealized App/Dep
Eventide Balanced Fund	\$ 330,964,579	\$ 55,495,744	\$ (13,471,845)	\$ 42,023,899
Eventide Core Bond Fund	139,317,627	368,275	(6,146,050)	(5,777,775)
Eventide Dividend Opportunities Fund	674,720,709	187,409,140	(12,647,085)	174,762,055
Eventide Exponential Technologies Fund	84,437,961	34,142,335	(8,472,672)	25,669,663
Eventide Gilead Fund	2,165,398,812	1,418,361,141	(239,363,587)	1,178,997,554
Eventide Healthcare & Life Sciences Fund	1,339,550,210	293,302,143	(240,634,604)	52,667,539
Eventide Large Cap Focus Fund	95,561,821	9,583,156	(2,352,126)	7,231,030
Eventide Limited-Term Bond Fund	144,701,807	273,054	(3,086,901)	(2,813,847)

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

The tax character of fund distributions for the years ended June 30, 2024, and June 30, 2023, was as follows:

Fund	<i>For the year ended June 30, 2024:</i>			
	Ordinary Income	Long-Term Capital Gains	Return of Capital	Total
Eventide Balanced Fund	\$ 5,888,612	\$ -	\$ -	\$ 5,888,612
Eventide Core Bond Fund	3,769,367	-	-	3,769,367
Eventide Dividend Opportunities Fund	3,699,013	-	-	3,699,013
Eventide Limited-Term Bond Fund	4,104,125	-	-	4,104,125

Fund	<i>For the year ended June 30, 2023:</i>			
	Ordinary Income	Long-Term Capital Gains	Return of Capital	Total
Eventide Balanced Fund	\$ 4,832,162	\$ 3,689,551	\$ 1,039,779	\$ 9,561,492
Eventide Core Bond Fund	1,536,982	-	-	1,536,982
Eventide Dividend Opportunities Fund	3,346,718	3,513,286	1,113,976	7,973,980
Eventide Gilead Fund	-	172,246,986	-	172,246,986
Eventide Large Cap Focus Fund	4,107	-	5,791	9,898
Eventide Limited-Term Bond Fund	2,675,469	-	42,422	2,717,891

As of June 30, 2024, the components of accumulated earnings/(losses) on a tax basis were as follows:

Fund	Undistributed Ordinary Income	Undistributed Long-Term Capital Gains	Post October Loss and Late Year Loss	Capital Loss Carry Forwards	Other Book/Tax Differences	Unrealized Appreciation/ (Depreciation)	Total Accumulated Earnings/(Losses)
Eventide Balanced Fund	\$ -	\$ -	\$ -	\$ (10,658,695)	\$ -	\$ 42,023,899	\$ 31,365,204
Eventide Core Bond Fund	134,336	-	(1,684,290)	(12,068,354)	-	(5,777,775)	(19,396,083)
Eventide Dividend Opportunities Fund	-	-	-	(29,963,628)	-	174,762,055	144,798,427
Eventide Exponential Technologies Fund	-	-	(4,059,785)	(54,162,724)	-	25,669,663	(32,552,846)
Eventide Gilead Fund	-	-	(26,704,302)	(37,418,371)	-	1,178,997,554	1,114,874,881
Eventide Healthcare & Life Sciences Fund	-	-	(6,684,024)	(27,962,098)	-	52,667,539	18,021,417
Eventide Large Cap Focus Fund	1,254,858	2,379,611	-	-	-	7,231,030	10,865,499
Eventide Limited-Term Bond Fund	42,977	-	(739,165)	(7,823,197)	-	(2,813,847)	(11,333,232)

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, mark-to-market on passive foreign investment companies and adjustments for C-Corporation return of capital.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such late year losses as follows:

Fund	Late Year Losses
Eventide Exponential Technologies Fund	\$ 765,745
Eventide Gilead Fund	13,609,786
Eventide Healthcare & Life Sciences Fund	6,684,024

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

Fund	Post October Losses
Eventide Core Bond Fund	\$ 1,684,290
Eventide Exponential Technologies Fund	3,294,040
Eventide Gilead Fund	13,094,516
Eventide Limited-Term Bond Fund	739,165

At June 30, 2024, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains and utilized prior year capital loss carry forwards, as follows:

Fund	Non-Expiring			CLCF
	Short-Term	Long-Term	Total	Utilized
Eventide Balanced Fund	\$ 6,503,285	\$ 4,155,410	\$ 10,658,695	\$ -
Eventide Core Bond Fund	4,065,397	8,002,957	12,068,354	-
Eventide Dividend Opportunities Fund	23,505,416	6,458,212	29,963,628	-
Eventide Exponential Technologies Fund	34,530,996	19,631,728	54,162,724	-
Eventide Gilead Fund	37,418,371	-	37,418,371	-
Eventide Healthcare & Life Sciences Fund	27,962,098	-	27,962,098	26,883,914
Eventide Large Cap Focus Fund	-	-	-	8,133
Eventide Limited-Term Bond Fund	1,876,557	5,946,640	7,823,197	-

During the fiscal year ended June 30, 2024, the Eventide Large Cap Focus Fund utilized tax equalization which is the use of earnings and profits distributions to shareholders on redemption of shares as part of the dividends paid deduction for income tax purposes. Permanent book and tax differences, primarily attributable to the book/tax basis treatment of net operating losses, distributions in excess, and use of tax equalization credits, resulted in reclassifications for the Funds for the fiscal year ended June 30, 2024, as follows:

Fund	Paid In Capital	Accumulated Earnings (Losses)
Eventide Balanced Fund	\$ (132,077)	\$ 132,077
Eventide Dividend Opportunities Fund	(5,622)	5,622
Eventide Exponential Technologies Fund	(1,216,276)	1,216,276
Eventide Gilead Fund	(25,143,436)	25,143,436
Eventide Healthcare & Life Sciences Fund	(17,141,800)	17,141,800
Eventide Large Cap Focus Fund	354,593	(354,593)



# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### (5) INVESTMENTS IN AFFILIATED COMPANIES

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at June 30, 2024 are noted in the Funds' Schedule of Investments. Transactions during the year with companies which are affiliates are as follows:

#### Eventide Gilead Fund

Description	Market Value at June 30, 2023	Share Balance at June 30, 2023	Purchases	Sales Proceeds	Corporate Actions	Dividends Credited to Income	Net Increase/Decrease in Appreciation (Depreciation)	Realized Gains (Losses)	Market Value at June 30, 2024	Share Balance at June 30, 2024
Beta Bionics, Inc. Series B	\$ 10,046,265	139,527	\$ -	\$ -	\$ -	\$ -	\$ 4,026,016	\$ -	\$ 14,072,281	1,881,321
Beta Bionics, Inc. Series B2	3,613,527	48,872	-	-	-	-	1,450,730	-	5,064,257	665,474
Beta Bionics, Inc. Series C	4,993,786	71,900	-	-	-	-	2,140,199	-	7,133,985	964,052
Beta Bionics, Inc. Series D	-	-	6,000,002	-	-	-	621,429	-	6,621,431	714,286
Beta Bionics, Inc. Series C Warrants	1,274,958	17,975	-	-	-	-	508,538	-	1,783,496	241,013
Beta Bionics, Inc. Series D Warrants	-	-	-	-	-	-	3,350,000	-	3,350,000	500,000
Mirum Pharmaceuticals, Inc. PIPE	-	-	6,000,015	-	-	-	1,814,862	-	7,814,877	228,572
Xometry, Inc. <sup>1</sup>	62,908,624	2,970,190	55,046,876	(19,636,919)	-	-	(9,965,297)	(23,986,094)	64,367,190	5,568,096
Zentalis Pharmaceuticals, Inc. <sup>1</sup>	81,161,129	2,877,034	31,299,055	(6,341,347)	-	-	(59,927,412)	(31,531,601)	14,659,824	3,584,309
Total	<u>\$ 163,998,289</u>	<u>6,125,498</u>	<u>\$ 98,345,948</u>	<u>\$ (25,978,266)</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ (55,980,935)</u>	<u>\$ (55,517,695)</u>	<u>\$ 124,867,341</u>	<u>14,347,123</u>

I. Not affiliated June 30, 2023.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Healthcare & Life Sciences Fund

Description	Market Value at June 30, 2023	Share Balance at June 30, 2023	Purchases	Sales Proceeds	Corporate Actions	Dividends Credited to Income	Net Increase/Decrease in Appreciation (Depreciation)	Realized Gains (Losses)	Market Value at June 30, 2024	Share Balance at June 30, 2024
Aura Biosciences, Inc.	\$ 36,253,660	2,935,519	\$ 25,888,469	\$ -	\$ -	\$ -	\$ (18,273,853)	\$ -	\$ 43,868,276	5,802,682
Inozyme Pharma, Inc.	-	-	18,423,540	-	-	-	(867,999)	-	17,555,541	3,936,220
Beta Bionics, Inc. Series B <sup>1</sup>	5,023,096	69,763	-	-	-	-	2,013,050	(10)	7,036,136	940,660
Beta Bionics, Inc. Series B2 <sup>1</sup>	4,394,836	59,439	-	-	-	-	1,764,400	(6)	6,159,230	809,360
Beta Bionics, Inc. Series C <sup>1</sup>	2,496,893	35,950	-	-	-	-	1,070,099	-	3,566,992	482,026
Beta Bionics, Inc. Series D <sup>1</sup>	-	-	3,999,996	-	-	-	414,285	-	4,414,281	476,190
Beta Bionics, Inc. Series C Warrant <sup>1</sup>	637,443	8,987	-	-	-	-	254,257	-	891,700	120,500
Beta Bionics, Inc. Series D Warrants	-	-	-	-	-	-	2,233,331	-	2,233,331	333,333
Casma Therapeutics, Inc. Series B1	2,185,000	5,000,000	-	-	-	-	(1,138,500)	-	1,046,500	5,000,000
Casma Therapeutics, Inc. Series B2	2,185,000	5,000,000	-	-	-	-	(1,138,500)	-	1,046,500	5,000,000
Casma Therapeutics, Inc. Series C1	795,520	1,820,413	-	-	-	-	(414,507)	-	381,013	1,820,413
Casma Therapeutics, Inc. Series C2	532,709	1,219,013	350,000	-	-	-	(468,320)	-	414,389	1,979,882
Goldfinch Biopharma, Inc. Series A	-	5,000,000	-	-	-	-	-	-	-	5,000,000
Goldfinch Biopharma, Inc. Series B	-	8,474,576	-	-	-	-	-	-	-	8,474,576
Goldfinch Biopharma, Inc. Series B2	-	4,237,288	-	-	-	-	-	-	-	4,237,288
Korro Bio, Inc. <sup>2</sup>	-	-	-	(9,921,131)	29,999,999	-	(8,074,844)	497,664	12,501,688	369,108
Lexeo Therapeutics, Inc. <sup>2</sup>	-	-	4,999,996	-	14,999,999	-	657,055	-	20,657,050	1,287,846
Lexeo Therapeutics, Inc. <sup>2</sup>	-	-	23,108,959	-	-	-	10,275,109	-	33,384,068	2,081,301
Mirum Pharmaceuticals, Inc. PIPE	-	-	4,000,001	-	-	-	1,209,905	-	5,209,906	152,381
Evida BioSciences, Inc.	667,148	1,017,770	-	-	-	-	35,113	-	702,261	1,017,770
Zentalis Pharmaceuticals, Inc.	112,840,001	4,000,000	47,498,996	(7,422,726)	-	-	(84,104,182)	(48,572,335)	20,239,754	4,948,595
<b>TOTAL</b>	<b>\$ 168,011,306</b>	<b>38,878,718</b>	<b>\$ 128,269,957</b>	<b>\$ (17,343,857)</b>	<b>\$ 44,999,998</b>	<b>\$ -</b>	<b>\$ (94,554,101)</b>	<b>\$ (48,074,687)</b>	<b>\$ 181,308,616</b>	<b>54,270,131</b>

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Healthcare & Life Sciences Fund (Continued)

Investments no longer affiliated as of June 30, 2024

Description	Market Value at June 30, 2023	Share Balance at June 30, 2023	Purchases	Sales Proceeds	Corporate Actions	Dividends Credited to Income	Net Increase/Decrease in Appreciation (Depreciation)	Realized Gains (Losses)	Market Value at June 30, 2024	Share Balance at June 30, 2024
Korro Bio, Inc. Series B1 <sup>2</sup>	\$ 10,118,775	3,831,418	\$ -	\$ -	\$ (10,000,001)	\$ -	\$ (118,774)	\$ -	\$ -	-
Korro Bio, Inc. Series B2 <sup>2</sup>	9,499,999	3,597,122	-	-	(9,999,999)	-	500,000	-	-	-
LEXEO Therapeutics Series B <sup>2</sup>	14,250,300	8,718,446	-	-	(14,999,999)	-	749,699	-	-	-
Marinus Pharmaceuticals, Inc.	34,460,919	3,173,197	10,013,184	(25,196,981)	-	-	(19,385,992)	108,870	-	-
Mirum Pharmaceuticals, Inc.	53,271,530	2,059,201	28,399,140	(43,165,596)	-	-	7,810,476	11,288,240	57,603,790	1,684,814
Reneo Pharmaceuticals, Inc.	11,480,000	1,750,000	3,422,079	(3,646,593)	-	-	2,520,000	(13,775,486)	-	-
<b>Total</b>	<u>\$ 133,081,523</u>	<u>23,129,384</u>	<u>\$ 41,834,403</u>	<u>\$ (72,009,170)</u>	<u>\$(34,999,999)</u>	<u>\$ -</u>	<u>\$ (7,924,591)</u>	<u>\$ (2,378,376)</u>	<u>\$ 57,603,790</u>	<u>1,684,814</u>
	<u>\$ 301,092,829</u>	<u>62,008,102</u>	<u>\$ 170,104,360</u>	<u>\$ (89,353,027)</u>	<u>\$ 9,999,999</u>	<u>\$ -</u>	<u>\$ (102,478,692)</u>	<u>\$ (50,453,063)</u>	<u>\$ 238,912,406</u>	<u>55,954,945</u>

1. Not affiliated June 30, 2023.
2. Conversion.

### (6) INVESTMENT IN RESTRICTED SECURITIES

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund's investment objectives and investment strategies. A Fund will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of the Fund's net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer's expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of June 30, 2024, the Eventide Balanced Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund were invested in the following restricted securities:

#### Eventide Balanced Fund

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
Vision Fund International, 3.7250%, 2/24/25	2/25/2022	3,800,000	\$ 3,800,000	\$ 3,739,496	1.0%

#### Eventide Dividend Opportunities Fund

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
Vision Fund International, 5.2600%, 11/30/25	12/1/2023	3,250,000	\$ 3,250,000	\$ 3,214,663	0.4%

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Exponential Technologies Fund

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
Vision Fund International, 5.2600%, 11/30/25	12/1/2023	750,000	\$ 750,000	\$ 741,845	0.6%

### Eventide Gilead Fund

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
Beta Bionics, Inc. Series B	8/31/2018	1,881,321	\$ 20,000,022	\$ 14,072,281	0.4%
Beta Bionics, Inc. Series B2	6/27/2019	665,474	7,399,998	5,064,257	0.2%
Beta Bionics, Inc. Series C	2/16/2022	964,052	9,999,867	7,133,985	0.2%
Beta Bionics, Inc. Series D	8/29/2023	714,286	6,000,002	6,621,431	0.2%
Beta Bionics, Inc. Series C Warrant	2/16/2022	241,013	-	1,783,496	0.1%
Beta Bionics, Inc. Series D Warrant	8/29/2023	500,000	-	3,350,000	0.1%
Hope Global International, 4.0000%, 01/07/28	12/28/2023	2,000,000	2,000,000	1,868,542	0.1%
Mirum Pharmaceuticals, Inc. PIPE	7/18/2023	228,572	6,000,015	7,814,877	0.2%
Peloton Therapeutics, Inc. - CVR	2/14/2019	3,982,940	-	3,365,186	0.1%
Vision Fund International, 3.1500%, 12/15/25	12/16/2021	5,000,000	5,000,000	4,796,460	0.1%
Vision Fund International, 3.2230%, 12/15/26	12/16/2021	5,000,000	5,000,000	4,681,510	0.1%
Vision Fund International, 4.7400%, 05/16/25	5/18/2022	5,000,000	5,000,000	4,941,120	0.1%
Vision Fund International, 5.9030%, 09/19/25	9/21/2022	5,000,000	5,000,000	4,988,200	0.1%
Vision Fund International, 5.2600%, 11/30/25	12/1/2023	9,000,000	9,000,000	8,902,143	0.3%

### Eventide Healthcare & Life Sciences Fund

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
Arch Oncology, Inc. Series C1	4/26/2021	4,643,043	\$ 5,952,381	\$ 128,798	0.0%
Avalyn Pharma Inc. Series C1	9/25/2023	20,482,289	15,000,000	15,000,000	1.0%
Beta Bionics, Inc. Series B	8/31/2018	940,660	10,000,006	7,036,136	0.5%
Beta Bionics, Inc. Series B2	6/27/2019	809,360	8,999,994	6,159,230	0.4%
Beta Bionics, Inc. Series C	2/16/2022	482,026	4,999,933	3,566,992	0.3%
Beta Bionics, Inc. Series D	8/29/2023	476,190	3,999,996	4,414,281	0.3%
Beta Bionics, Inc. Series C Warrant	2/16/2022	120,500	-	891,700	0.1%
Beta Bionics, Inc. Series D Warrant	8/29/2023	333,333	-	2,233,331	0.1%

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

### Eventide Healthcare & Life Sciences Fund (Continued)

Security	Initial Acquisition Date	Shares	Cost	Value	% of Net Assets
BioSplice Therapeutics, Inc. Series B-I	3/5/2021	295,276	\$ 15,000,021	\$ -	0.0%
BioSplice Therapeutics, Inc. Series C PIK, 10.5000%, 03/12/25	5/2/2023	3,500,000	3,500,000	394,520	0.0%
Biosplice Therapeutics, Inc. Series C Warrant	5/2/2023	103,150	-	-	0.0%
Bridgebio Pharma, Inc. PIPE	9/28/2023	137,513	3,749,979	3,483,204	0.2%
Casma Therapeutics, Inc. Series B1	8/26/2020	5,000,000	3,750,000	1,046,500	0.1%
Casma Therapeutics, Inc. Series B2	6/7/2021	5,000,000	3,750,000	1,046,500	0.1%
Casma Therapeutics, Inc. Series C1	7/6/2022	1,820,413	837,390	381,013	0.0%
Casma Therapeutics, Inc. Series C2	1/31/2023	1,979,882	910,746	414,389	0.0%
Flare Therapeutics, Inc. Series A	4/22/2021	1,097,561	1,097,561	1,320,366	0.1%
Flare Therapeutics, Inc. Series A2	5/31/2022	902,439	902,439	1,085,634	0.1%
Flare Therapeutics, Inc. Series B	2/1/2023	1,952,962	2,349,999	2,349,413	0.2%
Freenome Holdings, Inc. Series D	11/22/2021	930,436	6,999,994	1,526,101	0.1%
Freenome Holdings, Inc. Series F	1/26/2024	133,941	990,984	219,690	0.0%
Goldfinch Biopharma, Inc. Series A	3/15/2019	5,000,000	5,000,000	-	0.0%
Goldfinch Biopharma, Inc. Series B	6/29/2020	8,474,576	10,000,000	-	0.0%
Goldfinch Biopharma, Inc. Series B2	3/21/2022	4,237,288	5,000,000	-	0.0%
Kojin Therapeutics, Inc. Series A-1	6/2/2021	763,319	1,499,998	467,228	0.0%
Kojin Therapeutics, Inc. Series A-2	1/28/2022	763,319	1,499,998	467,228	0.0%
Korro Bio, Inc.	11/27/2023	369,108	20,078,868	12,501,688	0.9%
Lexeo Therapeutics, Inc.	11/27/2023	1,287,846	19,999,995	20,657,050	1.4%
Metagenomi, Inc.	12/20/2022	449,708	9,390,942	1,834,809	0.1%
Mirum Pharmaceuticals, Inc. PIPE	7/18/2023	152,381	4,000,001	5,209,906	0.4%
Peloton Therapeutics, Inc. - CVR	2/14/2019	1,528,871	-	1,291,743	0.1%
Evida BioSciences, Inc.	12/31/2020	1,017,770	702,262	702,261	0.1%
Shoreline Biosciences Series B	10/28/2021	1,489,958	15,000,003	12,673,435	0.9%

### (7) SECTOR EXPOSURE RISK

The Eventide Exponential Technologies Fund invests primarily in equity and equity-related securities of companies that the Adviser believes are participating in and benefitting from technologies, innovations, technology themes, or technology trends. The types of companies represented in the Fund's portfolio include, but are not limited to, companies falling within the information technology, e-commerce discretionary, internet media and services, healthcare technology, healthcare devices, or transaction and payment processing services industries. Because of its focus on technology companies, the Eventide Exponential Technologies Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Exponential Technologies Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare & Life Sciences Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

# Eventide Funds

## NOTES TO FINANCIAL STATEMENTS (Continued)

June 30, 2024

---

### (8) OPTIONS RISK

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

### (9) MARKET RISK

Overall market risks may also affect the value of the Funds. The market values of securities or other investments owned by the Funds will go up or down, sometimes rapidly or unpredictably. Factors such as economic growth and market conditions, interest rate levels, exchange rates and political events affect the securities markets. Changes in market conditions and interest rates generally do not have the same impact on all types of securities and instruments. Unexpected local, regional or global events and their aftermath, such as war; acts of terrorism; financial, political or social disruptions; natural, environmental or man-made disasters; climate-change and climate-related events; the spread of infectious illnesses or other public health issues; recessions and depressions; or other tragedies, catastrophes and events could have a significant impact on the Funds and their investments and could result in increased premiums or discounts to a Fund's net asset value, and may impair market liquidity, thereby increasing liquidity risk. Such events can cause investor fear and panic, which can adversely affect the economies of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen. The Funds could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. In times of severe market disruptions you could lose your entire investment.

### (10) LINE OF CREDIT

Effective January 24, 2024, the Eventide Funds have a \$150,000,000 uncommitted line of credit provided by U.S. Bank National Association (the "Bank") under an agreement (the "Uncommitted Line"), that is set to expire on January 22, 2025. Borrowings under the Uncommitted Line bear an interest at Prime Rate minus 0% per month. Any advance under the Uncommitted Line is contemplated primarily for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. Interest on borrowings is payable on an annualized basis. The Uncommitted Line is not a "committed" line of credit, which is to say that the Bank is not obligated to lend money to the Funds. Accordingly, it is possible that Funds may wish to borrow money for a temporary or emergency purpose but may not be able to do so. During the year ended June 30, 2024, none of the Eventide Funds accessed the line of credit.

### (11) BENEFICIAL OWNERSHIP

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of June 30, 2024, Charles Schwab & Co, Inc. Special Custody Account for the Exclusive Benefit of Customers held 37.31%, 28.74%, 40.09%, 31.98% and 28.90% of the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Large Cap Focus Fund and Eventide Limited-Term Bond Fund, respectively. As of June 30, 2024, National Financial Services LLC held 41.28% and 28.83% of the Eventide Core Bond Fund and Eventide Large Cap Focus Fund, respectively. As of June 30, 2024, American Enterprise Investment Services held 29.88% of the Eventide Limited-Term Bond Fund.

### (12) SUBSEQUENT EVENTS

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

## REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders of Eventide Balanced Fund, Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund and Board of Trustees of Mutual Fund Series Trust

### Opinion on the Financial Statements

We have audited the accompanying statements of assets and liabilities, including the schedules of investments, of Eventide Balanced Fund (formerly, Eventide Multi-Asset Income Fund), Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, and Eventide Limited-Term Bond Fund (the “Funds”), each a series of Mutual Fund Series Trust, as of June 30, 2024, the related statements of operations for the year then ended, the statements of changes in net assets and the financial highlights for each of the two years in the period then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Funds as of June 30, 2024, the results of their operations for the year then ended, the changes in net assets and the financial highlights for each of the two years in the period then ended, in conformity with accounting principles generally accepted in the United States of America.

The Funds’ financial highlights for the years and periods ended June 30, 2022, and prior, were audited by other auditors whose report dated August 29, 2022, expressed an unqualified opinion on those financial highlights.

### Basis for Opinion

These financial statements are the responsibility of the Funds’ management. Our responsibility is to express an opinion on the Funds’ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Funds in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our procedures included confirmation of securities owned as of June 30, 2024, by correspondence with the custodian, issuers, and brokers; when replies were not received from issuers and brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Funds’ auditor since 2023.

*Cohen & Company, Ltd*  
COHEN & COMPANY, LTD.

Philadelphia, Pennsylvania  
August 29, 2024

COHEN & COMPANY, LTD.

800.229.1099 | 866.818.4538 fax | [cohencpa.com](http://cohencpa.com)

# Eventide Funds

## Consideration and Renewal of Management Agreement

June 30, 2024

---

Consideration and Renewal of Management Agreement between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to Eventide Gilead Fund, Eventide Healthcare and Life Sciences Fund, Eventide Balanced, Eventide Dividend Opportunities Fund, Eventide Limited-Term Bond Fund, Eventide Exponential Technologies Fund, Eventide Core Bond Fund and Eventide Large Cap Focus Fund.

In connection with a meeting held on May 8, 9 and 28, 2024, the Board of Trustees (the “Board”) of Mutual Fund Series Trust (the “Trust”), including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the renewal of the advisory agreement (the “Eventide Agreement”) between the Trust and Eventide Asset Management, LLC (“Eventide”) with respect to Eventide Gilead Fund (“Eventide Gilead”), Eventide Healthcare and Life Sciences Fund (“Eventide HLS”), Eventide Balanced Fund (“Balanced”), Eventide Dividend Opportunities Fund (“Eventide DO”), Eventide Limited-Term Bond Fund (“Eventide LTB”), Eventide Exponential Technologies Fund (“Eventide ET”), Eventide Core Bond Fund (“Eventide CB”) and Eventide Large Cap Focus Fund (“Eventide LCF”) (collectively, the “Eventide Funds”)

The Board examined Eventide’s responses to a series of questions regarding, among other things, its advisory services provided to the Eventide Funds, comparative fee and expense information, and profitability from managing the Eventide Funds. The Board was assisted by legal counsel throughout the review process and relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Eventide Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to the renewal of the Eventide Agreement.

*Nature, Extent and Quality of Services.* The Board reviewed the key personnel and noted that Eventide hired additional analysts in the prior year. The Board discussed Eventide’s service to the Eventide Funds, noting Eventide provided continuous portfolio management services including making investment decisions and security selection consistent with the values principals articulated in each Eventide Fund’s prospectus. The Board noted that Eventide had strong internal research capabilities and utilized this research in serving the Eventide Funds. The Board recognized that Eventide provided continuous oversight and compliance services to the Eventide Funds that are sub-advised by Boyd Watterson Asset Management LLC (“Boyd Watterson”). The Board noted that Eventide used a third-party compliance service to monitor compliance with Fund investment restrictions on a pre- and post-trade basis. The Board recognized that Eventide increased security and adopted new security procedures in the prior year, noting that there were no material compliance issues reported. The Board concluded it expected Eventide to continue providing high quality service to each Eventide Fund and its shareholders.

*Performance.* The Board reviewed the performance of each Eventide Fund relative to its peer group and Morningstar category.

*Eventide Gilead:* The Board observed that the Fund underperformed its peer group average and Russell Mid Cap Growth Index for all time periods and Mid Cap Growth Morningstar category for the 1-, 3-, and 5- year periods. The Board noted that Eventide explained that the Fund differed from its peer group because it was consistently overweight in small-cap biotechnology stocks. The Board noted that Eventide remained confident in the Fund’s investment strategy and explained that the Fund had experienced higher relative volatility based on a smaller number of holdings.

*Eventide HLS:* The Board noted the Fund underperformed its peer group average, US Fund Health Morningstar category and S&P Biotechnology Selected Industry TR Index for the 1- year period. The Board discussed that Eventide HLS underperformed its peer group average and Morningstar category for 3-year and 5-year periods but outperformed the benchmark index for the 3-year and 5-year periods and outperformed all benchmarks for the 10-year period.

*Balanced:* The Board discussed that the Fund underperformed its peer group average and Morningstar category for the 1- and 3-year periods but outperformed the benchmark index for all time periods and the peer group and Morningstar category for 5-year and since inception periods. The Board noted that Eventide explained that the Fund unperformed the Morningstar category due to less exposure to equity markets.

*Eventide DO:* The Board observed that the Fund outperformed the peer group average, US Fund Mid-cap Blend Morningstar category and Russell Mid Cap TR Index for all time periods. The Board noted that Eventide referenced the Fund’s focus on investing in well-positioned and professionally managed securities.



# Eventide Funds

## Consideration and Renewal of Management Agreement (Continued)

June 30, 2024

---

Eventide LTB: The Board discussed that the Fund outperformed its peer group average and benchmark index for the 1-year and 10-year periods. The Board noted the Fund underperformed its peer group average and Morningstar category for the 3- and 5-year periods. The Board recognized that corporate bonds contributed the most to the Fund's performance, but that Eventide explained that the long-term bond mandate led to the underperformance related to the Morningstar category.

Eventide ET: The Board observed the Fund outperformed the benchmark index for the 1-year period but underperformed its peer group average and Morningstar category for the 1-, 3-year and since inception periods. The Board recognized that Eventide explained the Fund's underperformance was due to the Fund's focus on small-cap stocks while the peer group, Morningstar category and benchmark index benefited from the growth in large-cap stocks.

Eventide CB: The Board discussed that the Eventide CB trailed its peer group average, Morningstar category and benchmark index for all time periods. The Board noted that Eventide explained the underperformance related to the benchmark index was related to the timing of the Fund's launch in a higher interest rate environment. The Board recognized that Eventide CB had less exposure to US Treasuries and longer duration than funds in the peer group which led to underperformance.

Eventide LCF: The Board commented that the Fund outperformed its peer group average and Morningstar category for the 1-year and since inception periods and outperformed the S&P 500 TR Index for the 1-year period. The Board acknowledged that Eventide explained the Fund's performance was due to strong stock selection and portfolio allocation in the consumer staples and industrials sectors.

After discussion, the Board concluded that the performance of each Eventide Fund was acceptable.

*Fees and Expenses.* The Board discussed the advisory fee for each Eventide Fund compared to the average fees charged by each Eventide Fund's peer group and Morningstar category. The Board considered the soft dollar benefits received by Eventide; the sub-advisory fees paid with respect to certain Eventide Funds along with the indirect benefits of Rule 12b-1 fees received by Eventide with respect to the distribution of the Eventide Funds. The Board noted Eventide's belief that the advisory fees were reasonable given its expertise in technical research, dividend stock selection, specific ethical screening and active management of the Eventide Funds. The Board concluded that the advisory fee for each Eventide Fund was not unreasonable.

Eventide Gilead: The Board noted the advisory fee and net expense ratio were above the medians and averages for the peer group and Morningstar category but was well within the ranges for both.

Eventide HLS: The Board observed that the advisory fee was above the median and average for the peer group and Morningstar category but were below the highs. The Board noted that the net expense ratio was above the median and average for the peer group and Morningstar category but was well below the highs for each. The Board considered that the Fund's portfolio had a significantly lower average market capitalization than the peer group and Morningstar category funds, indicative of the specialized focus of the strategy.

Balanced: The Board discussed that the advisory fee and net expense ratio was in line with the medians and averages for the peer group and the advisory fee was below the peer group after the fee waiver. The Board noted that the advisory fee and net expense ratio was above the median and average for the Morningstar category but were both significantly below the highs.

Eventide DO: The Board noted Eventide DO's advisory fee was below the median and average for the peer group and in line with the with Morningstar category. The Board further noted the net expense ratio below the average for the peer group and in line with the median and average for the Morningstar category.

Eventide LTB: The Board commented that the advisory fee was below the median and average of the peer group and Morningstar category. The Board noted the net expense ratio was equal to the peer group average and above the Morningstar category median and average but well below the high. The Board further noted that Eventide had agreed to reduce its advisory fee by two basis points in the prior year.

Eventide ET: The Board observed the advisory fee and net expense ratio for the Fund were above the medians and averages for the peer group and Morningstar category but were below the highs for both.

# Eventide Funds

## ***Consideration and Renewal of Management Agreement (Continued)***

**June 30, 2024**

---

Eventide CB: The Board acknowledged the advisory fee was below the median and average for the peer group and Morningstar category. The Board noted the net expense ratio was above the peer group and Morningstar category average and median but was in line with and below the highs for both. The Board noted that Eventide had agreed to a reduce its advisory fee by two basis points in the prior year.

Eventide LCF: The Board noted the Eventide LCF advisory fee and net expense ratio were above the peer group and Morningstar category medians and averages but significantly below the highs.

The Board concluded that the advisory fee paid by each of the Eventide Funds to Eventide was not unreasonable.

*Profitability.* The Board reviewed the financial information provided by Eventide and discussed Eventide's profitability from its services to each of the Eventide Funds. The Board noted that some of Eventide's senior personnel received compensation in the form of ownership distributions that, if included as an operating expense in Eventide's calculations, would reduce the estimated profit levels. The Board observed that Eventide did not earn a profit from advising Eventide LTB, Eventide CB and Eventide LCF and earned a reasonable profit from Eventide Gilead, Eventide HLS, Balanced, Eventide DO, and Eventide ET. The Board considered the soft dollar benefits received by Eventide. The Board determined excess profitability was not a concern at this time.

*Economies of Scale.* The Board discussed potential breakpoints for the Eventide Funds, noting that the Eventide Fund's shareholders benefited from each Fund's expense cap. The Board discussed the impact of sub-adviser fee breakpoints on adviser economies. The Board recognized that Eventide had lowered its advisory fee for Eventide CB and Eventide LTB in 2023. The Board determined it would discuss breakpoints with Eventide in the future as the Eventide Funds increased AUM.

*Conclusion.* Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Eventide Agreement, and as assisted by the advice of counsel, the Board concluded that renewal of the Eventide Agreement was in the best interests of each Eventide Renewal Fund and its respective shareholders.

# Eventide Funds

## Consideration and Renewal of Management Agreement (Continued)

June 30, 2024

---

### Consideration and Renewal of the Sub-Advisory Agreements between Eventide Asset Management, LLC and Boyd Watterson Asset Management LLC with respect to Eventide Core Bond Fund, Eventide Limited-Term Bond Fund and Eventide Balanced Fund

In connection with a meeting held on May 8, 9 and 28, 2024, the Board of Trustees (the “Board”) of Mutual Fund Series Trust (the “Trust”), including a majority of the Trustees who are not “interested persons” as that term is defined in the Investment Company Act of 1940, as amended, discussed the renewal of the sub-advisory agreements (the “BW Agreement”) between Eventide Asset Management, LLC (“Eventide”) and Boyd Watterson Asset Management LLC (“Boyd Watterson”) with respect to Eventide Core Bond Fund (“Eventide CB”); Eventide Limited-Term Bond Fund (“Eventide LTB”) and Eventide Balanced Fund (“Balanced”).

The Board examined Boyd Watterson’s responses to a series of questions regarding, among other things, its sub-advisory services provided to Eventide CB, Eventide LTB and Balanced, comparative fee and expense information, and profitability from sub-advising Eventide CB, Eventide LTB and Balanced. The Board was assisted by legal counsel throughout the review process and relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Boyd Watterson Agreements and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to the various factors in reaching his conclusions with respect to renewal of the BW Agreement.

*Nature, Extent and Quality of Services.* The Board reviewed the changes in the key personnel servicing the Eventide Sub-Advised Funds, noting that a new position of COO had been created and filled. The Board agreed that the key personnel at Boyd Watterson had extensive experience in developing and operating fixed income strategies. The Board discussed that Boyd Watterson provided full portfolio investment management services to Eventide LTB and Eventide CB and managed the fixed income strategy portfolio of Eventide Balanced. The Board reviewed that Boyd Watterson utilized multiple committees and review processes along with a model-based approach to operate the Eventide Sub-Advised Funds’ investment strategies. The Board noted that Boyd Watterson used a bottom-up approach in selecting securities with a focus on income, consistency, and risk mitigation. The Board discussed that Boyd Watterson used a proprietary IT system to ensure compliance with investment restrictions for each of the Boyd Watterson Funds. The Board noted that the sub-adviser reported no material compliance issues or material litigation. The Board agreed that Boyd Watterson could be expected to continue providing quality services to the Eventide Sub-Advised Funds.

*Performance.* The Board reviewed the performance of each Eventide Sub-Advised Fund relative to its benchmarks.

*Eventide CB:* The Board discussed that Eventide CB trailed the peer group average, Morningstar category and benchmark index for all time periods. The Board noted that Boyd Watterson explained the underperformance related to the benchmark index was due to the timing of the Fund’s launch into a higher interest rate environment. The Board recognized that the Eventide CB has less exposure to US Treasuries and longer duration than other funds in the peer group which led to the underperformance.

*Eventide LTB:* The Board observed the Eventide LTB outperformed the peer group average and benchmark index for the 1-year and 10-year periods. The Board noted Eventide LTB underperformed the peer group average and Morningstar category for the 3- and 5-year periods. The Board recognized that corporate bonds contributed the most to Eventide LTB’s performance, but Boyd Watterson explained that the long-term bond mandate led to the underperformance related to the Morningstar category.

*Balanced:* The Board reviewed that Eventide Balanced underperformed the peer group average and Morningstar category for the 1-year and 3-year periods but outperformed the benchmark index for all time periods and the peer group and Morningstar category for the 5-year and since inception periods. The Board noted that Eventide explained that the Fund underperformed the Morningstar category due to less exposure to the equity markets than other funds in the category.

After discussion, the Board concluded that the performance of each Eventide Sub-Advised Fund was acceptable.

# Eventide Funds

## ***Consideration and Renewal of Management Agreement (Continued)***

**June 30, 2024**

---

*Fees and Expenses.* The Board reviewed the tiered structure to the sub-advisory fee for each of the Eventide Sub-Advised Funds. The Board discussed that Boyd Watterson received 0.15% sub-advisory fee for assets of \$100 million and under, 0.07% sub-advisory fee for assets over \$100 million and a sub-advisory fee of 0.06% for assets above \$500 million for the aggregate asset level of the Boyd Watterson Funds. The Board discussed the allocation of fees between Eventide and Boyd Watterson, given their respective duties and other factors and considering the fee breakpoints. The Board determined that the sub-advisory fees for the Eventide Sub-Advised Funds and the allocation between Eventide and Boyd Watterson were not unreasonable.

*Profitability.* The Board observed that Boyd Watterson earned a modest profit from sub-advising the Boyd Watterson Funds. The Board concluded excessive profitability was not a concern at this time.

*Economies of Scale.* The Board discussed whether the Boyd Watterson Funds had reached the size where Boyd Watterson benefited from economies of scale. The Board acknowledged economies of scale, including the impact of the current sub-advisory fee breakpoints, was an issue primarily considered by the Board when evaluating the advisory agreement with Eventide.

*Conclusion.* Having requested and received such information from Boyd Watterson as the Board believed to be reasonably necessary to evaluate the terms of the BW Agreement, and as assisted by the advice of counsel, the Board concluded that renewal of the BW Agreement was in the best interests of each of the Eventide Sub-Advised Funds and their respective shareholders.

# ***PRIVACY NOTICE***

## **MUTUAL FUND SERIES TRUST**

Rev. June 2011

### **FACTS**

#### **PERSONAL**

#### **WHAT DOES MUTUAL FUND SERIES TRUST DO WITH YOUR**

##### **Why?**

Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some, but not all sharing. Federal law also requires us to tell you how we collect, share, and protect your personal information. Please read this notice carefully to understand what we do.

##### **What?**

The types of personal information we collect and share depends on the product or service that you have with us. This information can include:

- Social Security number and wire transfer instructions
- account transactions and transaction history
- investment experience and purchase history

When you are *no longer* our customer, we continue to share your information as described in this notice.

##### **How?**

All financial companies need to share customers' personal information to run their everyday business. In the section below, we list the reasons financial companies can share their customers' personal information; the reasons Mutual Fund Series Trust chooses to share; and whether you can limit this sharing.

<b>Reasons we can share your personal information:</b>	<b>Does Mutual Fund Series Trust share information?</b>	<b>Can you limit this sharing?</b>
<b>For our everyday business purposes</b> - such as to process your transactions, maintain your account(s), respond to court orders and legal investigations, or report to credit bureaus.	<b>YES</b>	<b>NO</b>
<b>For our marketing purposes</b> - to offer our products and services to you.	<b>NO</b>	<b>We don't share</b>
<b>For joint marketing with other financial companies.</b>	<b>NO</b>	<b>We don't share</b>
<b>For our affiliates' everyday business purposes</b> - information about your transactions and records.	<b>NO</b>	<b>We don't share</b>
<b>For our affiliates' everyday business purposes</b> - information about your credit worthiness.	<b>NO</b>	<b>We don't share</b>
<b>For our affiliates to market to you</b>	<b>NO</b>	<b>We don't share</b>
<b>For non-affiliates to market to you</b>	<b>NO</b>	<b>We don't share</b>

**QUESTIONS? Call 1-866-447-4228**

# *PRIVACY NOTICE*

## MUTUAL FUND SERIES TRUST

Page 2

### What we do:

<p><b>How does Mutual Fund Series Trust protect my personal information?</b></p>	<p>To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards and secured files and buildings.</p> <p>Our service providers are held accountable for adhering to strict policies and procedures to prevent any misuse of your nonpublic personal information.</p>
<p><b>How does Mutual Fund Series Trust collect my personal information?</b></p>	<p>We collect your personal information, for example, when you</p> <ul style="list-style-type: none"> <li>• open an account or deposit money</li> <li>• direct us to buy securities or direct us to sell your securities</li> <li>• seek advice about your investments</li> </ul> <p>We also collect your personal information from others, such as credit bureaus, affiliates, or other companies.</p>
<p><b>Why can't I limit all sharing?</b></p>	<p>Federal law gives you the right to limit only:</p> <ul style="list-style-type: none"> <li>• sharing for affiliates' everyday business purposes – information about your creditworthiness.</li> <li>• affiliates from using your information to market to you.</li> <li>• sharing for non-affiliates to market to you.</li> </ul> <p>State laws and individual companies may give you additional rights to limit sharing.</p>

### Definitions

<p><b>Affiliates</b></p>	<p>Companies related by common ownership or control. They can be financial and non-financial companies.</p> <ul style="list-style-type: none"> <li>• <i>Mutual Fund Series Trust has no affiliates.</i></li> </ul>
<p><b>Non-affiliates</b></p>	<p>Companies not related by common ownership or control. They can be financial and non-financial companies.</p> <ul style="list-style-type: none"> <li>• <i>Mutual Fund Series Trust does not share with non-affiliates so they can market to you.</i></li> </ul>
<p><b>Joint marketing</b></p>	<p>A formal agreement between nonaffiliated financial companies that together market financial products or services to you.</p> <ul style="list-style-type: none"> <li>• <i>Mutual Fund Series Trust does not jointly market.</i></li> </ul>

## **Mutual Fund Series Trust**

4221 North 203rd Street, Suite 100  
Elkhorn, NE 68022

### **ADVISOR**

Eventide Asset Management, LLC  
One International Place, Suite 4210  
Boston, MA 02110

### **ADMINISTRATOR**

Ultimus Fund Solutions, LLC  
225 Pictoria Drive, Suite 450  
Cincinnati, OH 45246

### **TRANSFER AGENT**

Ultimus Fund Solutions, LLC  
225 Pictoria Drive, Suite 450  
Cincinnati, OH 45246

### **INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

Cohen & Company, Ltd.  
1835 Market Street, Suite 310  
Philadelphia, PA 19103

### **LEGAL COUNSEL**

Thompson Hine LLP  
41 South High Street, Suite 1700  
Columbus, OH 43215

### **CUSTODIAN BANK**

U.S. Bank  
1555 N. Rivercenter Drive, Suite 302  
Milwaukee, WI 53212